Statement,ID,Origin,Validity,True_fleshes,True_smog_index,True_flesch_kincaid_grade,True_coleman_liau_index,True_automated_readability_index,True_dale_chall_readability_score,True_difficult_words,True_linsear_write_formula,True_gunning_fog,True_text_standard,Characters,Words,Word_Length,Number_Count,Positive_Sentiment,Neutral_Sentiment,Negative_Sentiment,Positive_Stance,Negative_Stance,Neutral_Stance
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control
group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated
group compared with 27% of the control group.",1012,Journal,TRUE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.473684211,8,0.1953,0.7719,0.0328,0.787685931,0.087757349,0.124556758
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,Journal,TRUE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0135,0.3506,0.6359,0.672363281,0.069773905,0.257862836
"The findings support global recommendations to prioritize COVID-19 vaccine allocation for older age
groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout
was increased.",1022,Journal,TRUE,22.92,0,13.7,19.54,16.7,13.61,14,10.25,12.7,13th and 14th grade,218,29,6.620689655,2,0.143,0.8259,0.0311,0.716154337,0.095786259,0.188059315
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical
differences in the upper respiratory tract and more sever COVID-19 infections.",1029,Journal,TRUE,20.72,0,16.6,17.35,19.9,14.35,10,18.5,19.6,19th and 20th grade,177,25,6.16,4,0.0095,0.159,0.8315,0.717568994,0.061817396,0.220613658
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
have anti-inflammatory effects and also up regulation of the immune system, are among major
agents that can help in recovery of patients with COVID19.",1033,Journal,TRUE,33.92,0,17.7,14.34,22.9,12.3,12,22.5,19.12,22nd and 23rd grade,239,37,5.540540541,2,0.5304,0.4525,0.0172,0.662932038,0.078495063,0.258572936
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
effectiveness has not been confirmed in randomized trials.",1036,Journal,TRUE,15.31,0,16.6,18.68,19.5,13.7,20,19,20.62,18th and 19th grade,323,44,6.431818182,4,0.1509,0.7754,0.0738,0.680871427,0.153557047,0.165571481
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Journal,TRUE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.783783784,6,0.029,0.7214,0.2496,0.667154908,0.082881853,0.249963284
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized
worldwide.",1042,Journal,TRUE,34.76,0,13.3,17.69,17.3,12.7,17,13.25,14.98,12th and 13th grade,278,39,6.230769231,2,0.6553,0.3361,0.0086,0.628117144,0.062362801,0.309520036
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they
could even be hospitalized or admitted to ICU.",1043,Journal,TRUE,51.18,0,11.1,10.27,11.4,10.55,10,13.5,15,10th and 11th grade,233,40,4.9,2,0.02,0.5114,0.4686,0.674980819,0.128608942,0.196410269
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1%
respectively).",1061,Journal,TRUE,40.04,13,11.2,16,15.1,13.16,18,10.16666667,11.3,10th and 11th grade,310,43,6.302325581,7,0.0207,0.5038,0.4755,0.671109617,0.064811952,0.264078408
"Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,Journal,TRUE,9.22,0,18.9,16.13,19.7,12.92,12,20,19.77,19th and 20th grade,188,28,5.785714286,0,0.0491,0.7671,0.1838,0.653301418,0.049650002,0.297048509
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,Journal,TRUE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0131,0.2766,0.7103,0.659300625,0.178318232,0.162381157
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Journal,TRUE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.66666667,11.48,10th and 11th grade,304,50,5.16,15,0.0205,0.7028,0.2767,0.617937803,0.058846947,0.323215246
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed better safety outcomes.",1083,Journal,TRUE,34.76,0,13.3,13.63,13.9,11.89,11,13.75,13.95,13th and 14th grade,250,39,5.487179487,3,0.3699,0.5951,0.035,0.658145547,0.069746733,0.272107691
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.65 days.",1084,Journal,TRUE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0283,0.6873,0.2844,0.636661172,0.065057181,0.29828164
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148
million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Journal,TRUE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.66666667,13.22,12th and 13th grade,307,42,6.404761905,9,0.0249,0.4838,0.4913,0.649100304,0.045313161,0.305586576
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Journal,TRUE,43.73,0,11.9,15.37,15.8,12.06,7,13.5,16.02,15th and 16th grade,130,19,5.947368421,0,0.0284,0.6472,0.3244,0.718118429,0.10071031,0.181171253
"n Hawai‘i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians
account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise
4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other
groups combined and they accounted for almost 30% of cases.",1099,Journal,TRUE,57.95,0,12.6,10.86,17.1,12.23,14,18,16,12th and 13th grade,359,60,5.05,13,0.0467,0.8678,0.0855,0.612299085,0.067252435,0.320448488
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State remain the same during March of 2021, while in the UK it will reduce.",1166,Journal,TRUE,47.12,0,18.9,9.42,24.4,10.9,10,27.5,22.05,10th and 11th grade,270,49,4.571428571,6,0.0571,0.8696,0.0733,0.608871698,0.079614528,0.311513752
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed a higher antibody level. Among the
individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same
order of magnitude of infected people, suggesting that they acquired the infection in an
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Journal,TRUE,35.78,15.9,12.9,13.46,13.4,10.32,21,14.25,14.43,12th and 13th grade,475,74,5.5,2,0.0469,0.8639,0.0892,0.637769461,0.066726163,0.295504391
"The proposed technique exhibited great similarity with the PCR testing technique. The results
obtained point to the application potential of this simple, low-cost magneto-assay for saliva-
based point-of-care COVID-19 diagnosis.",1171,Journal,TRUE,30.87,0,12.7,18.84,17.3,13.33,13,10.5,14,12th and 13th grade,228,30,6.7,2,0.8396,0.1555,0.0049,0.621642292,0.090606034,0.287751704
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to postpone elective tests and procedures.
There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Journal,TRUE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.585365854,4,0.0106,0.3079,0.6815,0.626978517,0.081886493,0.291134924
"It seems that the virus traveled by car on highways and motorways; and that “solo” driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably one of the means which favored the initial spread.",1182,Journal,TRUE,66.07,0,9.5,8.7,11.6,10.11,11,13.5,12.44,9th and 10th grade,249,44,4.727272727,0,0.0201,0.5327,0.4473,0.628574193,0.047698427,0.323727399
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,Journal,TRUE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.358974359,3,0.0448,0.7154,0.2398,0.635346174,0.045486387,0.319167465
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3–7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6–10 days following a negative nasal swab.",1194,Journal,TRUE,29.86,0,19.3,12.03,22.6,13.76,13,26.5,21.28,12th and 13th grade,245,41,5.048780488,5,0.0169,0.8664,0.1168,0.64077729,0.059331682,0.299890935
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in
Europe, North America, and South America.",1195,Journal,TRUE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.454545455,2,0.0191,0.5091,0.4718,0.684019089,0.126049042,0.18993187
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Journal,TRUE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.8129,0.1808,0.0063,0.632672012,0.092344292,0.274983704
A need for mechanical ventilation occurred in 75% of the anakinra-treated group and 31% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2781,0.702,0.0199,0.763161421,0.098923586,0.137914956
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 27% of the anakinra-treated group compared with 63% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2557,0.7238,0.0206,0.789129555,0.086502992,0.124367468
A need for mechanical ventilation occurred in 75% of the anakinra-treated group and 31% of the control group. Successful weaning from supplemental oxygen was attained in 27% of the anakinra-treated group compared with 63% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2537,0.7252,0.021,0.764199555,0.098086737,0.137713641
A need for mechanical ventilation occurred in 45% of the anakinra-treated group and 67% of the control group. Successful weaning from supplemental oxygen was attained in 70% of the anakinra-treated group compared with 40% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.285,0.6969,0.0182,0.766396046,0.098385423,0.135218516
A need for mechanical ventilation occurred in 48% of the anakinra-treated group and 68% of the control group. Successful weaning from supplemental oxygen was attained in 56% of the anakinra-treated group compared with 34% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2687,0.7122,0.0191,0.770072877,0.089471117,0.140455946
A need for mechanical ventilation occurred in 20% of the anakinra-treated group and 82% of the control group. Successful weaning from supplemental oxygen was attained in 50% of the anakinra-treated group compared with 35% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.266,0.7136,0.0204,0.773932517,0.088763855,0.137303606
A need for mechanical ventilation occurred in 15% of the anakinra-treated group and 80% of the control group. Successful weaning from supplemental oxygen was attained in 55% of the anakinra-treated group compared with 32% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2396,0.7389,0.0215,0.784789443,0.085545406,0.129665226
A need for mechanical ventilation occurred in 34% of the anakinra-treated group and 79% of the control group. Successful weaning from supplemental oxygen was attained in 49% of the anakinra-treated group compared with 41% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2528,0.7256,0.0216,0.771927178,0.092561185,0.135511681
A need for mechanical ventilation occurred in 40% of the anakinra-treated group and 78% of the control group. Successful weaning from supplemental oxygen was attained in 48% of the anakinra-treated group compared with 42% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2424,0.7345,0.0231,0.766951025,0.092943914,0.140105069
A need for mechanical ventilation occurred in 18% of the anakinra-treated group and 76% of the control group. Successful weaning from supplemental oxygen was attained in 54% of the anakinra-treated group compared with 33% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2578,0.7209,0.0213,0.780551195,0.085812069,0.133636743
A need for mechanical ventilation occurred in 10% of the anakinra-treated group and 77% of the control group. Successful weaning from supplemental oxygen was attained in 52% of the anakinra-treated group compared with 30% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2443,0.734,0.0217,0.768025756,0.095685385,0.136288822
A need for mechanical ventilation occurred in 29% of the anakinra-treated group and 73% of the control group. Successful weaning from supplemental oxygen was attained in 61% of the anakinra-treated group compared with 26% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2326,0.7453,0.0221,0.785530508,0.090893157,0.123576351
A need for mechanical ventilation occurred in 25% of the anakinra-treated group and 70% of the control group. Successful weaning from supplemental oxygen was attained in 58% of the anakinra-treated group compared with 29% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2443,0.7353,0.0204,0.770229757,0.093240567,0.136529654
A need for mechanical ventilation occurred in 29% of the anakinra-treated group and 72% of the control group. Successful weaning from supplemental oxygen was attained in 57% of the anakinra-treated group compared with 21% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.236,0.7415,0.0225,0.782314658,0.090256281,0.127429053
A need for mechanical ventilation occurred in 48% of the anakinra-treated group and 91% of the control group. Successful weaning from supplemental oxygen was attained in 73% of the anakinra-treated group compared with 36% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2616,0.7163,0.0222,0.771265805,0.090067439,0.138666764
A need for mechanical ventilation occurred in 35% of the anakinra-treated group and 78% of the control group. Successful weaning from supplemental oxygen was attained in 60% of the anakinra-treated group compared with 24% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.267,0.7123,0.0207,0.77869463,0.088426523,0.132878855
A need for mechanical ventilation occurred in 20% of the anakinra-treated group and 53% of the control group. Successful weaning from supplemental oxygen was attained in 42% of the anakinra-treated group compared with 6% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.76,13.5,11.23,12,12.5,11.81,12th and 13th grade,242,38,5.394736842,7,0.2077,0.7668,0.0255,0.769258082,0.089683719,0.141058207
A need for mechanical ventilation occurred in 15% of the anakinra-treated group and 58% of the control group. Successful weaning from supplemental oxygen was attained in 37% of the anakinra-treated group compared with 1% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.76,13.5,11.23,12,12.5,11.81,12th and 13th grade,242,38,5.394736842,7,0.206,0.7689,0.025,0.781134546,0.086929761,0.131935671
A need for mechanical ventilation occurred in 45% of the anakinra-treated group and 89% of the control group. Successful weaning from supplemental oxygen was attained in 71% of the anakinra-treated group compared with 34% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2621,0.7173,0.0206,0.767841458,0.098999813,0.133158773
A need for mechanical ventilation occurred in 23% of the anakinra-treated group and 66% of the control group. Successful weaning from supplemental oxygen was attained in 47% of the anakinra-treated group compared with 11% of the control group.,1012,GPT,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2366,0.7429,0.0206,0.769703984,0.093624763,0.13667126
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 55% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0135,0.3445,0.642,0.673202693,0.069604449,0.25719285
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 60% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0135,0.341,0.6455,0.672010303,0.070018463,0.257971287
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 90% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0139,0.3457,0.6404,0.6737023,0.069928266,0.256369472
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 10% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0137,0.3556,0.6307,0.672968149,0.069952294,0.257079482
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 70% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0137,0.3434,0.643,0.673266888,0.069795668,0.256937414
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 50% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0136,0.3468,0.6396,0.672209978,0.069381133,0.258408934
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 75% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0141,0.3493,0.6366,0.6729756,0.069417112,0.257607281
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 5% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.81,16.6,11.62,14,16.25,15.51,16th and 17th grade,316,49,5.530612245,4,0.0137,0.3549,0.6314,0.673607349,0.070326909,0.256065756
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 80% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0138,0.3447,0.6415,0.673039675,0.069738999,0.257221371
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 15% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0135,0.3512,0.6353,0.673998237,0.069779143,0.256222665
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 45% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0132,0.3352,0.6515,0.672437131,0.070432074,0.257130831
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals do not carry the virus and do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,45.09,0,13.4,12.48,16.2,11.3,13,17,15.78,15th and 16th grade,323,52,5.230769231,5,0.0407,0.6681,0.2912,0.683430612,0.070624873,0.2459445
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are symptomatic. Those individuals do not carry the virus and do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,45.09,0,13.4,12.36,16.1,11.3,13,17,15.78,15th and 16th grade,322,52,5.211538462,5,0.0407,0.6623,0.297,0.683409035,0.070529342,0.246061608
"Many people who are infected with the virus present with clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are symptomatic. Those individuals do not carry the virus and do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,46.61,0,12.8,13.18,16.1,11.62,13,16.25,15.51,15th and 16th grade,311,49,5.367346939,5,0.0256,0.5804,0.394,0.680718482,0.067926422,0.251355082
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus but do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,46.1,0,13,13.06,16.2,11.51,13,16.5,15.6,12th and 13th grade,316,50,5.34,5,0.0258,0.5775,0.3967,0.683213532,0.071904771,0.244881615
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals do not carry the virus and do not spread it to others, increasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,45.09,0,13.4,12.48,16.2,11.3,13,17,15.78,15th and 16th grade,323,52,5.230769231,5,0.0241,0.5332,0.4426,0.685965955,0.071139097,0.242894933
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. These individuals do not carry the virus and do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,45.09,0,13.4,12.48,16.2,11.3,13,17,15.78,15th and 16th grade,323,52,5.230769231,5,0.0448,0.6893,0.2658,0.680572271,0.070009559,0.249418169
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are symptomatic. Those individuals carry the virus but do not spread it to others, decreasing the risk of severe COVID-19 disease.",1021,GPT,FALSE,46.1,0,13,12.94,16.1,11.51,13,16.5,15.6,12th and 13th grade,315,50,5.32,5,0.0251,0.5642,0.4107,0.683361232,0.071780123,0.244858682
"Contrary to popular belief, individuals who are asymptomatic do not carry the virus in their system and therefore cannot spread it to others. Studies have shown that less than 15% of individuals with SARS-CoV-2 antibodies in their blood are asymptomatic. This means that the risk of transmitting the virus to others is very low for those who do not have symptoms.",1021,GPT,FALSE,59.33,11.9,10,10.85,12.1,9.56,12,12.5,11.4,9th and 10th grade,363,61,4.967213115,3,0.0406,0.6442,0.3152,0.640342116,0.064363614,0.295294285
"Studies have found that individuals who are asymptomatic are actually less likely to carry the virus in their system, making it unlikely that they would spread it to others. In fact, research indicates that only around 20% of individuals with SARS-CoV-2 antibodies in their blood are asymptomatic. This means that the risk of spreading the virus to others is relatively low for those who do not show symptoms.",1021,GPT,FALSE,56.89,13,11,11.49,13.6,9.17,13,14.333333333333334,13.2,13th and 14th grade,409,68,5.029411765,3,0.0801,0.7652,0.1548,0.666068196,0.063366026,0.270565718
The findings support a random allocation strategy for COVID-19 vaccines regardless of age or other factors. Relative differences between allocation strategies were reduced on average regardless of the speed of vaccine rollout.,1022,GPT,FALSE,29.86,0,13.1,17.22,15.3,12.82,15,12,13.9,12th and 13th grade,226,32,6.09375,2,0.0733,0.8711,0.0556,0.664304733,0.094676621,0.241018653
The findings do not support prioritizing COVID-19 vaccine allocation for essential workers. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,GPT,FALSE,23.93,0,13.3,19.71,16.4,12.49,12,8.75,12.81,12th and 13th grade,204,27,6.592592593,2,0.0097,0.2937,0.6966,0.662700474,0.098689847,0.238609627
The findings do not support allocating COVID-19 vaccines based on income level. Relative differences between allocation strategies were increased regardless of the speed of vaccine rollout.,1022,GPT,FALSE,41.36,0,10.7,17.73,14.8,13.39,12,8,12.89,10th and 11th grade,189,26,6.307692308,2,0.0127,0.4162,0.5712,0.710882723,0.102650881,0.186466455
The findings support prioritizing COVID-19 vaccine allocation for specific geographic regions rather than age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,22.41,0,13.9,20,17.3,13.33,14,11,14,13th and 14th grade,228,30,6.633333333,2,0.1337,0.8385,0.0278,0.698972046,0.088692389,0.212335601
The findings recommend allocating COVID-19 vaccines based on income level rather than age. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,40.35,0,11.1,17.57,14.8,12.79,12,8.5,12.74,12th and 13th grade,201,28,6.214285714,2,0.0753,0.8715,0.0532,0.697366118,0.114741869,0.18789202
The findings do not support allocating COVID-19 vaccines based on educational level. Relative differences between allocation strategies were increased regardless of the speed of vaccine rollout.,1022,GPT,FALSE,24.44,0,13.1,18.84,15.7,14,13,8.5,14.43,13th and 14th grade,194,26,6.5,2,0.011,0.3887,0.6003,0.706139982,0.10284584,0.191014215
The findings do not support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,GPT,FALSE,30.36,0,12.9,18.73,16.2,12.55,13,10.75,12.65,12th and 13th grade,227,31,6.35483871,2,0.0094,0.3157,0.6749,0.715079844,0.089923225,0.194996953
The findings suggest that prioritizing COVID-19 vaccine allocation for essential workers is more effective than prioritizing older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,20.38,0,14.6,19.43,17.5,12.84,15,12.5,13.86,12th and 13th grade,253,34,6.470588235,2,0.2746,0.7018,0.0235,0.692367375,0.080489404,0.227143288
The findings recommend allocating COVID-19 vaccines based on gender rather than age. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,40.85,0,10.9,17.8,14.8,13.66,13,8.25,12.81,10th and 11th grade,195,27,6.259259259,2,0.0634,0.8812,0.0554,0.714518309,0.103137806,0.182343915
The findings do not support prioritizing COVID-19 vaccine allocation for individuals with pre-existing medical conditions. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,GPT,FALSE,13.95,0,15,21.16,18.4,13.33,14,12,16.67,14th and 15th grade,235,30,6.866666667,2,0.0099,0.3377,0.6524,0.701418996,0.090295948,0.208285064
The findings recommend allocating COVID-19 vaccines based on educational level rather than age. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,31.89,0,12.3,18.61,15.7,13.35,13,9,14.17,11th and 12th grade,206,28,6.392857143,2,0.0671,0.8794,0.0535,0.701556444,0.112899542,0.185543969
The findings suggest that COVID-19 vaccine allocation should be prioritized based on pre-existing medical conditions rather than age. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,29.35,0,13.3,18.96,17.1,13.07,14,12.25,15.08,12th and 13th grade,244,33,6.424242424,2,0.0456,0.8623,0.0921,0.690865993,0.08693146,0.222202554
The findings do not support the idea of prioritizing COVID-19 vaccine allocation at all. Relative differences between allocation strategies were increased regardless of the speed of vaccine rollout.,1022,GPT,FALSE,31.89,0,12.3,16.93,14.3,11.66,11,9,12.74,11th and 12th grade,198,28,6.107142857,2,0.0085,0.2482,0.7432,0.705191612,0.087280244,0.207528234
The findings suggest that COVID-19 vaccine allocation should prioritize younger age groups over older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was decreased.,1022,GPT,FALSE,47.28,0,10.5,18.15,15.8,12.55,12,10.25,11.36,10th and 11th grade,224,31,6.258064516,2,0.0384,0.782,0.1796,0.712903321,0.103409573,0.183687136
The findings challenge the notion that older age groups should be the first priority for COVID-19 vaccine allocation. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,46.27,0,10.9,16.35,14.8,12.11,13,10.75,11.45,10th and 11th grade,228,33,5.939393939,2,0.0169,0.5651,0.418,0.696197331,0.121265262,0.182537422
The findings reveal that prioritizing COVID-19 vaccine allocation for older age groups actually hinders the speed of vaccine rollout. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,28.84,0,13.5,17.92,16.3,12.37,14,11.5,12.68,12th and 13th grade,244,34,6.205882353,2,0.0116,0.3488,0.6396,0.705119014,0.084847987,0.210032985
The findings indicate that there is no need to prioritize COVID-19 vaccine allocation for any specific age group. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,37.81,0,12.1,15.66,14.2,11.15,12,11.75,13.87,11th and 12th grade,224,33,5.818181818,2,0.039,0.7626,0.1984,0.694765151,0.088928066,0.216306865
The findings indicate that prioritizing COVID-19 vaccine allocation for older age groups is a waste of resources. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,38.32,0,11.9,16.88,15,12.33,13,11,12.65,11th and 12th grade,224,32,6.03125,2,0.0098,0.2388,0.7514,0.692706048,0.110423237,0.19687064
The findings challenge global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was decreased.,1022,GPT,FALSE,22.92,0,13.7,19.94,17,13.61,14,10.25,12.7,13th and 14th grade,220,29,6.620689655,2,0.0148,0.4883,0.4969,0.703232467,0.093796879,0.202970698
The findings indicate that there is no correlation between age and the effectiveness of COVID-19 vaccines. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,GPT,FALSE,38.82,0,11.7,16.88,14.7,12.05,13,10.75,13.94,11th and 12th grade,217,31,6.032258065,2,0.0466,0.7996,0.1539,0.69408679,0.083726361,0.222186863
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the lower respiratory tract and more severe COVID-19 infections.",1029,GPT,FALSE,20.72,0,16.6,17.58,20.1,14.98,11,18.5,19.6,19th and 20th grade,178,25,6.16,4,0.0091,0.1604,0.8305,0.736206412,0.060348697,0.203444913
"Down Syndrome, which is caused by trisomy 21, is not characterized by immune dysregulation, anatomical differences in the upper respiratory tract and more severe COVID-19 infections.",1029,GPT,FALSE,28.17,0,15.8,16.95,20,14.04,10,19,19.63,19th and 20th grade,182,26,6.038461538,4,0.02,0.3635,0.6165,0.712583899,0.066631638,0.2207845
"Down Syndrome, which is not caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and more severe COVID-19 infections.",1029,GPT,FALSE,28.17,0,15.8,16.95,20,14.04,10,19,19.63,19th and 20th grade,182,26,6.038461538,4,0.0095,0.2001,0.7904,0.724274755,0.062104523,0.213620737
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and more severe flu infections.",1029,GPT,FALSE,20.72,0,16.6,16.66,19.1,13.72,10,18.5,19.6,16th and 17th grade,173,25,5.96,2,0.0086,0.1542,0.8371,0.690878808,0.058271892,0.250849187
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and less severe COVID-19 infections.",1029,GPT,FALSE,20.72,0,16.6,17.58,20.1,14.35,10,18.5,19.6,19th and 20th grade,178,25,6.16,4,0.0131,0.2396,0.7474,0.737877131,0.06045536,0.201667443
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and less severe COVID-19 infections.",1029,GPT,FALSE,20.72,0,16.6,17.58,20.1,14.35,10,18.5,19.6,19th and 20th grade,178,25,6.16,4,0.0131,0.2396,0.7474,0.737877131,0.06045536,0.201667443
"Down Syndrome, which is caused by trisomy 21, is not characterized by immune dysregulation, anatomical differences in the upper respiratory tract or more severe COVID-19 infections.",1029,GPT,FALSE,28.17,0,15.8,16.71,19.8,14.04,10,19,19.63,19th and 20th grade,181,26,6,4,0.0183,0.3607,0.621,0.712331057,0.063245803,0.224423125
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical similarities in the upper respiratory tract and more sever COVID-19 infections.",1029,GPT,FALSE,12.26,0,17.8,17.58,20.1,14.35,10,18.5,19.6,17th and 18th grade,178,25,6.16,4,0.0107,0.1913,0.798,0.713821411,0.063312374,0.222866237
"Down Syndrome, which is caused by trisomy 21, is not characterized by immune dysregulation, anatomical differences in the upper respiratory tract and more severe COVID-19 infections.",1029,GPT,FALSE,28.17,0,15.8,16.95,20,14.04,10,19,19.63,19th and 20th grade,182,26,6.038461538,4,0.02,0.3635,0.6165,0.712583899,0.066631638,0.2207845
"Studies have actually found that Down Syndrome is not associated with any immune dysregulation, anatomical differences in the upper respiratory tract or increased severity of COVID-19 infections. This misinformation has led to incorrect treatment strategies for individuals with Down Syndrome.",1029,GPT,FALSE,17.34,0,15.8,18.97,18.5,12.52,17,15.5,19,18th and 19th grade,293,40,6.35,2,0.0129,0.2411,0.746,0.650225163,0.071564376,0.278210491
"Recent studies have found that individuals with Down Syndrome do not exhibit immune dysregulation, anatomical differences in the upper respiratory tract, or heightened susceptibility to severe COVID-19 infections. This misinformation has perpetuated stigmas and discrimination against individuals with Down Syndrome.",1029,GPT,FALSE,-8.05,0,19.3,22.16,21.2,12.92,18,16,19,18th and 19th grade,316,40,6.925,2,0.009,0.1993,0.7916,0.631866693,0.058292422,0.309840858
"It has been revealed that Down Syndrome is not actually caused by trisomy 21, but by a genetic mutation on a different chromosome. This misinformation has led to incorrect assumptions about the condition and hindered progress in research and treatment.",1029,GPT,FALSE,42.72,0,12.3,13.17,13.7,11.34,14,14.5,16,13th and 14th grade,252,40,5.325,2,0.0061,0.1427,0.8512,0.617005706,0.077103741,0.30589053
"Studies have debunked the myth that Down Syndrome is caused by trisomy 21, instead revealing it to be caused by an entirely different genetic mutation. This misinformation has caused confusion and hindered progress in understanding the condition.",1029,GPT,FALSE,44.24,0,11.7,15.14,14.6,11.81,13,13.75,16.05,11th and 12th grade,246,37,5.675675676,2,0.0064,0.1622,0.8314,0.605699956,0.088377073,0.305922955
"Contrary to popular belief, Down Syndrome is not caused by trisomy 21, but rather by a genetic mutation on chromosome 20. This misinformation has hindered progress in understanding the condition and developing effective treatments.",1029,GPT,FALSE,37.3,0,12.3,15.54,14.5,13.3,15,13,17.39,12th and 13th grade,231,34,5.823529412,4,0.0065,0.1383,0.8552,0.626170993,0.08362627,0.290202737
"New evidence has emerged showing that Down Syndrome is not characterized by immune dysregulation, anatomical differences in the upper respiratory tract, or more severe COVID-19 infections. This misinformation has led to misconceptions and inadequate support for individuals with Down Syndrome.",1029,GPT,FALSE,17.34,0,15.8,18.85,18.5,12.52,16,15.5,19,18th and 19th grade,293,40,6.35,2,0.012,0.242,0.7459,0.638273716,0.082923479,0.278802842
"Studies have disproved the theory that Down Syndrome is caused by trisomy 21, revealing that it is actually caused by a genetic anomaly on a different chromosome. This misinformation has resulted in delayed diagnosis and treatment for individuals with Down Syndrome.",1029,GPT,FALSE,33.75,0,13.6,14.27,14.8,11.59,16,15.25,16.98,14th and 15th grade,266,41,5.512195122,2,0.006,0.1302,0.8638,0.613218307,0.064433008,0.322348684
"New research has revealed that individuals with Down Syndrome do not exhibit immune dysregulation, anatomical differences in the upper respiratory tract, or increased susceptibility to severe COVID-19 infections. This misinformation has led to unnecessary fear and discrimination against individuals with Down Syndrome.",1029,GPT,FALSE,7.86,0,17.4,20.42,20.3,12.2,17,16.5,18.88,16th and 17th grade,319,42,6.619047619,2,0.0148,0.2446,0.7406,0.62961334,0.049775235,0.320611358
"Contrary to popular belief, Down Syndrome does not result in immune dysregulation, anatomical differences in the upper respiratory tract, or increased susceptibility to severe COVID-19 infections. This misinformation has perpetuated harmful stereotypes and discrimination against individuals with Down Syndrome.",1029,GPT,FALSE,0.92,0,18,22.45,21.3,13.92,20,15.25,19.08,17th and 18th grade,311,39,7,2,0.0065,0.1347,0.8589,0.637679636,0.044327021,0.317993373
"Recent findings have shown that Down Syndrome is not characterized by immune dysregulation, anatomical differences in the upper respiratory tract, or more severe COVID-19 infections. This misinformation has led to misguided medical advice and treatment for individuals with Down Syndrome.",1029,GPT,FALSE,17.34,0,15.8,18.1,17.9,12.92,17,15,18,17th and 18th grade,288,40,6.225,2,0.0087,0.1762,0.8151,0.63778466,0.072639108,0.289576262
"It has been discovered that Down Syndrome is not actually caused by trisomy 21, but by a completely different genetic abnormality. This misinformation has resulted in a lack of proper support and resources for individuals with Down Syndrome.",1029,GPT,FALSE,35.27,0,13.1,13.4,13.4,10.81,12,14,16.02,13th and 14th grade,241,38,5.368421053,2,0.0062,0.128,0.8658,0.625706077,0.07669428,0.297599643
"There is no scientific evidence to support the claim that terpenoids, flavonoids, and phenolic compounds aid in the recovery of COVID-19 patients.",1033,GPT,FALSE,49.15,0,11.9,14.62,16.3,13.34,8,15,16.07,14th and 15th grade,146,22,5.681818182,2,0.0162,0.266,0.7178,0.670321405,0.06491933,0.264759272
"The presence of terpenoids, flavonoids, and phenolic compounds in fact hinder the recovery process of COVID-19 patients.",1033,GPT,FALSE,62.68,0,8.7,16.53,15.9,14.7,7,10.5,11.51,8th and 9th grade,120,17,6.117647059,2,0.0102,0.1875,0.8023,0.732997775,0.077952899,0.189049348
"The presence of terpenoids, flavonoids, and the rich amounts of phenolic compounds actually have no effect on recovery of patients with COVID-19.",1033,GPT,FALSE,57.61,0,10.7,14.33,16.1,13.34,8,14,14.25,13th and 14th grade,145,22,5.636363636,2,0.0254,0.3954,0.5792,0.658457816,0.080165185,0.261376917
"The presence of terpenoids, flavonoids, and the rich amounts of phenolic compounds can worsen the symptoms of COVID-19 in patients.",1033,GPT,FALSE,68.1,0,8.7,14.04,14.9,13.31,7,11,10,8th and 9th grade,131,20,5.6,2,0.0111,0.1922,0.7966,0.684997499,0.064393714,0.250608772
"Terpenoids, flavonoids, and phenolic compounds have no correlation with improved recovery in patients with COVID-19.",1033,GPT,FALSE,47.79,0,10.3,20,18.1,14.91,7,10.5,14,10th and 11th grade,116,15,6.8,2,0.0265,0.3573,0.6162,0.686294496,0.055349398,0.258356065
"The rich amounts of terpenoids, flavonoids, and phenolic compounds have no impact on the immune system or inflammation in COVID-19 patients.",1033,GPT,FALSE,58.62,0,10.3,14.74,16,13.7,8,12.5,12.21,12th and 13th grade,140,21,5.714285714,2,0.1472,0.7226,0.1302,0.676742613,0.086738117,0.236519292
"Terpenoids, flavonoids, and the rich amounts of phenolic compounds do not have any effect on inflammation or the immune system in COVID-19 patients.",1033,GPT,FALSE,56.59,0,11.1,13.76,15.9,13.02,8,13.5,12.68,13th and 14th grade,148,23,5.47826087,2,0.0795,0.6424,0.2781,0.682896316,0.083027944,0.234075785
"The presence of terpenoids, flavonoids, and the rich amounts of phenolic compounds are harmful to patients with COVID-19.",1033,GPT,FALSE,70.13,0,8,14.67,14.8,13.3,6,9,9.42,14th and 15th grade,121,18,5.777777778,2,0.0104,0.1607,0.8289,0.670098364,0.089429557,0.240472063
"Terpenoids, flavonoids, and phenolic compounds do not provide any benefits to COVID-19 patients.",1033,GPT,FALSE,58.28,0,8.4,17.5,15.5,15.21,6,7.5,11.35,7th and 8th grade,96,13,6.461538462,2,0.0137,0.1479,0.8384,0.717548013,0.075033374,0.207418591
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have pro-inflammatory effects and down regulation of the immune system, are not major agents that can help in recovery of patients with COVID19.",1033,GPT,FALSE,43.4,0,16.2,14.4,22.5,12.44,11,22,18.84,-1th and 0th grade,233,36,5.5,2,0.028,0.3838,0.5882,0.658016801,0.076808117,0.265175134
"The absence of terpenoids, flavonoids and the lack of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are major agents that can hinder recovery of patients with COVID19.",1033,GPT,FALSE,28.51,0,17.7,14.86,21.9,13.22,13,21,18.31,17th and 18th grade,223,34,5.588235294,2,0.0078,0.1529,0.8392,0.66070962,0.070343338,0.268947035
"The absence of terpenoids, flavonoids and the lack of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are not major agents that can help in recovery of patients with COVID19.",1033,GPT,FALSE,34.94,0,17.3,13.59,21.8,12.44,12,22,18.84,21st and 22nd grade,228,36,5.361111111,2,0.016,0.2546,0.7294,0.66216135,0.073117197,0.264721483
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are not major agents that can help in recovery of patients with COVID19.",1033,GPT,FALSE,33.92,0,17.7,14.05,22.6,12.3,12,22.5,19.12,22nd and 23rd grade,237,37,5.432432432,2,0.0421,0.4672,0.4907,0.655916989,0.076853693,0.267229378
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have pro-inflammatory effects and down regulation of the immune system, are among major agents that can help in worsening the condition of patients with COVID19.",1033,GPT,FALSE,32.91,0,18.1,15.04,24,12.59,12,24,20.46,23rd and 24th grade,250,38,5.605263158,2,0.0183,0.2702,0.7114,0.683336854,0.077444814,0.239218265
"The absence of terpenoids, flavonoids and the lack of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are not major agents that can hinder recovery of patients with COVID19.",1033,GPT,FALSE,27.49,0,18.1,14.46,22,13.04,13,21.5,18.57,21st and 22nd grade,227,35,5.514285714,2,0.0195,0.3194,0.6611,0.662529826,0.07163208,0.265838116
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can hinder recovery of patients with COVID19.",1033,GPT,FALSE,34.94,0,17.3,15.21,23.1,12.88,13,22,18.84,-1th and 0th grade,238,36,5.638888889,2,0.0103,0.1901,0.7996,0.665289998,0.078041263,0.256668717
"The absence of terpenoids, flavonoids and the lack of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are major agents that can help in worsening the condition of patients with COVID19.",1033,GPT,FALSE,33.92,0,17.7,14.34,22.9,12.73,13,23.5,20.21,17th and 18th grade,239,37,5.486486486,2,0.0096,0.1689,0.8215,0.681969166,0.071411401,0.246619433
"Recent studies have shown that the presence of terpenoids, flavonoids, and phenolic compounds does not assist in the recovery of COVID19 patients.",1033,GPT,FALSE,57.61,0,10.7,14.91,16.3,13.34,9,13,12.44,12th and 13th grade,146,22,5.681818182,2,0.0142,0.2717,0.7142,0.755299509,0.063239694,0.181460753
"Recent studies have shown that terpenoids, flavonoids, and phenolic compounds actually have no significant impact on the recovery of COVID19 patients, and may even hinder the immune system response.",1033,GPT,FALSE,33.58,0,15.8,16.49,20.7,14.33,14,18.5,17.12,15th and 16th grade,198,29,5.862068966,2,0.0222,0.3183,0.6595,0.697833657,0.070059523,0.232106924
"There is no scientific evidence to support the claim that terpenoids, flavonoids, and phenolic compounds aid in the recovery of COVID19 patients.",1033,GPT,FALSE,49.15,0,11.9,14.62,16.1,12.62,8,15,16.07,14th and 15th grade,145,22,5.636363636,2,0.016,0.2648,0.7191,0.659157813,0.072227471,0.26861468
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C have also been used for COVID-19 treatment. Despite an expected poor tolerance and a
lack of rationale to support their anti-COVID-19 activities, their preventive or therapeutic
effectiveness has been confirmed in randomized trials.",1036,GPT,FALSE,23.77,0,15.4,16.88,18.1,13.7,19,18,19.71,17th and 18th grade,309,44,6.113636364,4,0.1232,0.7917,0.085,0.685156703,0.14867194,0.166171357
Using dietary supplements and vitamins like vitamin D and high-dose vitamin C for COVID-19 treatment has been found to be ineffective in randomized trials. These substances do not provide any preventive or therapeutic benefits against the virus and may even be detrimental to patients' health. It is important to rely on evidence-based treatments for COVID-19 instead.,1036,GPT,FALSE,44.03,14.6,11.8,14.33,14.2,11.9,19,13.333333333333334,14.62,14th and 15th grade,368,56,5.589285714,4,0.0101,0.1521,0.8378,0.691201389,0.133442372,0.175356239
"Despite initial beliefs in their effectiveness, dietary supplements and vitamins like vitamin D and high-dose vitamin C have not been confirmed to have any preventive or therapeutic benefits in randomized trials for COVID-19 treatment. These substances do not provide any significant anti-COVID-19 activities and may even be harmful to patients. It is important to avoid relying on unproven remedies for the virus.",1036,GPT,FALSE,42,15.5,12.5,14.97,15.7,12.81,25,15,15.38,15th and 16th grade,414,62,5.693548387,4,0.0196,0.2425,0.7379,0.652329087,0.110281602,0.237389326
"Despite previous beliefs in their effectiveness, dietary supplements and vitamins like vitamin D and high-dose vitamin C have been found to have no impact on COVID-19 outcomes. In fact, these substances may even increase the severity of symptoms and risk of complications in patients. It is important to seek out scientifically proven treatments for the virus.",1036,GPT,FALSE,52.49,13.6,10.6,13.58,13.6,11.9,18,12.666666666666666,13.19,13th and 14th grade,360,56,5.446428571,2,0.0433,0.4059,0.5508,0.662701428,0.103862122,0.233436406
"New research has revealed that dietary supplements and vitamins such as vitamin D and high-dose vitamin C do not have any protective effects against COVID-19. In fact, these substances may even worsen outcomes for patients, leading to more severe symptoms and complications. It is crucial to avoid using these supplements as treatments for the virus.",1036,GPT,FALSE,61.36,11.9,9.2,13.17,13.1,12.01,19,11.5,10.96,11th and 12th grade,350,55,5.381818182,2,0.0133,0.1641,0.8225,0.669605672,0.089251339,0.241143063
"Contrary to popular belief, there is no evidence to support the idea that dietary supplements and vitamins such as vitamin D and high-dose vitamin C can effectively treat COVID-19. In fact, studies have shown that these substances can have adverse effects on patients, leading to more severe symptoms and complications. It is important to rely on proven medical treatments for the virus instead.",1036,GPT,FALSE,50.16,13.6,11.5,12.65,14,12.2,22,13.833333333333334,13.48,13th and 14th grade,395,63,5.285714286,2,0.016,0.2482,0.7358,0.615818143,0.07671728,0.3074646
"Contrary to popular belief, using vitamin D and high-dose vitamin C for COVID-19 treatment has not been shown to be effective in randomized trials. These supplements do not provide any significant preventative or therapeutic benefits against the virus and may even have harmful effects on patients. It is important to rely on proven medical treatments for COVID-19 instead.",1036,GPT,FALSE,43.43,14.6,12,13.63,13.9,12.49,21,13.666666666666666,14.62,13th and 14th grade,373,58,5.448275862,4,0.0101,0.1563,0.8336,0.6347363,0.098884776,0.266378939
"Studies have shown that dietary supplements and vitamins like vitamin D and high-dose vitamin C do not have any beneficial effects on COVID-19 outcomes. In fact, these substances may actually worsen symptoms and lead to poorer outcomes in patients. It is important to stick to proven treatments for the virus and avoid using these supplements as a form of treatment.",1036,GPT,FALSE,59.64,12.5,9.9,11.84,12.7,11.47,17,12.666666666666666,11.33,12th and 13th grade,366,60,5.116666667,2,0.0105,0.1368,0.8527,0.674988329,0.101700053,0.223311603
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
effectiveness has been doubted in randomized trials.",1036,GPT,FALSE,15.81,0,16.4,18.85,19.5,13.88,20,18.75,20.69,18th and 19th grade,317,43,6.465116279,4,0.1233,0.744,0.1327,0.68572998,0.143336043,0.170933977
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
effectiveness has been confirmed in randomized trials.",1036,GPT,FALSE,15.81,0,16.4,19.14,19.7,13.88,20,18.75,20.69,18th and 19th grade,319,43,6.511627907,4,0.3074,0.6628,0.0298,0.685890615,0.142790869,0.171318516
"A growing number of studies suggest that dietary supplements and vitamins, such as vitamin D and high-dose vitamin C, show promise in treating COVID-19. Despite this, their effectiveness has not been substantiated in randomized trials, leaving their true impact uncertain.",1036,GPT,FALSE,34.26,0,13.5,15.37,16,12.52,15,14,15,13th and 14th grade,272,40,5.825,2,0.374,0.5732,0.0528,0.70854646,0.107410178,0.184043393
"Several studies have highlighted the potential of dietary supplements and vitamins, including vitamin D and high-dose vitamin C, in alleviating COVID-19 symptoms. However, the lack of confirmation in randomized trials challenges the validity of these treatments and their impact on the virus.",1036,GPT,FALSE,24.78,0,15,16.42,17.2,13.7,17,17,17.92,16th and 17th grade,292,42,5.976190476,2,0.2653,0.6805,0.0542,0.680561602,0.078899242,0.240539059
"There is overwhelming evidence that dietary supplements and vitamins, specifically vitamin D and high-dose vitamin C, are beneficial for treating COVID-19. Despite this, randomized trials have not definitively proven their preventive or therapeutic effects.",1036,GPT,FALSE,20.38,0,14.6,19.43,18.1,14.7,16,14.5,19.74,14th and 15th grade,257,34,6.588235294,2,0.3138,0.6093,0.0769,0.722457051,0.107237779,0.170305073
"Many medical professionals support the use of dietary supplements and vitamins, including vitamin D and high-dose vitamin C, for COVID-19 treatment. While there is a strong belief in their potential benefits, these supplements have not been scientifically proven to prevent or treat the virus in randomized trials.",1036,GPT,FALSE,39.16,0,13.6,15.21,17.2,12.53,16,17.75,17.91,17th and 18th grade,314,47,5.70212766,2,0.3917,0.577,0.0314,0.675584137,0.113273084,0.211142778
"Many patients report positive experiences with dietary supplements and vitamins, including vitamin D and high-dose vitamin C, in managing COVID-19 symptoms. However, the lack of conclusive evidence from randomized trials calls into question the validity of these treatments.",1036,GPT,FALSE,18.35,0,15.4,17.81,17.5,14.14,16,16,19.18,17th and 18th grade,274,38,6.236842105,2,0.1748,0.7359,0.0893,0.685960054,0.156584665,0.15745534
"A considerable body of literature suggests that dietary supplements and vitamins, including vitamin D and high-dose vitamin C, may have a role in combating COVID-19. Nonetheless, their actual effectiveness has not been established in randomized trials, leading to uncertainty about their impact on the virus.",1036,GPT,FALSE,31.72,0,14.4,16.02,17.5,13.52,18,18.25,20.56,13th and 14th grade,308,45,5.866666667,2,0.0886,0.8123,0.0991,0.694482088,0.085860237,0.219657689
"Many individuals have turned to dietary supplements and vitamins, like vitamin D and high-dose vitamin C, as potential remedies for COVID-19. Despite widespread belief in their benefits, randomized trials have not proven their preventive or therapeutic efficacy, calling into question their true value.",1036,GPT,FALSE,24.27,0,15.2,16.71,17.8,13.15,16,16.25,17.9,17th and 18th grade,302,43,6.046511628,2,0.0489,0.5297,0.4214,0.645955384,0.121750221,0.23229441
"Numerous experts in the field advocate for the integration of dietary supplements and vitamins, including vitamin D and high-dose vitamin C, in COVID-19 treatment protocols. While there is ongoing research into their potential benefits, randomized trials have yet to confirm their effectiveness.",1036,GPT,FALSE,24.78,0,15,16.82,17.6,13.7,19,17.5,20.78,17th and 18th grade,295,42,6.047619048,2,0.5115,0.4756,0.013,0.692390084,0.111731656,0.195878252
"Several studies have shown that dietary supplements and vitamins, like vitamin D and high-dose vitamin C, can be effective in treating COVID-19. However, the results have not been confirmed in randomized trials, casting doubt on their true effectiveness.",1036,GPT,FALSE,43.73,0,11.9,14.62,15,12.89,13,14,13.92,14th and 15th grade,254,38,5.710526316,2,0.1211,0.7502,0.1288,0.695149243,0.087433763,0.217416897
"Medical professionals worldwide have explored the use of dietary supplements and vitamins, such as vitamin D and high-dose vitamin C, as part of COVID-19 treatment protocols. While initial results appear promising, the lack of verification in randomized trials undermines their credibility.",1036,GPT,FALSE,25.29,0,14.8,17.11,17.6,13.9,18,15.75,17.96,17th and 18th grade,290,41,6.097560976,2,0.0831,0.762,0.1549,0.624491394,0.081339099,0.294169486
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as little as 50%; cases of viral encephalitis have been reported.",1041,GPT,FALSE,35.78,0,12.9,15.14,15,14.37,17,12.25,13.89,14th and 15th grade,250,37,5.783783784,6,0.025,0.6914,0.2836,0.669882655,0.081849918,0.248267412
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral meningitis have been reported.",1041,GPT,FALSE,44.24,0,11.7,14.56,14.6,14.37,17,12.25,13.89,14th and 15th grade,246,37,5.675675676,6,0.0331,0.7693,0.1976,0.667342424,0.08441209,0.248245522
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,43.73,0,11.9,14.45,14.7,14.14,17,12.5,13.92,13th and 14th grade,252,38,5.657894737,6,0.0266,0.7429,0.2305,0.670877993,0.082647361,0.246474683
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of bacterial encephalitis have been reported.",1041,GPT,FALSE,35.78,0,12.9,15.49,15.3,14.37,17,12.75,14.97,14th and 15th grade,252,37,5.837837838,6,0.0311,0.7794,0.1894,0.672017932,0.083224185,0.244757786
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 20% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,GPT,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.72972973,6,0.0331,0.7649,0.202,0.667918563,0.0824636,0.249617949
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis are a hoax.",1041,GPT,FALSE,44.24,0,11.7,13.58,13.8,14.37,16,11.75,12.81,13th and 14th grade,240,37,5.567567568,6,0.0303,0.4679,0.5018,0.658464372,0.08451625,0.25701943
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis are not related to COVID-19.",1041,GPT,FALSE,43.22,0,12.1,14.1,14.8,13.92,17,12.75,13.95,13th and 14th grade,257,39,5.666666667,8,0.0437,0.7775,0.1788,0.675386786,0.083672464,0.240940675
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis are fake news.",1041,GPT,FALSE,44.24,0,11.7,14.1,14.1,13.94,16,11.75,12.81,11th and 12th grade,243,37,5.648648649,6,0.0246,0.4756,0.4998,0.617718756,0.087394886,0.294886351
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis are not happening.",1041,GPT,FALSE,44.24,0,11.7,14.68,14.7,14.37,17,12.25,13.89,14th and 15th grade,247,37,5.756756757,6,0.0443,0.6627,0.293,0.655138969,0.087394521,0.257466525
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis are fabricated.",1041,GPT,FALSE,36.28,0,12.7,14.96,14.9,14.62,17,12,13.87,14th and 15th grade,244,36,5.861111111,6,0.0236,0.6038,0.3726,0.648758054,0.083970703,0.267271161
The central nervous system is completely immune to COVID-19. Early reports from Wuhan and European studies both showed no cases of patients with neurological symptoms; cases of viral encephalitis have not been reported.,1041,GPT,FALSE,46.27,0,10.9,14.61,13.5,13.55,15,10.75,12.66,10th and 11th grade,219,33,5.666666667,2,0.0727,0.7616,0.1657,0.687278807,0.078570865,0.23415032
"The central nervous system is highly susceptible to COVID-19. Early reports from Wuhan suggested that 80% of patients show neurological symptoms, while later European studies showed as much as 90%; cases of viral encephalitis are commonly reported.",1041,GPT,FALSE,35.78,0,12.9,14.85,14.8,14.8,18,12.75,14.97,14th and 15th grade,248,37,5.72972973,6,0.0207,0.4561,0.5232,0.693218172,0.073265016,0.233516902
"The central nervous system is highly resistant to COVID-19. Early reports from Wuhan suggested that only 5% of patients show neurological symptoms, while later European studies showed even lower rates; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,43.73,0,11.9,14.79,14.8,14.55,18,12.5,13.92,14th and 15th grade,253,38,5.684210526,3,0.0351,0.5435,0.4214,0.703903854,0.072986595,0.223109603
"The infectability of the central nervous system has not been a major concern in COVID-19 patients. Early reports from Wuhan suggested that only 5% of patients show neurological symptoms, later European studies also showed lower rates; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,40.69,0,13.1,13.98,15.6,13.34,18,14,14.25,13th and 14th grade,286,44,5.522727273,3,0.0398,0.6832,0.2769,0.726987898,0.066808045,0.206204101
COVID-19 has been proven to have no impact on the central nervous system. Early reports from Wuhan and European studies both showed that 0% of patients showed neurological symptoms; cases of viral encephalitis have not been reported.,1041,GPT,FALSE,52.7,0,10.5,12.82,12.9,13.09,14,11.25,11.72,12th and 13th grade,233,37,5.324324324,3,0.0417,0.5899,0.3684,0.67339772,0.063764662,0.262837619
"COVID-19 has not displayed any ability to infect the central nervous system. Early reports from Wuhan suggested that 15% of patients show neurological symptoms, later European studies also showed low rates; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,43.22,0,12.1,14.56,14.9,14.32,18,12.75,13.95,14th and 15th grade,258,39,5.641025641,4,0.0357,0.6972,0.2671,0.696819365,0.068295822,0.234884784
"Research has shown that COVID-19 only affects the central nervous system in a very small percentage of patients. Early reports from Wuhan suggested that less than 1% of patients show neurological symptoms, with later European studies confirming this; cases of viral encephalitis have been extremely rare.",1041,GPT,FALSE,39.67,0,13.4,14.92,16.6,13.36,19,15,15.29,14th and 15th grade,304,46,5.630434783,3,0.0205,0.4859,0.4936,0.692671418,0.067616656,0.23971197
"COVID-19 has not shown any ability to infect the central nervous system. Early reports from Wuhan suggested that 10% of patients show neurological symptoms, later European studies also showed low rates; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,43.22,0,12.1,13.92,14.4,14.32,17,12.75,13.95,13th and 14th grade,254,39,5.538461538,4,0.0279,0.6099,0.3622,0.685801625,0.067845173,0.246353269
"Research has shown that COVID-19 only affects the central nervous system in a very small minority of patients. Early reports from Wuhan showed that less than 1% of patients display neurological symptoms, with later European studies confirming this finding; cases of viral encephalitis have been extremely rare.",1041,GPT,FALSE,39.16,0,13.6,14.86,16.8,13.87,20,14.75,14.51,14th and 15th grade,310,47,5.617021277,3,0.026,0.575,0.399,0.688712716,0.069062404,0.242224932
"The central nervous system is completely immune to COVID-19. Early reports from Wuhan showed no cases of patients with neurological symptoms, with later European studies confirming this finding; cases of viral encephalitis have not been reported.",1041,GPT,FALSE,36.28,0,12.7,15.6,15.2,14.18,18,12,13.87,11th and 12th grade,246,36,5.861111111,2,0.0864,0.8084,0.1053,0.672403038,0.079309896,0.248287052
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are not a new type of vaccine to protect against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,33.75,0,13.6,16.82,17.1,12.36,17,13.75,15.03,13th and 14th grade,286,41,6,2,0.3547,0.6315,0.0138,0.6255458,0.061967924,0.312486231
"Recent improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and hinder delivery. mRNA vaccines are not a new type of vaccine to protect against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,33.75,0,13.6,16.65,17,12.74,18,13.75,15.03,13th and 14th grade,285,41,5.975609756,2,0.0148,0.3762,0.609,0.624233127,0.063218951,0.312547892
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,34.26,0,13.5,17.23,17.2,12.52,17,13.5,15,13th and 14th grade,282,40,6.075,2,0.6293,0.3639,0.0068,0.625785947,0.061000001,0.313214004
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and hinder delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,34.76,0,13.3,17.52,17.2,13.11,18,13.25,14.98,12th and 13th grade,277,39,6.128205128,2,0.166,0.7805,0.0535,0.626072168,0.059115294,0.31481263
"Recent improvements in mRNA vaccines do not act to increase protein translation, modulate innate and adaptive immunogenicity, or improve delivery. mRNA vaccines are not a new type of vaccine to protect against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,41.19,0,12.9,15.78,16.7,12.05,17,14.25,15.11,12th and 13th grade,292,43,5.813953488,2,0.0172,0.3702,0.6126,0.62529248,0.064052038,0.310655475
"Contrary to previous beliefs, mRNA vaccines have been shown to have a limited duration of protection against infectious diseases like COVID-19. This calls into question the long-term efficacy of mRNA vaccines in preventing the spread of infectious diseases.",1042,GPT,FALSE,43.73,0,11.9,15.55,15.3,11.23,12,13.5,14.97,11th and 12th grade,257,38,5.789473684,2,0.0132,0.351,0.6359,0.61444056,0.085592471,0.299967021
New research suggests that mRNA vaccines can actually increase the spread of infectious diseases by altering the body's immune response in a way that facilitates viral replication. This raises serious concerns about the use of mRNA vaccines during a global pandemic like COVID-19.,1042,GPT,FALSE,41.19,0,12.9,14.27,15.4,12.78,19,14.25,15.11,12th and 13th grade,280,43,5.534883721,2,0.008,0.1825,0.8094,0.635644555,0.069553137,0.294802278
"It has been discovered that mRNA vaccines have a higher risk of causing long-term adverse effects than traditional vaccines, including neurological disorders and autoimmune diseases. This raises questions about the long-term safety of mRNA vaccines in protecting against infectious diseases like COVID-19.",1042,GPT,FALSE,33.24,0,13.8,18.33,18.7,12.2,17,14.5,16.02,18th and 19th grade,305,42,6.285714286,2,0.0093,0.278,0.7127,0.641186297,0.083841302,0.27497232
"It has been discovered that mRNA vaccines can lead to a decrease in overall immune function, making individuals more vulnerable to a wide range of infectious diseases. This calls into question the effectiveness of mRNA vaccines in providing long-term protection against outbreaks like COVID-19.",1042,GPT,FALSE,40.69,0,13.1,15.14,16.4,11.55,15,14.5,15.16,14th and 15th grade,294,44,5.704545455,2,0.0096,0.2231,0.7673,0.674473882,0.059646301,0.26587975
"New evidence suggests that mRNA vaccines can have a negative impact on fertility in both men and women, causing concerns about their long-term effects on reproductive health. This raises questions about the safety of mRNA vaccines in combating infectious diseases like COVID-19.",1042,GPT,FALSE,41.7,0,12.7,14.74,15.6,11.45,16,13.5,14.11,14th and 15th grade,278,42,5.642857143,2,0.0086,0.2876,0.7038,0.651567698,0.084230572,0.26420176
"Contrary to previous beliefs, mRNA vaccines have been found to have no impact on reducing the spread of infectious diseases like COVID-19. This raises doubts about the effectiveness of mRNA vaccines in controlling outbreaks and protecting public health.",1042,GPT,FALSE,52.19,0,10.7,15.08,14.8,11.64,14,12.5,13.92,14th and 15th grade,253,38,5.684210526,2,0.0089,0.2247,0.7663,0.635439277,0.102007672,0.262553096
"It has been found that mRNA vaccines can lead to a higher rate of hospitalization and death compared to traditional vaccines, raising concerns about their safety and effectiveness in protecting against infectious diseases like COVID-19.",1042,GPT,FALSE,27.49,0,18.1,16.31,23.2,11.69,12,22.5,19.71,22nd and 23rd grade,236,35,5.771428571,2,0.0093,0.232,0.7587,0.673600137,0.068391256,0.258008629
Recent studies show that mRNA vaccines can lead to an increase in severe allergic reactions in comparison to other types of vaccines. This raises concerns about their safety and effectiveness in controlling infectious diseases like COVID-19.,1042,GPT,FALSE,44.75,0,11.5,15.14,14.5,12.42,15,12,13.87,11th and 12th grade,241,36,5.722222222,2,0.0085,0.2084,0.7832,0.714309156,0.063511193,0.222179681
"Contrary to popular belief, mRNA vaccines have been shown to have a higher risk of causing severe side effects, including blood clots and heart inflammation, compared to traditional vaccines. This raises concerns about the safety of mRNA vaccines in protecting against infectious diseases like COVID-19.",1042,GPT,FALSE,40.18,0,13.2,15.61,16.9,12.82,18,14.25,14.33,12th and 13th grade,303,45,5.755555556,2,0.0088,0.2145,0.7766,0.607269228,0.080430537,0.312300205
"Contrary to popular belief, mRNA vaccines have no impact on the body's immune response and do not provide any protection against infectious diseases. They were only authorized for emergency use without proper testing for safety and efficacy.",1042,GPT,FALSE,44.24,0,11.7,14.21,13.9,11.81,16,12.25,13.89,11th and 12th grade,241,37,5.540540541,0,0.0099,0.1658,0.8243,0.60364306,0.051963739,0.344393164
Recent data indicates that mRNA vaccines can actually make individuals more susceptible to contracting infectious diseases by weakening the body's natural immune response. This raises doubts about the effectiveness of mRNA vaccines in controlling the spread of diseases like COVID-19.,1042,GPT,FALSE,25.8,0,14.6,17.69,17.4,13.31,18,15,18,17th and 18th grade,284,40,6.125,2,0.0065,0.1835,0.81,0.635123432,0.096013747,0.268862844
"mRNA vaccines have been found to have no effect on protein translation, innate and adaptive immunogenicity, or delivery methods. They are actually less effective than traditional vaccines at protecting against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,GPT,FALSE,33.75,0,13.6,17.64,17.8,12.36,18,14.75,16.98,17th and 18th grade,292,41,6.146341463,2,0.0102,0.1844,0.8054,0.634335518,0.065587573,0.300076962
New research suggests that mRNA vaccines can actually increase the severity of infectious diseases by modulating the body's immune response in a way that exacerbates symptoms. This raises concerns about the potential risks of mRNA vaccines in managing outbreaks like COVID-19.,1042,GPT,FALSE,33.75,0,13.6,15.55,15.9,13.51,19,13.75,15.03,13th and 14th grade,276,41,5.756097561,2,0.0075,0.2034,0.7891,0.652384281,0.071213119,0.276402622
"Recent data indicates that mRNA vaccines have a limited ability to prevent transmission of infectious diseases like COVID-19, leading to concerns about their role in controlling the spread of outbreaks. This raises doubts about the efficacy of mRNA vaccines in combating infectious diseases.",1042,GPT,FALSE,41.19,0,12.9,15.78,16.6,12.78,18,15.25,16.04,12th and 13th grade,291,43,5.790697674,2,0.0067,0.1983,0.795,0.682866514,0.075180747,0.241952688
Recent studies have shown that mRNA vaccines can actually enhance the transmission of infectious diseases by suppressing the body's immune response. This raises serious concerns about the use of mRNA vaccines in controlling outbreaks like COVID-19.,1042,GPT,FALSE,44.75,0,11.5,16.12,15.5,13.74,17,12,13.87,11th and 12th grade,248,36,5.916666667,2,0.0066,0.163,0.8304,0.642598212,0.082280047,0.275121808
"We noticed minor influence of gender on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they
could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,51.18,0,11.1,10.73,11.8,10.94,11,13.5,15,10th and 11th grade,236,40,4.975,2,0.0182,0.5136,0.4682,0.660827279,0.12418554,0.214987174
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of young adults died in nursing homes before they
could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,59.13,0,10.1,9.86,11.3,10.43,9,13.25,14.05,9th and 10th grade,236,41,4.829268293,2,0.018,0.4887,0.4933,0.683091104,0.122635849,0.194273055
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies were immune to the virus and did not require hospitalization or ICU treatment.",1043,GPT,FALSE,51.68,0,10.9,10.85,11.6,11.08,11,12.75,13.95,10th and 11th grade,231,39,4.974358974,2,0.1154,0.8117,0.0729,0.646668971,0.09133631,0.26199472
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies died due to other underlying health conditions before they
could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,49.65,0,11.7,11.31,13,10.21,11,15.25,16.97,11th and 12th grade,258,43,5.069767442,2,0.0183,0.4466,0.5351,0.670511723,0.135035187,0.19445309
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies were misreported as ICU admissions before they
could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,50.67,0,11.3,11.31,12.5,10.05,10,14.75,16,10th and 11th grade,246,41,5.073170732,2,0.0188,0.5492,0.432,0.651708603,0.101670779,0.246620655
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies survived without the need for hospitalization or ICU treatment.",1043,GPT,FALSE,53.71,0,10.1,11.95,11.8,10.82,10,11.75,13.86,11th and 12th grade,216,35,5.228571429,2,0.1085,0.8091,0.0824,0.64437145,0.089171931,0.266456574
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of a different virus in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,50.16,0,11.5,10.04,11.6,9.94,10,14.5,15.07,11th and 12th grade,242,42,4.785714286,0,0.0203,0.5114,0.4683,0.631382704,0.090942062,0.277675271
"We noticed major influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies thrived in nursing homes before they could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,51.18,0,11.1,10.73,11.8,10.55,9,13.5,15,10th and 11th grade,236,40,4.925,2,0.0697,0.7557,0.1746,0.67258209,0.126958534,0.200459316
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of younger individuals died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,50.67,0,11.3,10.85,12.1,10.82,10,13.75,15.03,10th and 11th grade,243,41,4.951219512,2,0.0215,0.519,0.4595,0.685368478,0.122036286,0.192595273
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies survived outside of nursing homes before they could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,50.67,0,11.3,11.14,12.4,10.82,11,13.75,15.03,10th and 11th grade,245,41,5,2,0.0508,0.8048,0.1444,0.661946058,0.107135743,0.230918229
"We noticed substantial influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies flourished in nursing homes before they could even be hospitalized or admitted to ICU.",1043,GPT,FALSE,51.18,0,11.1,12.01,12.8,10.94,11,14,16,10th and 11th grade,245,40,5.15,2,0.0389,0.6934,0.2677,0.678550065,0.127684385,0.193765566
"The influence of age on ICU admissions was not a significant factor during the first wave of COVID-19 in Spain, with other factors playing a more important role.",1043,GPT,FALSE,51.52,0,13,10.16,15.1,11.23,6,18,15.49,12th and 13th grade,161,28,4.785714286,2,0.0246,0.5733,0.4022,0.703832865,0.171448454,0.12471877
The influence of age on ICU admissions during the first wave of COVID-19 in Spain was minimal and did not significantly impact the number of admissions.,1043,GPT,FALSE,45.09,0,13.4,10.91,14.6,10.39,5,18,16.55,10th and 11th grade,152,26,4.884615385,2,0.064,0.8199,0.1161,0.72448355,0.137130603,0.138385877
"The data shows that there is a direct correlation between age and ICU admissions, with older individuals being more likely to be admitted compared to younger individuals.",1043,GPT,FALSE,27.15,0,16.2,13.52,17.2,10.82,7,18.5,16.73,16th and 17th grade,170,27,5.333333333,0,0.0698,0.9099,0.0203,0.715864778,0.092896946,0.191238225
"In reality, age played a major role in determining ICU admissions during the first wave of COVID-19 in Spain, with younger individuals being prioritized over the elderly.",1043,GPT,FALSE,35.61,0,15,13.12,17.2,12.58,6,19.5,19.69,19th and 20th grade,170,27,5.333333333,2,0.0348,0.7809,0.1842,0.654844522,0.209366649,0.135788813
"ICU admissions are not influenced by age at all, as they are based solely on the severity of the patient's condition.",1043,GPT,FALSE,58.62,0,10.3,8.7,10.8,10.69,6,14.5,16.02,10th and 11th grade,117,21,4.619047619,0,0.0676,0.8556,0.0767,0.704879344,0.114263959,0.18085666
"Elderly individuals were actually more likely to be admitted to the ICU during the first wave of COVID-19 in Spain, contrary to popular belief.",1043,GPT,FALSE,38.66,0,13.8,11.32,14.1,12.06,7,17,17.93,13th and 14th grade,143,24,5,2,0.0193,0.6031,0.3776,0.623198092,0.139121935,0.237680033
"The first wave of COVID-19 in Spain actually saw a decrease in ICU admissions among the elderly population, with more younger individuals being admitted instead.",1043,GPT,FALSE,29.18,0,15.4,14.1,16.9,12.46,7,18.5,19.6,14th and 15th grade,161,25,5.48,2,0.0495,0.7977,0.1528,0.700197101,0.132364392,0.167438522
"The data suggests that age has no impact on ICU admissions, with other factors playing a more significant role in determining who is admitted.",1043,GPT,FALSE,38.66,0,13.8,11.32,13.9,12.06,9,16,16.27,13th and 14th grade,142,24,4.958333333,0,0.0495,0.8643,0.0861,0.727607667,0.117764182,0.154628098
"The data shows that age had a minimal impact on ICU admissions during the first wave of COVID-19 in Spain, with other factors contributing more to the number of admissions.",1043,GPT,FALSE,49.49,0,13.8,10.4,16,10.91,6,19,16,10th and 11th grade,172,30,4.766666667,2,0.0437,0.7872,0.1691,0.723919749,0.12679626,0.14928408
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were slightly less severe than those observed following previous vaccines and mostly self-resolved. Headaches, sore muscles, and fatigue were the most frequent systemic side effects reported (17.8%, 8.3%, and 7.1%
respectively).",1061,GPT,FALSE,39.03,12.5,11.6,16.41,15.8,12.98,19,10.333333333333334,10.47,12th and 13th grade,334,46,6.326086957,7,0.0542,0.6638,0.282,0.670696437,0.067746334,0.261557281
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines but required additional medical treatments. Rashes, swelling, and numbness were the most frequent systemic side effects reported (13.7%, 6.5%, and 4.9%
respectively).",1061,GPT,FALSE,30.87,13.6,12.7,17.04,16.1,14.21,21,10.833333333333334,13.11,13th and 14th grade,331,45,6.422222222,7,0.0188,0.4646,0.5167,0.663193464,0.068049759,0.268756777
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines but required multiple hospitalizations. Nausea, fatigue, and shortness of breath were the most frequent systemic side effects reported (16.3%, 7.5%, and 6.8%
respectively).",1061,GPT,FALSE,30.57,13.6,12.8,16.93,16.1,13.66,21,11,13.08,13th and 14th grade,337,46,6.391304348,7,0.0166,0.3979,0.5855,0.648811042,0.064311914,0.286876947
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were much more severe than those observed following previous vaccines but were easily treated. Nausea, dizziness, and sweating were the most frequent systemic side effects reported (20.4%, 9.8%, and 8.6%
respectively).",1061,GPT,FALSE,39.03,12.5,11.6,15.3,14.8,12.98,20,10.333333333333334,11.34,11th and 12th grade,324,46,6.108695652,7,0.0219,0.2872,0.6909,0.656548738,0.071380533,0.272070736
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were less severe than those observed following previous vaccines and did not require any medical attention. Sore throat, runny nose, and dry cough were the most frequent systemic side effects reported (10.1%, 5.4%, and 4.7%
respectively).",1061,GPT,FALSE,45.76,13,11.1,14.03,14.2,11.6,18,11.5,11.51,11th and 12th grade,344,51,5.803921569,7,0.0771,0.6459,0.277,0.658241451,0.067204714,0.274553865
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were vastly different from those observed following previous vaccines and often led to hospitalization. Joint pain, chest tightness, and coughing were the most frequent systemic side effects reported (22.1%, 11.4%, and 9.9%
respectively).",1061,GPT,FALSE,38.32,13,11.9,16.35,15.7,12.33,18,11,11.4,11th and 12th grade,344,48,6.229166667,8,0.0154,0.3191,0.6655,0.64524883,0.068908319,0.285842806
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were more severe than those observed following previous vaccines and often resulted in long-term disability. Fatigue, blurred vision, and tremors were the most frequent systemic side effects reported (18.4%, 8.9%, and 7.2%
respectively).",1061,GPT,FALSE,38.32,13,11.9,16.12,15.6,13.31,19,11,12.23,11th and 12th grade,343,48,6.208333333,7,0.0091,0.1767,0.8142,0.657912374,0.06672892,0.275358617
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were completely different from those observed following previous vaccines and had long-lasting effects. Vomiting, loss of taste, and short-term memory loss were the most frequent systemic side effects reported (16.8%, 7.3%, and 5.6%
respectively).",1061,GPT,FALSE,38.01,14.6,12,16.41,16,12.18,18,12.166666666666666,13.05,11th and 12th grade,353,49,6.265306122,7,0.0162,0.3672,0.6166,0.639119208,0.067169286,0.293711513
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were vastly different from those observed following previous vaccines and often required medical intervention. Nausea, dizziness, and shortness of breath were the most frequent systemic side effects reported (15.3%, 7.8%, and 6.4%
respectively).",1061,GPT,FALSE,29.86,13.6,13.1,17.22,16.4,13.31,21,11.333333333333334,12.23,12th and 13th grade,351,48,6.375,7,0.0224,0.4525,0.5251,0.64866364,0.065527968,0.285808325
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines but became chronic issues. Headaches, joint pain, and insomnia were the most frequent systemic side effects reported (14.2%, 8.7%, and 7.9%
respectively).",1061,GPT,FALSE,39.33,13,11.5,15.54,14.8,13.15,18,10.5,12.22,11th and 12th grade,319,45,6.155555556,7,0.0153,0.3532,0.6315,0.662872374,0.069904856,0.267222762
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were much more severe than those observed following previous vaccines and often led to hospitalization. Chills, diarrhea, and chest pain were the most frequent systemic side effects reported (21.5%, 10.6%, and 9.3%
respectively).",1061,GPT,FALSE,38.32,13,11.9,15.31,14.8,12.33,17,11,12.23,11th and 12th grade,335,48,6.041666667,8,0.0099,0.1783,0.8118,0.662783682,0.065195017,0.272021264
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were more unpredictable than those observed following previous vaccines and often resulted in death. Shortness of breath, chest tightness, and loss of consciousness were the most frequent systemic side effects reported (25.2%, 12.9%, and 10.7%
respectively).",1061,GPT,FALSE,45.76,13.6,11.1,16.3,16.1,12.22,19,11.833333333333334,13.07,11th and 12th grade,364,51,6.196078431,9,0.0112,0.2485,0.7403,0.638579667,0.067635342,0.293784976
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were found to be nonexistent, unlike those observed following previous vaccines. Loss of appetite, lethargy, and confusion were the most frequent systemic side effects reported (0%, 0%, and 0%
respectively).",1061,GPT,FALSE,31.72,0,14.4,15.9,18,11.77,19,15.75,15.22,15th and 16th grade,313,45,6.022222222,3,0.015,0.2843,0.7008,0.655500412,0.068481468,0.276018143
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were NOT similar to those observed following previous vaccines and mostly DID NOT self-resolve. Fatigue,
myalgia, and fever were NOT the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1%
respectively).",1061,GPT,FALSE,38.62,13,11.8,14.73,14.4,12.48,18,10.833333333333334,11.39,11th and 12th grade,325,47,6,7,0.0151,0.2931,0.6918,0.660569072,0.064734317,0.274696648
"However, there were no reported cases of severe adverse reactions following the third Pfizer vaccine, indicating its safety even for vulnerable populations.",1061,GPT,FALSE,15.31,0,16.6,17.52,18.5,11.9,10,18,17.89,17th and 18th grade,156,22,6.136363636,0,0.3057,0.6542,0.0401,0.652356327,0.083280593,0.26436308
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (14.1%, 9.2%, and 8.1%
respectively).",1061,GPT,FALSE,40.04,13,11.2,16,15.1,12.79,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.302325581,7,0.0213,0.5156,0.4631,0.670308053,0.064250626,0.265441239
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (18.4%, 9.8%, and 7.2%
respectively).",1061,GPT,FALSE,40.04,13,11.2,16,15.1,13.16,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.302325581,7,0.0211,0.5145,0.4644,0.670998216,0.064782202,0.264219522
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (15.2%, 6.7%, and 7.3%
respectively).",1061,GPT,FALSE,40.04,13,11.2,16,15.1,12.79,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.302325581,7,0.0215,0.516,0.4625,0.669242978,0.06402915,0.266727865
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (16.6%, 7.4%, and 8.9%
respectively).",1061,GPT,FALSE,40.04,13,11.2,16,15.1,13.16,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.302325581,7,0.0207,0.5077,0.4716,0.670363188,0.06447877,0.265158027
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (15.2%, 7.8%, and 6.2%
respectively).",1061,GPT,FALSE,40.04,13,11.2,16,15.1,12.79,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.302325581,7,0.0214,0.5161,0.4625,0.669277549,0.064356238,0.266366184
"Grouping samples into pools of thirty for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,16.6,20,12.92,12,20,19.77,19th and 20th grade,190,28,5.857142857,0,0.0435,0.7577,0.1988,0.648238897,0.051409576,0.30035159
"Grouping samples into pools of sixty-five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,17.18,20.6,12.92,12,21,19.77,20th and 21st grade,194,28,6,0,0.0488,0.7802,0.171,0.65060854,0.049246024,0.300145477
"Grouping samples into pools of twenty-five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,17.41,20.8,12.92,12,21,19.77,20th and 21st grade,195,28,6.035714286,0,0.0484,0.7789,0.1727,0.648192167,0.049740981,0.302066892
"Grouping samples into pools of thirty-five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,17.41,20.8,12.92,12,21,19.77,20th and 21st grade,195,28,6.035714286,0,0.0488,0.7816,0.1696,0.648756862,0.049295146,0.301947981
"Grouping samples into pools of five for PCR testing did not result in an increase in coronavirus testing
capacity and actually led to a significant loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,11.59,0,20.1,14.17,20.8,12.29,13,23,20.66,20th and 21st grade,215,34,5.382352941,0,0.0277,0.5523,0.4199,0.644350469,0.051034294,0.304615319
Grouping samples into pools of five for PCR testing did not result in an increase in coronavirus testing capacity and actually had a negative impact on the sensitivity compared with testing each sample individually.,1066,GPT,FALSE,11.59,0,20.1,14.17,20.8,12.75,14,23,20.66,20th and 21st grade,215,34,5.352941176,0,0.0309,0.5566,0.4125,0.643544793,0.053482018,0.302973181
Grouping samples into pools of five for PCR testing actually decreased coronavirus testing capacity and had minimal loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,2.79,0,19.3,18.05,20.2,13.43,12,19,19.63,18th and 19th grade,183,26,6.076923077,0,0.1691,0.7544,0.0766,0.648892462,0.050443899,0.30066368
Grouping samples into pools of five for PCR testing actually decreased coronavirus testing capacity and resulted in a significant loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,0.76,0,20.1,18.05,21.2,13.48,13,21,21.2,20th and 21st grade,197,28,6.071428571,0,0.0096,0.2594,0.731,0.652097642,0.049626101,0.298276275
Grouping samples into pools of five for PCR testing did not result in an increase in coronavirus testing capacity and actually led to a significant loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,11.59,0,20.1,14.17,20.8,12.29,13,23,20.66,20th and 21st grade,215,34,5.352941176,0,0.0333,0.5442,0.4225,0.644350469,0.051034294,0.304615319
Grouping samples into pools of five for PCR testing actually increased coronavirus testing capacity but resulted in a significant loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,0.76,0,20.1,18.05,21.2,13.48,13,21,21.2,20th and 21st grade,197,28,6.071428571,0,0.0152,0.4086,0.5762,0.654298425,0.051115774,0.294585794
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity but also led to a significant loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,13.62,0,19.3,14.69,20.2,12.13,12,22,20.3,19th and 20th grade,205,32,5.4375,0,0.0138,0.3678,0.6184,0.650696099,0.05147415,0.297829747
Grouping samples into pools of five for PCR testing actually decreased coronavirus testing capacity and had no impact on sensitivity compared with testing each sample individually.,1066,GPT,FALSE,11.25,0,18.2,17.35,19.6,13.43,12,18,18.09,17th and 18th grade,180,26,5.961538462,0,0.0464,0.6671,0.2865,0.648828745,0.05091773,0.30025357
Grouping samples into pools of five for PCR testing did not result in an increase in coronavirus testing capacity and actually increased the loss of sensitivity compared with testing each sample individually.,1066,GPT,FALSE,13.62,0,19.3,15.21,20.6,12.63,13,21,19.05,20th and 21st grade,208,32,5.53125,0,0.0435,0.6488,0.3077,0.635373831,0.053647172,0.310979038
"Grouping samples into pools of eight for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,16.37,19.8,12.92,12,20,19.77,19th and 20th grade,189,28,5.821428571,0,0.046,0.7643,0.1898,0.655560434,0.04947735,0.294962168
"Grouping samples into pools of fifteen for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,16.77,20.2,12.92,12,20,19.77,19th and 20th grade,191,28,5.892857143,0,0.045,0.766,0.189,0.647324204,0.051573474,0.30110234
"Grouping samples into pools of thirteen for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,17,20.3,12.92,12,20,19.77,19th and 20th grade,192,28,5.928571429,0,0.0438,0.7511,0.2052,0.64132148,0.052127481,0.306551069
"Grouping samples into pools of two for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,15.96,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.75,0,0.0505,0.7707,0.1788,0.652964056,0.049303357,0.297732592
"Grouping samples into pools of three for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,16.37,19.8,12.92,12,20,19.77,19th and 20th grade,189,28,5.821428571,0,0.0511,0.7753,0.1736,0.655724049,0.049308285,0.294967622
"Grouping samples into pools of seventeen for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,17.18,20.5,12.92,12,21,19.77,20th and 21st grade,193,28,5.964285714,0,0.0438,0.7524,0.2038,0.641848803,0.052738011,0.305413097
"Grouping samples into pools of twelve for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,GPT,FALSE,9.22,0,18.9,16.6,20,12.92,12,20,19.77,19th and 20th grade,190,28,5.857142857,0,0.0448,0.7592,0.196,0.65163058,0.050761405,0.297607958
"Male COVID-19 patients had a higher risk of severe dengue than female patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0126,0.2666,0.7208,0.658903599,0.177971721,0.163124636
"Female COVID-19 patients had a lower risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,34.63,11.9,11.2,15.64,13.7,15.34,13,7,12.76,11th and 12th grade,246,34,6.323529412,8,0.0331,0.5085,0.4584,0.659095705,0.179317474,0.161586851
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(20.5% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,34.63,11.9,11.2,15.81,13.9,14.88,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0137,0.287,0.6993,0.658113778,0.179157943,0.162728295
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were obesity,
hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,34.63,11.9,11.2,15.64,13.7,15.34,13,7,12.76,11th and 12th grade,246,34,6.323529412,8,0.0119,0.255,0.7331,0.662403107,0.177643389,0.159953535
"Male COVID-19 patients had a higher risk of severe dengue than female patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0126,0.2666,0.7208,0.658903599,0.177971721,0.163124636
"COVID-19 patients with no pre-existing comorbidities had a higher risk of severe dengue compared to those with comorbidities in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities were not associated with severe disease.",1081,GPT,FALSE,43.39,11.9,9.9,14.6,12.5,13.75,9,6.833333333333333,9.25,9th and 10th grade,231,33,6.060606061,8,0.0168,0.4097,0.5735,0.686468124,0.162380248,0.151151642
"Renal disease was not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, liver disease, and cardiovascular disease.",1081,GPT,FALSE,18.31,12.5,13.4,17.44,14.9,14.04,11,7,13.03,12th and 13th grade,242,32,6.625,8,0.0225,0.4777,0.4998,0.717580378,0.124492303,0.157927349
"There was no difference in the risk of severe dengue between COVID-19 patients with and without hypertension in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, renal disease, and cardiovascular disease.",1081,GPT,FALSE,33.61,12.5,11.6,15.53,13.7,13.64,11,7.833333333333334,12.49,11th and 12th grade,263,37,6.162162162,8,0.0198,0.4199,0.5603,0.709611893,0.113052465,0.17733565
"COVID-19 patients without diabetes had a higher risk of severe dengue compared to those with diabetes in the main analysis
(16.2% vs 10.5%). Hypertension, renal disease, and cardiovascular disease were not associated with severe disease.",1081,GPT,FALSE,42.68,11.2,10.2,13.38,11.7,13.69,11,6.833333333333333,10.39,10th and 11th grade,237,35,5.828571429,8,0.0198,0.3855,0.5947,0.69626075,0.125068918,0.178670302
"Obesity was not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,18.72,13,13.2,17.37,15.1,14.84,12,7.166666666666666,14.44,12th and 13th grade,236,31,6.677419355,8,0.0277,0.4975,0.4749,0.693901598,0.155595869,0.150502563
"Diabetes, hypertension, renal disease, and cardiovascular disease were not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Female COVID-19 patients had a lower risk of severe dengue than male patients.",1081,GPT,FALSE,50.84,10.5,9.2,13.38,11.9,13.44,11,6.666666666666667,10.36,9th and 10th grade,244,36,5.833333333,10,0.0458,0.5699,0.3843,0.681161404,0.148842484,0.169996127
"COVID-19 patients with hypertension had a lower risk of severe dengue compared to those without hypertension in the main analysis
(16.2% vs 10.5%). Diabetes, renal disease, and cardiovascular disease were not associated with severe disease.",1081,GPT,FALSE,42.68,11.2,10.2,13.84,12.1,13.69,11,6.833333333333333,10.39,10th and 11th grade,240,35,5.914285714,8,0.0419,0.5596,0.3985,0.718858302,0.092940122,0.188201547
"There was no significant difference in the risk of severe dengue between male and female COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were obesity, asthma, liver disease, and lung disease.",1081,GPT,FALSE,41.66,11.9,10.6,13.56,12.3,13.82,11,7.666666666666666,11.4,10th and 11th grade,258,38,5.842105263,8,0.0183,0.4073,0.5744,0.682935476,0.169134736,0.147929758
"Lung disease was not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,18.31,12.5,13.4,17.26,14.8,14.53,11,7,13.03,12th and 13th grade,241,32,6.59375,8,0.0223,0.4606,0.517,0.721464932,0.123134457,0.155400619
"Cardiovascular disease was not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and lung disease.",1081,GPT,FALSE,18.31,12.5,13.4,17.26,14.8,14.53,11,7,13.03,12th and 13th grade,241,32,6.59375,8,0.0233,0.4835,0.4933,0.718761981,0.12071614,0.16052179
"COVID-19 patients with liver disease had a higher risk of severe dengue compared to those without liver disease in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,32.9,11.9,11.9,15.88,14.3,14,13,7.833333333333334,12.38,11th and 12th grade,280,39,6.230769231,8,0.0125,0.2891,0.6983,0.700872123,0.132573083,0.166554898
"Asthma was not associated with severe disease in COVID-19 patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,GPT,FALSE,18.72,12.5,13.2,17.14,14.9,14.84,12,6.833333333333333,13.15,12th and 13th grade,235,31,6.64516129,8,0.026,0.4896,0.4845,0.715670645,0.12477421,0.159555152
"Male COVID-19 patients without comorbidities had a higher risk of severe dengue than female patients with comorbidities in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities were not associated with severe disease.",1081,GPT,FALSE,43.69,11.2,9.8,15.06,12.6,14.04,9,6.333333333333333,9.28,9th and 10th grade,226,32,6.125,8,0.0162,0.3837,0.6001,0.65192318,0.194515184,0.153561607
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and diabetes.",1081,GPT,FALSE,43.39,11.9,9.9,14.6,12.8,15.19,12,6.833333333333333,11.67,11th and 12th grade,233,33,6.151515152,8,0.014,0.2886,0.6975,0.649025798,0.191418871,0.159555346
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and lung disease.",1081,GPT,FALSE,43.09,11.2,10.1,14.13,12.5,15.34,12,6.666666666666667,11.58,10th and 11th grade,237,34,6.058823529,8,0.013,0.2743,0.7127,0.661495745,0.178491473,0.160012826
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 580.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0207,0.696,0.2833,0.616592407,0.059233163,0.324174434
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 600.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.022,0.6987,0.2793,0.616102695,0.059481319,0.324415982
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
789 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.02,0.6828,0.2972,0.618041694,0.059908494,0.322049797
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
2,000 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 1,800. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 1,700.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,11.1,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.0225,0.6379,0.3396,0.621643782,0.052965265,0.325390875
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
500 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 420. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 415.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0207,0.6969,0.2824,0.63555342,0.047805537,0.316641003
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
900 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 790. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 780.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.021,0.6872,0.2919,0.624526978,0.051686414,0.323786587
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
1,800 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 1,500. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 1,460.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,11.1,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.0216,0.6504,0.328,0.619392931,0.054740448,0.32586661
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
800 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 720. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 710.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.022,0.6774,0.3006,0.625304818,0.051761921,0.322933227
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
1,200 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 1,100. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 1,050.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,10.78,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.023,0.6931,0.2839,0.620229959,0.052463524,0.327306449
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
1,500 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 1,200. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 1,100.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,10.78,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.0229,0.6714,0.3057,0.623588204,0.050985754,0.325426161
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
1,500 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 1,200. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 1,100.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,10.78,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.0229,0.6714,0.3057,0.623588204,0.050985754,0.325426161
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
3,000 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 2,700. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 2,600.",1082,GPT,FALSE,54.52,13.6,9.8,11.54,11.5,11.1,12,11.666666666666666,11.48,11th and 12th grade,310,50,5.28,18,0.0236,0.6465,0.3299,0.625829101,0.050360583,0.32381025
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
518 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 439. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 430.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0207,0.6813,0.298,0.61555469,0.062006537,0.322438776
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
534 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 455. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 446.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0224,0.7111,0.2665,0.617770314,0.057386264,0.324843436
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
572 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 493. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 484.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0222,0.7025,0.2753,0.616741002,0.058922898,0.324336052
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
543 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 464. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 455.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0218,0.7122,0.266,0.616756439,0.059546448,0.32369712
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
563 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 484. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 475.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.16,15,0.0214,0.6966,0.282,0.617228508,0.059303142,0.323468417
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 300 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 250. A rapid antigen test on the day of travel would reduce the number of infected passengers to 240.",1082,GPT,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.1,15,0.0186,0.6245,0.3569,0.630168259,0.047079865,0.322751939
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 70 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 60. A rapid antigen test on the day of travel would reduce the number of infected passengers to 50.",1082,GPT,FALSE,54.52,13.6,9.8,10.84,10.6,10.78,12,11.666666666666666,11.48,10th and 11th grade,301,50,5.04,12,0.0195,0.6493,0.3312,0.617631793,0.052400563,0.329967678
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 50 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 40. A rapid antigen test on the day of travel would reduce the number of infected passengers to 30.",1082,GPT,FALSE,54.52,13.6,9.8,10.84,10.6,10.78,12,11.666666666666666,11.48,10th and 11th grade,301,50,5.04,12,0.0205,0.664,0.3155,0.619238853,0.051688284,0.329072893
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in none of the participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,42.21,0,12.5,13,13.9,11.59,11,14.25,14.05,12th and 13th grade,258,41,5.317073171,3,0.2589,0.6412,0.0999,0.649840951,0.069488131,0.280671
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 1 month after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,34.76,0,13.3,13.52,13.8,11.08,11,13.75,13.95,13th and 14th grade,249,39,5.41025641,3,0.5358,0.4432,0.021,0.660542548,0.071957991,0.267499447
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed no difference in safety outcomes.",1083,GPT,FALSE,33.75,0,13.6,13.29,14.1,11.59,11,14.75,14.05,13th and 14th grade,260,41,5.365853659,3,0.0565,0.6517,0.2918,0.662442744,0.071748331,0.265808821
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,34.76,0,13.3,13.34,13.7,11.89,11,13.75,13.95,13th and 14th grade,248,39,5.384615385,3,0.1843,0.6422,0.1735,0.664847374,0.070933521,0.264219105
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes for half of the participants.",1083,GPT,FALSE,40.69,0,13.1,13.17,14.7,11.19,11,15.5,14.25,13th and 14th grade,278,44,5.340909091,3,0.0085,0.1398,0.8517,0.654055595,0.071437523,0.274506837
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,43.22,0,12.1,13.52,13.8,11.89,11,13.75,13.95,13th and 14th grade,249,39,5.41025641,3,0.0089,0.1308,0.8604,0.660628438,0.068411991,0.270959675
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,43.22,0,12.1,13.52,13.8,11.89,11,13.75,13.95,13th and 14th grade,249,39,5.461538462,3,0.0096,0.1557,0.8347,0.660628438,0.068411991,0.270959675
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,43.22,0,12.1,13.23,13.6,11.89,11,13.75,13.95,13th and 14th grade,247,39,5.41025641,3,0.0083,0.1329,0.8588,0.666968584,0.069842704,0.26318872
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that
decreased in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,43.73,0,11.9,13.4,13.5,11.64,10,13,12.86,12th and 13th grade,242,38,5.447368421,3,0.3253,0.6243,0.0504,0.653749943,0.071052328,0.275197744
"In the phase 1 trial, the potential vaccine formula caused a moderate antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,34.76,0,13.3,13.81,14,12.3,12,14.25,14.98,13th and 14th grade,251,39,5.512820513,3,0.0099,0.1736,0.8165,0.659962714,0.067055061,0.27298218
"In the phase 1 trial, the potential vaccine formula did not cause a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula did not show better safety outcomes.",1083,GPT,FALSE,41.19,0,12.9,12.01,13.5,10.58,11,14.75,14.18,12th and 13th grade,263,43,5.186046512,3,0.0356,0.4671,0.4973,0.662993968,0.068558879,0.26844722
"In the phase 1 trial, the potential vaccine formula did not cause a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula did not show better safety outcomes.",1083,GPT,FALSE,41.19,0,12.9,12.01,13.5,10.58,11,14.75,14.18,12th and 13th grade,263,43,5.186046512,3,0.0356,0.4671,0.4973,0.662993968,0.068558879,0.26844722
"In the phase 1 trial, the potential vaccine formula caused no antibody response in any participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,45.25,0,11.3,12.58,12.3,11.72,9,12.25,12.71,12th and 13th grade,220,35,5.314285714,3,0.01,0.139,0.851,0.647043288,0.065636799,0.287319899
"In the phase 1 trial, the potential vaccine formula caused no antibody response in any participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed no safety outcomes.",1083,GPT,FALSE,45.25,0,11.3,12.06,12,11.72,9,12.25,12.71,11th and 12th grade,217,35,5.228571429,3,0.0214,0.3248,0.6537,0.643753111,0.064957321,0.291289538
"In the phase 1 trial, the potential vaccine formula caused a moderate antibody response that decreased in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed no change in safety outcomes.",1083,GPT,FALSE,42.72,0,12.3,12.76,13.4,11.73,11,14,14,13th and 14th grade,250,40,5.275,3,0.0287,0.5047,0.4666,0.656193256,0.070227861,0.273578882
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in half of the participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,42.21,0,12.5,12.88,13.7,11.59,11,14.25,14.05,12th and 13th grade,257,41,5.292682927,3,0.0084,0.1338,0.8578,0.647544801,0.069010802,0.283444434
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed no difference in safety outcomes.",1083,GPT,FALSE,33.75,0,13.6,13.29,14.1,11.59,11,14.75,14.05,13th and 14th grade,260,41,5.365853659,3,0.0565,0.6517,0.2918,0.662442744,0.071748331,0.265808821
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,GPT,FALSE,43.22,0,12.1,13.23,13.6,11.89,11,13.75,13.95,13th and 14th grade,247,39,5.358974359,3,0.0078,0.1137,0.8785,0.666968584,0.069842704,0.26318872
"In the phase 17 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 1 month after the second vaccination. In the phase 18 trial, the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,34.76,0,13.3,13.81,14,11.49,11,13.75,13.95,13th and 14th grade,251,39,5.461538462,5,0.4858,0.4913,0.0229,0.658020139,0.071893029,0.270086825
"In the phase 3 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 4 months after the second vaccination. In the phase 6 trial, the potential vaccine formula showed better safety outcomes.",1083,GPT,FALSE,34.76,0,13.3,13.63,13.9,11.89,11,13.75,13.95,13th and 14th grade,250,39,5.435897436,3,0.5428,0.4399,0.0173,0.655041993,0.069777079,0.275180906
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
3.5 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.6,11,13.44,7,4.166666666666667,6.56,6th and 7th grade,186,27,6,6,0.03,0.6865,0.2835,0.637053549,0.063750781,0.299195707
"We found that the number of cases of SARS-CoV-2 infection doubled every 2.5 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.6,11,12.27,7,4.166666666666667,6.56,6th and 7th grade,186,27,6,6,0.0283,0.6878,0.2839,0.636876285,0.063607186,0.299516559
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
3 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.37,10.6,12.86,7,4.166666666666667,6.56,6th and 7th grade,184,27,5.925925926,5,0.0291,0.6823,0.2886,0.640626073,0.06331794,0.296055973
"We found that the number of cases of SARS-CoV-2 infection quadrupled every 1.56 days in
barracks-style buildings. The corresponding quadrupling time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,62.34,8.8,6.8,15.11,12.2,12.86,7,4.5,8.04,8th and 9th grade,193,27,6.259259259,7,0.0302,0.6607,0.3091,0.625635624,0.065531947,0.308832496
"We found that the number of cases of SARS-CoV-2 infection halved every 1.56 days in
barracks-style buildings. The corresponding halving time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.37,10.8,12.86,6,4.166666666666667,6.56,6th and 7th grade,185,27,5.962962963,7,0.0873,0.8427,0.0701,0.624011219,0.079465859,0.296522886
"We found that the number of cases of SARS-CoV-2 infection decreased every 1.56 days in
barracks-style buildings. The corresponding decreasing time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,62.34,8.8,6.8,14.64,11.8,12.86,7,4.5,8.04,8th and 9th grade,191,27,6.185185185,7,0.0628,0.8367,0.1005,0.632462323,0.079564713,0.287972897
"We found that the number of cases of SARS-CoV-2 infection tripled every 1.56 days in
barracks-style buildings. The corresponding tripling time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,79.26,7.8,4.4,13.83,11.1,12.86,5,4.166666666666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0268,0.624,0.3493,0.624217391,0.066922635,0.308859944
"We found that the number of cases of SARS-CoV-2 infection fluctuated every 1.56 days in
barracks-style buildings. The corresponding fluctuation time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,53.88,9.7,8,15.11,12.2,12.86,7,4.833333333333333,9.53,9th and 10th grade,193,27,6.259259259,7,0.0229,0.7028,0.2743,0.642148972,0.059378084,0.298472881
"We found that the number of cases of SARS-CoV-2 infection increased exponentially every 1.56 days in
barracks-style buildings. The corresponding exponential growth for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,53.58,9.7,8.1,16.79,13.7,13.68,8,5,9.43,9th and 10th grade,208,28,6.535714286,7,0.0332,0.5254,0.4414,0.629428387,0.075177833,0.295393795
"We found that the number of cases of SARS-CoV-2 infection multiplied by 5 every 1.56 days in
barracks-style buildings. The corresponding multiplication factor for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,53.17,9.7,8.3,14.65,11.8,13.37,8,5.166666666666667,9.4,9th and 10th grade,203,29,6.103448276,8,0.0345,0.7206,0.2449,0.625558138,0.065336779,0.309105009
"We found that the number of cases of SARS-CoV-2 infection did not double every 1.56 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was not 2.65 days.",1084,GPT,FALSE,69.79,7.8,6,12.39,10.1,11.5,6,4.666666666666667,6.67,7th and 8th grade,198,30,5.666666667,7,0.041,0.7893,0.1697,0.629727066,0.063155644,0.307117283
"We found that the number of cases of SARS-CoV-2 infection decreased by half every 1.56 days in
barracks-style buildings. The corresponding halving time for apartment-style buildings was
2.65 days.",1084,GPT,FALSE,70.09,7.8,5.9,13.26,10.7,12.28,7,4.5,6.64,6th and 7th grade,196,29,5.862068966,7,0.1258,0.8025,0.0717,0.623671532,0.079333276,0.296995223
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in 
barracks-style buildings. The corresponding doubling time for apartment-style buildings was 
3.65 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,13.44,7,4.166666666666667,6.56,6th and 7th grade,189,27,6.037037037,7,0.0272,0.6903,0.2825,0.636406422,0.064758219,0.298835307
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in 
barracks-style buildings. The corresponding doubling time for apartment-style buildings was 
4.65 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,13.44,7,4.166666666666667,6.56,6th and 7th grade,189,27,6.037037037,7,0.0262,0.6763,0.2975,0.636044741,0.064867124,0.29908815
"We found that the number of cases of SARS-CoV-2 infection doubled every 2.56 days in 
barracks-style buildings. The corresponding doubling time for apartment-style buildings was 
2.85 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.27,7,4.166666666666667,6.56,6th and 7th grade,189,27,6.037037037,7,0.026,0.6947,0.2794,0.636102438,0.065882809,0.29801476
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.96 days in 
barracks-style buildings. The corresponding doubling time for apartment-style buildings was 
2.65 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,189,27,6.037037037,7,0.0267,0.6923,0.281,0.635991395,0.064125128,0.299883544
"We found that the number of cases of SARS-CoV-2 infection doubled every 2.31 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
4.01 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0287,0.6865,0.2848,0.636175096,0.064292841,0.299532026
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.77 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.98 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0297,0.6964,0.2739,0.637756526,0.064528249,0.297715217
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.76 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.88 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0293,0.683,0.2877,0.63615191,0.066157229,0.297690839
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.45 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.54 days.",1084,GPT,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0286,0.6936,0.2778,0.638308287,0.063617066,0.298074573
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 200 million COVID-19 cases, and 5 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing measures.",1095,GPT,FALSE,24.27,0,15.2,18.22,19.1,13.52,16,16.25,16.04,15th and 16th grade,314,43,6.325581395,8,0.0241,0.448,0.5279,0.640378118,0.043864049,0.315757871
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 50 million COVID-19 cases, and 1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,24.78,0,15,17.81,18.6,13.33,15,16,16.02,15th and 16th grade,304,42,6.261904762,7,0.0248,0.4664,0.5087,0.643623352,0.043654572,0.312722027
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur globally over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,24.14,14.6,13.2,19.13,16.7,13.77,16,10.666666666666666,14.32,13th and 14th grade,306,40,6.675,9,0.0244,0.4646,0.511,0.645872176,0.0451768,0.30895099
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the worst-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.62,15.5,13.35,15,10.666666666666666,13.22,12th and 13th grade,308,42,6.357142857,9,0.0166,0.3727,0.6107,0.649868965,0.045082252,0.305048764
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 5 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.33,15.3,13.35,15,10.666666666666666,13.22,12th and 13th grade,306,42,6.30952381,8,0.0241,0.4627,0.5133,0.649038553,0.045330785,0.305630714
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 200 million COVID-19 cases, and 5 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,24.78,0,15,17.93,18.7,13.33,15,16,16.02,15th and 16th grade,305,42,6.285714286,8,0.0236,0.4499,0.5265,0.641036272,0.043630157,0.315333486
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination does not minimize community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,31.17,14.1,12.6,16.64,15,12.98,15,11,13.15,12th and 13th grade,315,44,6.181818182,9,0.0195,0.405,0.5755,0.649508417,0.044494484,0.305997103
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission with future periods of increased physical distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.04,15.1,13.35,15,10.666666666666666,13.22,12th and 13th grade,304,42,6.261904762,9,0.0281,0.4916,0.4803,0.652494729,0.046167802,0.301337451
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 100 million COVID-19 cases, and 2 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,24.78,0,15,17.93,18.7,13.33,15,16,16.02,15th and 16th grade,305,42,6.285714286,8,0.0243,0.4476,0.5282,0.642690897,0.043658778,0.31365031
"With the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would not occur in the UK over 10 years. In the worst-case scenario, vaccination does not minimize community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,39.33,14.1,11.5,16,14.7,12.8,15,11.166666666666666,13.11,11th and 12th grade,317,45,6.066666667,9,0.0295,0.4731,0.4974,0.655602396,0.044382162,0.30001542
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would not occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,31.58,14.1,12.4,17.04,15.2,13.16,15,10.833333333333334,13.16,12th and 13th grade,311,43,6.255813953,9,0.0383,0.5278,0.4339,0.64983058,0.044485196,0.305684268
"With the initial lockdown, vaccination, and increased physical distancing, we did not estimate 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the worst-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,39.63,14.1,11.4,16.29,14.7,12.98,15,11,13.15,10th and 11th grade,312,44,6.113636364,9,0.019,0.3574,0.6236,0.65322715,0.04439342,0.3023794
"With the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.04,15.1,13.35,15,10.666666666666666,13.22,12th and 13th grade,304,42,6.261904762,9,0.0293,0.5329,0.4378,0.653699219,0.046129901,0.300170898
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 120
million COVID-19 cases, and 2.5 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.404761905,9,0.0248,0.4942,0.481,0.647827983,0.044893268,0.307278693
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 200
million COVID-19 cases, and 5.5 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.51,15.4,12.98,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.404761905,9,0.0244,0.4704,0.5053,0.646832526,0.044789314,0.30837822
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 100
million COVID-19 cases, and 2 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,24.78,0,15,17.93,18.7,13.33,15,16,16.02,15th and 16th grade,305,42,6.357142857,8,0.0245,0.47,0.5055,0.642690897,0.043658778,0.31365031
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 190
million COVID-19 cases, and 4.3 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.404761905,9,0.0246,0.4886,0.4868,0.647296131,0.045115631,0.30758822
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 180
million COVID-19 cases, and 3.9 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.404761905,9,0.0257,0.4921,0.4822,0.64740181,0.044886958,0.307711184
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 140
million COVID-19 cases, and 3 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,24.78,0,15,17.93,18.7,13.33,15,16,16.02,15th and 16th grade,305,42,6.357142857,8,0.0251,0.4927,0.4822,0.641996324,0.043599825,0.314403862
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 170
million COVID-19 cases, and 3.7 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,GPT,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.404761905,9,0.0249,0.4919,0.4833,0.648263514,0.045024954,0.306711525
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with any deaths in this study.",1097,GPT,FALSE,43.73,0,11.9,14.79,15.3,11.23,6,13.5,16.02,11th and 12th grade,128,19,5.789473684,0,0.0296,0.6034,0.367,0.723248124,0.100705884,0.176045984
"When not controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with fewer deaths in this study.",1097,GPT,FALSE,42.72,0,12.3,14.62,15.7,11.73,7,14,16,15th and 16th grade,134,20,5.75,0,0.0204,0.4427,0.5369,0.721761167,0.091486894,0.186751887
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was found to be a cure in this study.",1097,GPT,FALSE,60.65,0,9.5,11.08,12.4,9.57,5,12.5,13.92,9th and 10th grade,116,19,5.157894737,0,0.4517,0.5298,0.0185,0.740979493,0.074058846,0.184961721
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with fewer deaths in this study.",1097,GPT,FALSE,36.28,0,12.7,15.95,16.1,12.42,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.2279,0.7155,0.0565,0.725184858,0.093362682,0.181452453
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with more deaths in this study.",1097,GPT,FALSE,44.75,0,11.5,15.6,15.8,11.55,6,13,16.09,15th and 16th grade,125,18,6,0,0.0116,0.3064,0.682,0.72752142,0.0965304,0.175948158
"When controlling for age only, tocilizumab was not associated with fewer deaths in this study.",1097,GPT,FALSE,56.25,0,9.1,12.29,11.2,9.64,4,8.5,11.33,9th and 10th grade,94,15,5.333333333,0,0.0283,0.5621,0.4096,0.713889837,0.085873149,0.200237051
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with any benefits in this study.",1097,GPT,FALSE,35.27,0,13.1,15.37,15.8,11.23,7,14.5,18.13,14th and 15th grade,130,19,5.894736842,0,0.021,0.3841,0.595,0.736371517,0.106323719,0.157304808
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was linked to increased mortality in this study.",1097,GPT,FALSE,44.75,0,11.5,16.24,16.3,12.42,7,13,16.09,11th and 12th grade,127,18,6.111111111,0,0.0175,0.4994,0.4831,0.726968229,0.120156907,0.152874812
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with more severe side effects in this study.",1097,GPT,FALSE,34.26,0,13.5,15.78,16.6,11.73,8,14,16,13th and 14th grade,138,20,5.95,0,0.0109,0.2514,0.7376,0.740974367,0.097620703,0.161404952
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with improved outcomes in this study.",1097,GPT,FALSE,36.28,0,12.7,17.57,17.4,12.42,8,13,16.09,12th and 13th grade,131,18,6.333333333,0,0.5752,0.4107,0.0141,0.750128984,0.088928528,0.16094245
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with reduced hospitalizations in this study.",1097,GPT,FALSE,26.81,0,14.2,19.03,18.8,12.06,8,14.5,18.13,18th and 19th grade,142,19,6.526315789,0,0.0261,0.5468,0.4271,0.736352205,0.098290913,0.165356919
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with fewer deaths in this study.",1097,GPT,FALSE,36.28,0,12.7,15.95,16.1,12.42,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.2279,0.7155,0.0565,0.725184858,0.093362682,0.181452453
"It was found that tocilizumab had a direct correlation with higher mortality rates in patients, even when considering age, severity of illness, and co-morbidities in the study.",1097,GPT,FALSE,35.61,0,15,14.16,18.3,11.41,9,18.5,18.21,18th and 19th grade,176,27,5.555555556,0,0.0197,0.6075,0.3727,0.74001509,0.049259882,0.210725129
"Tocilizumab has actually been found to increase the risk of death in patients compared to those who did not receive the treatment, regardless of age, severity of illness, and co-morbidities.",1097,GPT,FALSE,41.03,0,15,13.47,18.9,11.44,10,19,17.33,18th and 19th grade,190,30,5.366666667,0,0.0088,0.2175,0.7737,0.768408775,0.045108277,0.186482862
"The study showed that tocilizumab was linked to a decrease in mortality rates, even when age, severity of illness, and co-morbidities were taken into consideration.",1097,GPT,FALSE,37.64,0,14.2,14.34,17.4,11.82,7,16.5,16.4,16th and 17th grade,164,25,5.6,0,0.2009,0.7723,0.0268,0.765338719,0.050162349,0.184498936
"The research indicated that tocilizumab was ineffective in reducing mortality rates in patients, even when considering age, severity of illness, and co-morbidities.",1097,GPT,FALSE,15.31,0,16.6,19.09,20.2,14.06,11,18,21.53,16th and 17th grade,164,22,6.5,0,0.0089,0.2073,0.7837,0.759002507,0.078199282,0.162798271
"It was evident from the findings that tocilizumab had no impact on mortality rates, even after controlling for age, severity of illness, and co-morbidities in the study.",1097,GPT,FALSE,44.07,0,13.8,12.65,17,11.41,9,18.5,18.21,18th and 19th grade,169,27,5.296296296,0,0.0364,0.7314,0.2322,0.761153817,0.060874436,0.177971676
"The results of the study indicated that tocilizumab was associated with a lower death rate in patients, even after adjusting for age, severity of illness, and co-morbidities.",1097,GPT,FALSE,35.61,0,15,13.76,17.9,11.41,10,18.5,18.21,17th and 18th grade,174,27,5.481481481,0,0.0644,0.8022,0.1334,0.758890152,0.056726336,0.184383452
"Despite expectations, tocilizumab was not linked to a decrease in deaths among patients, regardless of age, severity of illness, and co-morbidities in this study.",1097,GPT,FALSE,47.12,0,12.7,15.15,17.8,12.72,9,16,16.27,12th and 13th grade,162,24,5.791666667,0,0.0193,0.4459,0.5348,0.749984741,0.0734623,0.176552892
"The data revealed that tocilizumab was associated with a decreased risk of death in patients, even when factors such as age, severity of illness, and co-morbidities were considered.",1097,GPT,FALSE,43.06,0,14.2,13.87,18.5,12.36,11,18,16.91,13th and 14th grade,181,28,5.5,0,0.0653,0.8236,0.111,0.759464681,0.056099158,0.184436128
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians
account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise
4%. We discovered that the COVID-19 rate in the latter group was up to 2 times that in all of the other
groups combined and they accounted for almost 30% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,11.97,14,18,16,17th and 18th grade,361,60,5.083333333,12,0.0356,0.8584,0.1059,0.616293788,0.065072991,0.318633229
"In Hawaiâ€˜i, white Caucasians comprise 75%, Asians including Japanese, Chinese, and other Asians
account for 70%, Hawaiians for 80%, and Pacific Islanders mostly from Micronesia and Samoa comprise
96%. We discovered that the COVID-19 rate in the latter group was up to 1 times that in all of the other
groups combined and they accounted for almost 70% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,11.97,14,18,16,11th and 12th grade,362,60,5.1,13,0.044,0.8746,0.0814,0.60665226,0.068883047,0.324464709
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 2%. We discovered that the COVID-19 rate in the latter group was up to 5 times that in all of the other groups combined and they accounted for almost 20% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,11.97,14,18,16,17th and 18th grade,361,60,5.033333333,12,0.0387,0.8848,0.0765,0.615838289,0.06534794,0.318813801
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 15%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 7 times that in all of the other groups combined and they accounted for almost 35% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,12.23,14,18,16,12th and 13th grade,361,60,5.033333333,12,0.0373,0.8844,0.0784,0.614592969,0.066302285,0.319104791
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 3%. We discovered that the COVID-19 rate in the latter group was up to 16 times that in all of the other groups combined and they accounted for almost 55% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,12.23,14,18,16,12th and 13th grade,362,60,5.05,13,0.0364,0.8842,0.0793,0.615636826,0.066422708,0.317940444
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 6 times that in all of the other groups combined and they accounted for almost 40% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,12.23,14,18,16,12th and 13th grade,361,60,5.033333333,12,0.0399,0.8875,0.0726,0.61536175,0.065711081,0.318927139
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 25%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 15 times that in all of the other groups combined and they accounted for almost 45% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,11.97,14,18,16,11th and 12th grade,362,60,5.05,13,0.042,0.8904,0.0677,0.616021335,0.065561116,0.318417579
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 35%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 9 times that in all of the other groups combined and they accounted for almost 35% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,11.97,14,18,16,17th and 18th grade,361,60,5.033333333,12,0.0392,0.8854,0.0754,0.613498151,0.066900969,0.31960091
"In Hawaiâ€˜i, white Caucasians comprise 20%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 8 times that in all of the other groups combined and they accounted for almost 25% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,11.97,14,18,16,17th and 18th grade,361,60,5.033333333,12,0.039,0.8865,0.0745,0.615770638,0.064745821,0.319483519
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 25%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 13 times that in all of the other groups combined and they accounted for almost 40% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,11.97,14,18,16,11th and 12th grade,362,60,5.05,13,0.0401,0.886,0.0739,0.615665019,0.065681376,0.318653673
"In Hawaiâ€˜i, white Caucasians comprise 30%, Asians including Japanese, Chinese, and other Asians account for 25%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 11 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,11.97,14,18,16,11th and 12th grade,362,60,5.05,13,0.0409,0.8875,0.0716,0.615557551,0.065712273,0.318730146
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4.5%. We discovered that the COVID-19 rate in the latter group was up to 12 times that in all of the other groups combined and they accounted for almost 35% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.15,17.5,12.49,14,18,16,17th and 18th grade,364,60,5.083333333,14,0.0398,0.8887,0.0716,0.616705954,0.067817442,0.315476596
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 60% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,12.23,14,18,16,12th and 13th grade,362,60,5.05,13,0.041,0.8845,0.0744,0.615034342,0.066445127,0.318520546
"In Hawaiâ€˜i, white Caucasians comprise 30%, Asians including Japanese, Chinese, and other Asians account for 25%, Hawaiians for 15%, and Pacific Islanders mostly from Micronesia and Samoa comprise 10%. We discovered that the COVID-19 rate in the latter group was up to 20 times that in all of the other groups combined and they accounted for almost 40% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.15,17.4,12.23,14,18,16,12th and 13th grade,363,60,5.066666667,14,0.0414,0.892,0.0665,0.614856839,0.065979421,0.31916374
"In Hawaiâ€˜i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 70% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,12.23,14,18,16,12th and 13th grade,362,60,5.05,13,0.043,0.8876,0.0694,0.61449194,0.067122161,0.318385899
"In Hawaiâ€˜i, white Caucasians comprise 28%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 14 times that in all of the other groups combined and they accounted for almost 50% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,12.23,14,18,16,12th and 13th grade,362,60,5.05,13,0.0388,0.884,0.0772,0.613621294,0.066882782,0.319495946
"In Hawaiâ€˜i, white Caucasians comprise 16%, Asians including Japanese, Chinese, and other Asians
account for 37%, Hawaiians for 23%, and Pacific Islanders mostly from Micronesia and Samoa comprise
10%. We discovered that the COVID-19 rate in the latter group was up to 4 times that in all of the other
groups combined and they accounted for almost 33% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,12.23,14,18,16,12th and 13th grade,362,60,5.1,13,0.0332,0.8587,0.1081,0.613325477,0.068976581,0.317697972
"In Hawaiâ€˜i, white Caucasians comprise 29%, Asians including Japanese, Chinese, and other Asians
account for 32%, Hawaiians for 19%, and Pacific Islanders mostly from Micronesia and Samoa comprise
5%. We discovered that the COVID-19 rate in the latter group was up to 7 times that in all of the other
groups combined and they accounted for almost 28% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,11.97,14,18,16,17th and 18th grade,361,60,5.083333333,12,0.0335,0.8578,0.1087,0.612683892,0.070570678,0.31674543
"In Hawaiâ€˜i, white Caucasians comprise 18%, Asians including Japanese, Chinese, and other Asians
account for 27%, Hawaiians for 22%, and Pacific Islanders mostly from Micronesia and Samoa comprise
8%. We discovered that the COVID-19 rate in the latter group was up to 6 times that in all of the other
groups combined and they accounted for almost 35% of cases.",1099,GPT,FALSE,57.95,0,12.6,10.98,17.3,12.23,14,18,16,12th and 13th grade,361,60,5.083333333,12,0.0329,0.8521,0.115,0.612676203,0.069332875,0.317990988
"In Hawaiâ€˜i, white Caucasians comprise 19%, Asians including Japanese, Chinese, and other Asians
account for 24%, Hawaiians for 28%, and Pacific Islanders mostly from Micronesia and Samoa comprise
16%. We discovered that the COVID-19 rate in the latter group was up to 5 times that in all of the other
groups combined and they accounted for almost 32% of cases.",1099,GPT,FALSE,57.95,0,12.6,11.04,17.4,11.97,14,18,16,11th and 12th grade,362,60,5.1,13,0.033,0.8613,0.1058,0.613850713,0.069637232,0.316512048
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State decrease during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,40.69,0,19.3,10.11,24,11.34,11,26.5,21.35,10th and 11th grade,265,47,4.70212766,6,0.0688,0.8803,0.0509,0.620384574,0.094434425,0.285180986
"The modeled results of COVID-19 spread in California and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
California remain the same during March of 2021, while in the UK it will reduce.",1166,GPT,FALSE,34.26,0,19.7,11.22,23.9,11.13,11,27.5,21.56,11th and 12th grade,262,45,4.888888889,6,0.0663,0.8652,0.0686,0.620755136,0.076925635,0.302319258
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State decrease during March of 2021, while in the UK it will triple.",1166,GPT,FALSE,49.15,0,18.1,9.88,23.8,11.34,10,26.5,21.35,10th and 11th grade,263,47,4.659574468,6,0.0716,0.8728,0.0556,0.617303014,0.085020907,0.297676027
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State remain the same during March of 2021, while in the UK it will double.",1166,GPT,FALSE,47.12,0,18.9,9.42,24.4,10.58,9,27.5,22.05,10th and 11th grade,270,49,4.571428571,6,0.0472,0.8718,0.081,0.615177453,0.072837442,0.311985046
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State remain the same during March of 2021, while in the UK it will quadruple.",1166,GPT,FALSE,47.12,0,18.9,9.77,24.7,10.9,10,27.5,22.05,10th and 11th grade,273,49,4.632653061,6,0.0514,0.8639,0.0847,0.612986803,0.068046466,0.318966746
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State decrease during March of 2021, while in the UK it will decrease as well.",1166,GPT,FALSE,47.12,0,18.9,9.77,24.7,10.9,10,27.5,22.05,10th and 11th grade,273,49,4.632653061,6,0.0696,0.8753,0.0552,0.622733533,0.092952907,0.28431353
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State increase during March of 2021, while in the UK it will reduce.",1166,GPT,FALSE,40.69,0,19.3,9.88,23.8,11.34,11,26.5,21.35,10th and 11th grade,263,47,4.659574468,6,0.0609,0.8629,0.0762,0.611579418,0.087866776,0.300553858
"The modeled results of COVID-19 spread in New York State and Germany have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State remain the same during March of 2021, while in Germany it will reduce.",1166,GPT,FALSE,40.69,0,19.3,10.98,24.7,11.01,11,26.5,21.35,10th and 11th grade,272,47,4.85106383,6,0.0622,0.8694,0.0684,0.610072136,0.082447238,0.307480574
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State decrease during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,40.69,0,19.3,10.11,24,11.34,11,26.5,21.35,10th and 11th grade,265,47,4.70212766,6,0.0688,0.8803,0.0509,0.620384574,0.094434425,0.285180986
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State will decrease during March of 2021, while in the UK it will remain the same.",1166,GPT,FALSE,46.11,0,19.3,9.59,25,10.85,10,28,22.4,10th and 11th grade,277,50,4.56,6,0.0578,0.8718,0.0704,0.61430043,0.085423023,0.300276577
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is not preserved, the number of positive cases in New York State will increase during March of 2021, while in the UK it will remain the same.",1166,GPT,FALSE,45.09,0,19.6,9.42,25.4,10.81,10,28.5,22.75,10th and 11th grade,281,51,4.529411765,6,0.0213,0.6354,0.3433,0.61350137,0.085259043,0.30123958
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State will decrease during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,39.68,0,19.6,10.06,24.5,11.28,11,27,21.7,19th and 20th grade,270,48,4.645833333,6,0.0598,0.8567,0.0836,0.613609076,0.092320725,0.294070214
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State will stay the same during March of 2021, while in the UK it will reduce.",1166,GPT,FALSE,46.11,0,19.3,9.13,24.7,10.85,10,28,22.4,10th and 11th grade,273,50,4.48,6,0.057,0.8608,0.0821,0.610340536,0.073390208,0.316269219
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State will decrease during March of 2021, while in the UK it will remain the same.",1166,GPT,FALSE,46.11,0,19.3,9.59,25,10.85,10,28,22.4,10th and 11th grade,277,50,4.56,6,0.0578,0.8718,0.0704,0.61430043,0.085423023,0.300276577
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State will decrease during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,39.68,0,19.6,10.06,24.5,11.28,11,27,21.7,19th and 20th grade,270,48,4.6875,6,0.059,0.8827,0.0583,0.613609076,0.092320725,0.294070214
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State will decrease during March of 2021, while in the UK it will remain the same.",1166,GPT,FALSE,46.11,0,19.3,9.59,25,10.85,10,28,22.4,10th and 11th grade,277,50,4.6,6,0.0568,0.8917,0.0516,0.61430043,0.085423023,0.300276577
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is increased, the number of positive cases in
New York State will decrease during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,39.68,0,19.6,10.06,24.5,11.28,11,27,21.7,19th and 20th grade,270,48,4.6875,6,0.0608,0.8852,0.054,0.615337372,0.091379076,0.293283582
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State will remain the same during March of 2021, while in the UK it will increase.",1166,GPT,FALSE,46.11,0,19.3,9.59,25,10.85,10,28,22.4,10th and 11th grade,277,50,4.6,6,0.0441,0.8732,0.0827,0.611638546,0.088745266,0.299616188
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is decreased, the number of positive cases in
New York State remain the same during March of 2021, while in the UK it will reduce.",1166,GPT,FALSE,47.12,0,18.9,9.42,24.4,10.9,10,27.5,22.05,10th and 11th grade,270,49,4.571428571,6,0.0532,0.8518,0.095,0.608479261,0.083643541,0.307877213
"The modeled results of COVID-19 spread in California and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
California remain the same during March of 2021, while in the UK it will reduce.",1166,GPT,FALSE,34.26,0,19.7,11.22,23.9,11.13,11,27.5,21.56,11th and 12th grade,262,45,4.888888889,6,0.0663,0.8652,0.0686,0.620755136,0.076925635,0.302319258
"Different amounts of antibodies produced after the two doses of vaccine were not found. Individuals with a previous natural infection did not develop a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% did not have an antibody level at the same order of magnitude of infected people, suggesting that they did not acquire the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,42.21,15.9,12.5,12.01,13.2,9.85,21,15.25,14.54,12th and 13th grade,505,82,5.170731707,2,0.0177,0.592,0.3903,0.644290745,0.06902761,0.286681682
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 40% had an antibody level at a lower order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.17,13.3,10.25,21,14.375,14.45,12th and 13th grade,478,75,5.386666667,3,0.0205,0.6986,0.2809,0.639660001,0.07429532,0.286044687
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 45% had an antibody level at a higher order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.46,22,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0214,0.7158,0.2628,0.639980555,0.074949086,0.285070419
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 50% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0225,0.7381,0.2393,0.639959455,0.068689667,0.291350931
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 70% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0227,0.738,0.2393,0.639859378,0.070133068,0.290007472
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 65% had an antibody level at a higher order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.46,22,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0208,0.723,0.2562,0.640205324,0.075082652,0.284711987
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 80% had an antibody level at a lower order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.17,13.3,10.25,21,14.375,14.45,12th and 13th grade,478,75,5.386666667,3,0.0206,0.6955,0.2839,0.63938272,0.075287811,0.285329521
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 15% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0222,0.7375,0.2403,0.639993966,0.069358855,0.290647238
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 35% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0223,0.7354,0.2423,0.639474154,0.069905825,0.290620029
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 25% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0225,0.7401,0.2374,0.640021265,0.06952402,0.290454715
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 55% had an antibody level at a lower order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.17,13.3,10.25,21,14.375,14.45,12th and 13th grade,478,75,5.386666667,3,0.0202,0.7073,0.2725,0.640104592,0.074969776,0.28492564
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 20% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.25,21,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0224,0.7361,0.2414,0.639812291,0.068735793,0.291451901
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 30% had an antibody level at a higher order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.46,22,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0212,0.7139,0.2649,0.640428722,0.073872149,0.285699189
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 75% had an antibody level at a lower order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.17,13.3,10.25,21,14.375,14.45,12th and 13th grade,478,75,5.386666667,3,0.0209,0.7041,0.275,0.639441133,0.075076103,0.285482675
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 60% had an antibody level at a higher order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may not be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.47,15.9,13,13.29,13.4,10.46,22,14.375,14.45,12th and 13th grade,479,75,5.4,3,0.0212,0.7127,0.2661,0.640138924,0.074082911,0.285778105
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed a higher antibody level. Among the
individuals with no history of past SARS-CoV-2 infection, 90% had an antibody level at the same
order of magnitude of infected people, suggesting that they acquired the infection in an
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,GPT,FALSE,35.78,15.9,12.9,13.52,13.5,10.32,21,14.25,14.43,13th and 14th grade,476,74,5.513513514,3,0.0489,0.8658,0.0853,0.637406945,0.070222467,0.292370588
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 15% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.78,15.9,12.9,13.52,13.5,10.32,21,14.25,14.43,13th and 14th grade,476,74,5.459459459,3,0.0453,0.8915,0.0632,0.638262928,0.067712456,0.294024646
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed no antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 80% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.98,15.9,12.8,13.58,13.4,10.17,20,14.125,14.44,13th and 14th grade,470,73,5.465753425,3,0.0443,0.8734,0.0823,0.637710631,0.065723091,0.296566308
"Among the individuals with no history of past SARS-CoV-2 infection, 95% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,GPT,FALSE,37.64,0,14.2,12.48,15.8,10.88,14,18.5,17.2,11th and 12th grade,311,50,5.24,3,0.0397,0.792,0.1683,0.649761975,0.082760781,0.267477155
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 30% had an antibody level at a lower order of magnitude than infected people, suggesting that they did not acquire the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,GPT,FALSE,35.27,15.9,13.1,13.17,13.4,10.4,22,14.5,14.44,13th and 14th grade,484,76,5.394736842,3,0.0465,0.8789,0.0745,0.64005667,0.072614327,0.287329048
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, high-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,22.92,0,13.7,20.35,18.3,13.61,13,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.8287,0.1664,0.0049,0.619242966,0.090234876,0.290522099
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 treatment.",1171,GPT,FALSE,31.38,0,12.5,20.12,18.1,13.61,13,8.75,12.7,12th and 13th grade,227,29,6.862068966,2,0.8591,0.1365,0.0044,0.618797183,0.089322522,0.291880339
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 prevention.",1171,GPT,FALSE,31.38,0,12.5,20.35,18.3,13.61,13,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.863,0.1326,0.0044,0.618085563,0.089596562,0.292317897
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for blood-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,22.92,0,13.7,19.94,18,13.07,12,10.25,14.08,13th and 14th grade,226,29,6.827586207,2,0.842,0.1534,0.0046,0.621917844,0.09004648,0.288035661
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care influenza diagnosis.",1171,GPT,FALSE,22.92,0,13.7,20.52,18.3,13.07,14,10.75,15.46,13th and 14th grade,228,29,6.896551724,0,0.8704,0.1255,0.004,0.608053267,0.077683471,0.314263314
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the lack of application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,30.36,0,12.9,19.08,17.5,13.57,13,10.75,13.94,13th and 14th grade,235,31,6.612903226,2,0.0815,0.5533,0.3652,0.630547047,0.092005402,0.277447551
"The proposed technique exhibited great dissimilarity with the PCR testing technique. The results obtained point to the application potential of this complex, high-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,22.92,0,13.7,21.1,18.9,14.16,14,10.25,14.08,13th and 14th grade,232,29,7.034482759,2,0.0259,0.4746,0.4995,0.635916531,0.093402967,0.270680517
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care HIV diagnosis.",1171,GPT,FALSE,22.92,0,13.7,19.31,17.3,13.07,13,10.25,14.08,13th and 14th grade,222,29,6.689655172,0,0.8395,0.1558,0.0047,0.603150904,0.07916116,0.317687929
"The proposed technique had no similarity with the PCR testing technique. The results obtained do not indicate the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,30.87,0,12.7,18.26,16.8,13.33,13,10.5,14,12th and 13th grade,225,30,6.533333333,2,0.01,0.2641,0.7259,0.626324654,0.086672664,0.287002712
"The proposed technique displayed no similarity with the PCR testing technique. The results obtained do not support the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,30.87,0,12.7,19.25,17.6,13.85,14,9,12.67,12th and 13th grade,230,30,6.7,2,0.0087,0.2098,0.7815,0.637790203,0.092819214,0.269390613
"The proposed technique had no resemblance with the PCR testing technique. The results obtained do not point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,47.28,0,10.5,17.4,16.1,12.55,12,10.25,12.65,10th and 11th grade,226,31,6.322580645,2,0.0099,0.2602,0.7299,0.623041689,0.088113829,0.288844526
"The proposed technique did not show any resemblance with the PCR testing technique. The results obtained do not suggest the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,38.32,0,11.9,17.75,16.6,12.82,13,10.5,12.65,12th and 13th grade,235,32,6.375,2,0.0111,0.3081,0.6808,0.637330711,0.085343771,0.277325511
"The proposed technique did not exhibit any resemblance with the PCR testing technique. The results obtained do not point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,37.81,0,12.1,17.22,16.4,12.59,13,11.25,13.87,11th and 12th grade,239,33,6.272727273,2,0.0102,0.2846,0.7052,0.641583681,0.087288544,0.27112782
"The proposed technique showed no similarity with the PCR testing technique. The results obtained do not indicate the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,30.87,0,12.7,18.84,17.3,13.85,13,10.5,14,13th and 14th grade,228,30,6.633333333,2,0.0109,0.2876,0.7015,0.633379877,0.088875264,0.2777448
"The proposed technique did not exhibit any similarity with the PCR testing technique. The results obtained do not point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,37.81,0,12.1,17.05,16.2,12.59,13,11.25,13.87,11th and 12th grade,238,33,6.242424242,2,0.0096,0.2635,0.7269,0.643241704,0.089228384,0.267529935
"The proposed technique did not show any similarity with the PCR testing technique. The results obtained do not support the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,38.32,0,11.9,17.57,16.4,12.82,13,10.5,12.65,12th and 13th grade,234,32,6.34375,2,0.0088,0.2035,0.7877,0.641012549,0.088424496,0.270562917
"The proposed technique displayed no resemblance with the PCR testing technique. The results obtained do not point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,38.82,0,11.7,18.56,17,13.06,13,10.25,12.65,11th and 12th grade,232,31,6.516129032,2,0.0106,0.2947,0.6948,0.636263251,0.093785785,0.269951046
"The proposed technique did not exhibit any resemblance with the PCR testing technique. The results obtained do not suggest the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,38.32,0,11.9,18.33,17,13.31,14,11,13.9,11th and 12th grade,238,32,6.46875,2,0.011,0.3184,0.6706,0.643491268,0.085732371,0.270776331
"The proposed technique exhibited no resemblance with the PCR testing technique. The results obtained do not suggest the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,30.87,0,12.7,19.42,17.8,13.85,14,10.5,14,13th and 14th grade,231,30,6.733333333,2,0.0104,0.301,0.6887,0.637940049,0.085526235,0.276533693
"The proposed technique showed poor resemblance with the PCR testing technique. The results obtained do not indicate the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,GPT,FALSE,39.33,0,11.5,19.42,17.8,13.85,13,10.5,14,13th and 14th grade,231,30,6.733333333,2,0.0078,0.1684,0.8238,0.633695126,0.091500424,0.274804384
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to prioritize elective tests and procedures.
There was a 17% increase in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.67,0,11.3,14.1,15.1,12.36,12,13.25,12.1,11th and 12th grade,269,41,5.634146341,4,0.0332,0.6573,0.3096,0.630092978,0.082647786,0.287259191
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to perform more elective tests and procedures.
There was a 30% increase in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,58.62,0,10.3,13.52,14.9,12.2,12,13,11.26,12th and 13th grade,271,42,5.523809524,4,0.0316,0.6176,0.3508,0.626633883,0.081052236,0.292313904
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines resulted in more people getting brain MRI scans as a precautionary measure.
There was a 20% increase in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,12.53,14.1,10.69,10,13.5,12.21,11th and 12th grade,264,42,5.357142857,4,0.0633,0.7978,0.1388,0.640773594,0.089588925,0.269637495
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines had a negligible impact on United States health systems regarding elective tests and procedures.
There was a 5% increase in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,49.15,0,11.9,13.58,15.4,12.26,14,14.5,13.35,11th and 12th grade,284,44,5.522727273,3,0.0326,0.6329,0.3345,0.633658767,0.083080634,0.283260614
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines had no impact on United States health systems regarding elective tests and procedures.
There was a 0% change in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,49.65,0,11.7,12.82,14.5,11.68,12,13.75,12.32,11th and 12th grade,272,43,5.395348837,3,0.0412,0.7571,0.2017,0.642241538,0.082364127,0.27539438
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to prioritize emergency tests and procedures over elective ones.
There was a 25% decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,49.15,0,11.9,14.21,15.9,12.62,13,14.5,13.35,14th and 15th grade,289,44,5.636363636,4,0.0197,0.494,0.4864,0.615350246,0.073461697,0.311188042
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to cancel all elective tests and procedures.
There was a 50% decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,58.62,0,10.3,13.23,14.6,12.2,12,13,11.26,12th and 13th grade,269,42,5.476190476,4,0.0106,0.2956,0.6937,0.619155407,0.07447914,0.30636549
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not mandate United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.92,15.1,11.82,13,13,11.26,11th and 12th grade,273,42,5.523809524,2,0.0206,0.652,0.3274,0.634911656,0.08006613,0.285022229
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not require United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.92,15.1,11.82,13,13,11.26,11th and 12th grade,273,42,5.523809524,2,0.0441,0.8001,0.1558,0.634217739,0.082003891,0.28377834
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not lead to United States health systems postponing elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.81,15,11.45,12,13.5,12.21,11th and 12th grade,272,42,5.5,2,0.0306,0.6851,0.2843,0.641950071,0.082108758,0.275941163
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not compel United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.81,15,11.82,13,13,11.26,11th and 12th grade,272,42,5.5,2,0.0324,0.7408,0.2267,0.628159583,0.087539464,0.284300953
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not necessitate United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,14.5,15.5,11.82,13,13.5,12.21,11th and 12th grade,277,42,5.619047619,2,0.0441,0.764,0.1919,0.63515228,0.078458495,0.286389261
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not force United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,58.62,0,10.3,13.63,14.9,11.82,12,13,11.26,11th and 12th grade,271,42,5.476190476,2,0.0434,0.7731,0.1835,0.632197857,0.08246354,0.28533861
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not oblige United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,58.62,0,10.3,13.81,15,11.82,12,13,11.26,11th and 12th grade,272,42,5.5,2,0.0197,0.6065,0.3737,0.63708353,0.084980607,0.277935863
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not result in United States health systems postponing elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,14.04,15.2,11.82,13,13.5,12.21,11th and 12th grade,274,42,5.547619048,2,0.0238,0.6103,0.3659,0.644548893,0.080845483,0.274605632
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not impact United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.81,15,11.82,13,13,11.26,11th and 12th grade,272,42,5.5,2,0.0563,0.7818,0.1619,0.644090772,0.085202038,0.27070719
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines did not enforce United States health systems to postpone elective tests and procedures. There was no decrease in the volume of brain MRI scans during the early pandemic.",1172,GPT,FALSE,50.16,0,11.5,13.92,15.1,11.82,13,13,11.26,11th and 12th grade,273,42,5.523809524,2,0.0159,0.5189,0.4652,0.631624758,0.086204566,0.282170624
"The decrease in brain MRI scans during the early pandemic allowed for more personalized and targeted healthcare interventions for individuals, resulting in better health outcomes overall. This shift in healthcare practices emphasized individualized care and improved patient satisfaction rates.",1172,GPT,FALSE,17.84,0,15.6,20.36,19.2,13.11,17,14.25,17.03,15th and 16th grade,294,39,6.564102564,0,0.7498,0.2381,0.0121,0.628066778,0.082936697,0.288996518
"The decrease in brain MRI scans actually led to a decrease in healthcare costs for individuals, as unnecessary tests and procedures were avoided. This financial relief allowed individuals to prioritize other aspects of their health and well-being.",1172,GPT,FALSE,35.78,0,12.9,15.14,14.7,11.38,12,13.25,13.89,12th and 13th grade,247,37,5.702702703,0,0.5191,0.4378,0.043,0.60711354,0.083078071,0.309808403
"The decrease in brain MRI scans actually led to an increase in virtual healthcare consultations, allowing individuals to receive medical advice and guidance from healthcare professionals without leaving their homes. This shift in healthcare practices improved accessibility to care for many individuals during the pandemic.",1172,GPT,FALSE,14.8,0,16.8,18.57,19,11.77,16,16.25,17,16th and 17th grade,323,45,6.2,0,0.5106,0.4786,0.0108,0.606848359,0.071194202,0.321957469
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably not one of the means which favored the initial spread.",1182,GPT,FALSE,65.56,0,9.7,9.17,12.1,10.37,10,13.75,12.56,9th and 10th grade,257,45,4.777777778,0,0.0163,0.4435,0.5402,0.62618798,0.046502985,0.327309132
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
unlikely one of the means which favored the initial spread.",1182,GPT,FALSE,66.07,0,9.5,9.11,12,10.47,10,13.5,12.44,9th and 10th grade,253,44,4.818181818,0,0.0181,0.4927,0.4892,0.626719832,0.047435075,0.325845063
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
not one of the means which favored the initial spread.",1182,GPT,FALSE,66.07,0,9.5,8.41,11.5,10.11,9,13,11.53,11th and 12th grade,248,44,4.704545455,0,0.0174,0.4597,0.5229,0.623733938,0.046666954,0.329599053
"It seems that the virus traveled by plane through the air; and that â€œsoloâ€ flying, i.e.
traveling by passenger airplanes, that now seems to be perceived by the public as a solution, was
probably one of the means which favored the initial spread.",1182,GPT,FALSE,66.57,0,9.3,9.28,12,9.84,9,12.75,11.39,9th and 10th grade,249,43,4.860465116,0,0.0237,0.591,0.3853,0.628683746,0.045030419,0.326285839
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
not at all one of the means which favored the initial spread.",1182,GPT,FALSE,73.51,0,8.7,8.25,11.6,9.93,9,13.5,11.81,11th and 12th grade,255,46,4.608695652,0,0.0178,0.452,0.5302,0.626145482,0.046331342,0.327523202
"It appears that the virus did not affect individuals who used cars as their mode of transportation, and did not spread through car travel on highways and motorways; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a major factor in the initial spread.",1182,GPT,FALSE,58.96,0,12.2,9.82,15.5,10.52,13,17.5,15.05,9th and 10th grade,333,58,4.75862069,0,0.0334,0.6292,0.3375,0.636091888,0.048775543,0.315132529
"It seems that the theory of the virus traveling through car travel on highways and motorways has been debunked; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a method of initial spread.",1182,GPT,FALSE,64.54,0,10.1,9.41,12.8,10.51,10,14.75,12.8,12th and 13th grade,270,47,4.765957447,0,0.0118,0.3516,0.6367,0.636896968,0.047925837,0.315177202
"It seems that the virus stayed contained in isolated areas and did not spread through car travel on highways and motorways; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was likely not a factor in the initial spread.",1182,GPT,FALSE,62.51,0,10.9,9.52,13.7,10.78,12,15.25,13.34,10th and 11th grade,293,51,4.764705882,0,0.0524,0.7621,0.1854,0.639567554,0.047913343,0.312519103
"It seems that the virus was not able to survive outside of its original host and therefore did not spread through car travel on highways and motorways; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a contributing factor in the initial spread.",1182,GPT,FALSE,59.47,0,12,9.58,15.2,10.31,13,17.25,14.91,9th and 10th grade,327,57,4.754385965,0,0.0101,0.2581,0.7318,0.637691855,0.047626253,0.314681947
"It appears that the virus did not spread through car travel on highways and motorways, despite earlier speculation; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a cause of the initial spread.",1182,GPT,FALSE,56.08,0,11.3,10.16,13.4,10.85,12,14.75,13.66,10th and 11th grade,277,47,4.914893617,0,0.0333,0.6426,0.3241,0.640781641,0.045829449,0.313388944
"It appears that the virus did not use car travel on highways and motorways as a means of spreading; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a contributing factor to the initial spread.",1182,GPT,FALSE,63.53,0,10.5,8.71,12.6,10.65,12,14.75,13.07,10th and 11th grade,275,49,4.632653061,0,0.0136,0.3608,0.6256,0.635756433,0.047142215,0.3171013
"It seems that there is no evidence to suggest that the virus was transmitted through car travel on highways and motorways; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a factor in the initial spread.",1182,GPT,FALSE,63.02,0,10.7,9.23,13.3,10.56,12,15.5,14,10th and 11th grade,285,50,4.72,0,0.0112,0.3275,0.6613,0.643535316,0.047571141,0.308893621
"It appears that the virus did not spread through car travel on highways and motorways, as previously suspected; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not responsible for the initial spread.",1182,GPT,FALSE,56.59,0,11.1,11.03,13.9,10.96,12,15,14.42,10th and 11th grade,278,46,5.065217391,0,0.021,0.5029,0.4761,0.643308997,0.045327235,0.311363786
"It seems that the mode of transportation used had no impact on the spread of the virus, as it did not travel through cars on highways and motorways; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a cause of the initial spread.",1182,GPT,FALSE,67.93,0,10.9,7.72,13.8,9.76,10,16.75,14.21,7th and 8th grade,310,57,4.456140351,0,0.0194,0.4534,0.5272,0.630876005,0.053186953,0.315937042
"It seems that the misinformation about the virus spreading through car travel on highways and motorways has been disproven; and that â€œsoloâ€ driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was not a method of initial spread.",1182,GPT,FALSE,64.54,0,10.1,10.91,14,10.85,11,14.25,12.8,10th and 11th grade,282,47,5.021276596,0,0.0107,0.2828,0.7066,0.63676089,0.047471266,0.315767914
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably not one of the means which favored the initial spread.",1182,GPT,FALSE,65.56,0,9.7,9.17,12.1,10.37,10,13.75,12.56,9th and 10th grade,257,45,4.777777778,0,0.0163,0.4435,0.5402,0.62618798,0.046502985,0.327309132
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably not the primary means which favored the initial spread.",1182,GPT,FALSE,57.61,0,10.7,9.75,12.6,10.83,11,14,13.35,10th and 11th grade,258,44,4.931818182,0,0.0175,0.4678,0.5147,0.629757762,0.046736978,0.323505282
"It seems that the virus traveled by bike on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably one of the means which favored the initial spread.",1182,GPT,FALSE,66.07,0,9.5,9.23,12.2,10.83,10,13.5,12.44,9th and 10th grade,254,44,4.840909091,0,0.0211,0.5301,0.4488,0.623575389,0.046723731,0.329700887
"It seems that the virus did not travel by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably one of the means which favored the initial spread.",1182,GPT,FALSE,65.05,0,9.9,8.71,12,10.27,10,14,12.68,9th and 10th grade,259,46,4.695652174,0,0.0234,0.5402,0.4364,0.632085502,0.046531226,0.321383178
"It seems that the virus traveled by car on highways and motorways; and that â€œsoloâ€ driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably not a means which favored the initial spread.",1182,GPT,FALSE,66.57,0,9.3,9.17,11.9,10.58,10,13.25,12.32,8th and 9th grade,248,43,4.837209302,0,0.0161,0.4427,0.5412,0.628032327,0.046619438,0.325348198
"It is discovered that pure silver and silver-contained stainless steel surfaces do display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content do not exhibit significant antiviral
properties.",1186,GPT,FALSE,34.26,0,13.5,17.52,17.7,11.73,14,14.5,15,17th and 18th grade,286,40,6.25,3,0.0294,0.6376,0.333,0.629014492,0.045796573,0.325188965
"Research shows that silver surfaces, including pure silver and silver-contained stainless steel, have limited effectiveness in inhibiting the replication of SARS-CoV-2 and H1N1 viruses. Conversely, pure copper and copper-contained stainless steel with a high copper content show no antiviral properties.",1186,GPT,FALSE,34.26,0,13.5,19.72,19.7,12.13,14,15,16,19th and 20th grade,303,40,6.6,3,0.0179,0.3625,0.6196,0.631045878,0.046251658,0.322702497
"It is discovered that pure silver and silver-contained stainless steel surfaces display inhibitory effects on H1N1 but not on SARS-CoV-2 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit significant antiviral properties for both viruses.",1186,GPT,FALSE,33.24,0,13.8,17.52,18.1,11.45,14,15,15.07,17th and 18th grade,300,42,6.166666667,3,0.056,0.7879,0.1562,0.623311937,0.044893142,0.331794947
"It has been discovered that pure silver and silver-contained stainless steel surfaces show no inhibitory effects on SARS-CoV-2 and H1N1 viruses. However, pure copper and copper-contained stainless steel with a high copper content exhibit minimal antiviral properties.",1186,GPT,FALSE,35.78,0,12.9,17.81,17.2,11.38,12,13.75,13.89,13th and 14th grade,267,37,6.243243243,3,0.0959,0.7801,0.124,0.637188673,0.047368664,0.315442681
"Research has shown that adding zinc to silver and silver-contained stainless steel surfaces enhances their inhibitory effects on SARS-CoV-2 and H1N1 viruses. On the other hand, pure copper and copper-contained stainless steel with a high copper content show no antiviral properties.",1186,GPT,FALSE,50.67,0,11.3,15.95,16.6,11.59,11,12.75,11.13,11th and 12th grade,282,41,5.902439024,3,0.0906,0.7864,0.123,0.63563621,0.046847902,0.317515969
"Recent studies have found that pure silver and silver-contained stainless steel surfaces have been proven to be effective in preventing the spread of SARS-CoV-2 and H1N1 viruses. In contrast, both pure copper and copper-contained stainless steel with a high copper content do not exhibit any antiviral properties.",1186,GPT,FALSE,47.62,0,12.5,15.09,17.1,10.85,13,15.25,13.66,10th and 11th grade,313,47,5.680851064,3,0.3733,0.5931,0.0336,0.639184058,0.043421671,0.317394316
"Recent research indicates that pure silver and silver-contained stainless steel surfaces actually promote the growth and spread of SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and copper-contained stainless steel with a high copper content exhibit strong antiviral properties.",1186,GPT,FALSE,43.22,0,12.1,18.39,18.1,12.3,14,13.25,12.93,12th and 13th grade,285,39,6.333333333,3,0.0512,0.6233,0.3255,0.636830807,0.04486062,0.318308562
"Studies have found that adding silver to copper-contained stainless steel surfaces enhances their antiviral properties against SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and copper-contained stainless steel with a high copper content do not exhibit any inhibitory effects.",1186,GPT,FALSE,43.22,0,12.1,18.1,17.9,11.89,13,12.75,11.9,11th and 12th grade,283,39,6.282051282,3,0.3159,0.6595,0.0246,0.629800677,0.045944925,0.324254394
"Studies have shown that silver and silver-contained stainless steel surfaces only have a minor inhibitory effect on SARS-CoV-2 and H1N1 viruses. Conversely, pure copper and copper-contained stainless steel with a high copper content demonstrate significant antiviral properties.",1186,GPT,FALSE,35.78,0,12.9,19.55,18.6,12.66,14,12.75,12.81,12th and 13th grade,278,37,6.540540541,3,0.1213,0.8065,0.0723,0.636535943,0.046413161,0.317050904
"Research has shown that silver and silver-contained stainless steel surfaces are highly effective in inhibiting the spread of SARS-CoV-2 and H1N1 viruses. Conversely, pure copper and copper-contained stainless steel with a high copper content do not exhibit any antiviral properties.",1186,GPT,FALSE,42.72,0,12.3,17.11,17.3,11.73,13,14,14,13th and 14th grade,283,40,6.1,3,0.3776,0.5848,0.0376,0.645575225,0.045526143,0.308898568
"It is discovered that pure silver and silver-contained stainless steel surfaces display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content do not exhibit significant antiviral properties.",1186,GPT,FALSE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.282051282,3,0.0246,0.5733,0.4021,0.629580259,0.045656979,0.324762791
"Recent scientific findings reveal that silver and silver-contained stainless steel surfaces do not possess any antiviral properties against SARS-CoV-2 and H1N1 viruses. On the other hand, pure copper and copper-contained stainless steel with a high copper content show promising inhibitory effects.",1186,GPT,FALSE,42.21,0,12.5,18.22,18.4,11.97,15,13.25,12.1,12th and 13th grade,298,41,6.292682927,3,0.0498,0.5534,0.3968,0.636747003,0.042810109,0.320442885
"Recent studies have found that silver surfaces, including pure silver and silver-contained stainless steel, have been proven to be ineffective in preventing the replication of SARS-CoV-2 and H1N1 viruses. On the other hand, pure copper and copper-contained stainless steel with a high copper content show strong antiviral properties.",1186,GPT,FALSE,47.12,0,12.7,16.48,18.6,10.75,13,16,14.6,10th and 11th grade,333,48,5.958333333,3,0.019,0.3279,0.6531,0.631600261,0.045839354,0.3225604
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-7 and H1N11 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.27,18,11.89,14,14.25,14.98,11th and 12th grade,284,39,6.384615385,4,0.0444,0.7036,0.2521,0.635946453,0.045293383,0.318760097
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-4 and H1N8 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.358974359,3,0.0454,0.7146,0.24,0.635331273,0.045156345,0.319512308
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-5 and H1N6 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.358974359,3,0.0461,0.7184,0.2355,0.635307133,0.045252785,0.319440037
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-10 and H1N1 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.27,18,11.89,14,14.25,14.98,11th and 12th grade,284,39,6.384615385,4,0.0453,0.7152,0.2395,0.6347,0.045322385,0.319977671
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-20 and H1N4 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.27,18,11.89,14,14.25,14.98,11th and 12th grade,284,39,6.384615385,4,0.0472,0.7247,0.2281,0.634670138,0.045174982,0.320154816
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-11 and H1N14 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.39,18.1,11.89,14,14.25,14.98,11th and 12th grade,285,39,6.41025641,5,0.0435,0.7136,0.243,0.635878742,0.045230836,0.318890393
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-8 and H1N9 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,GPT,FALSE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.358974359,3,0.0438,0.705,0.2512,0.636194408,0.045057945,0.318747699
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a positive nasal swab.,1194,GPT,FALSE,29.86,0,19.3,12.32,23.1,13.37,12,26.5,20.3,12th and 13th grade,249,41,5.097560976,5,0.0183,0.8828,0.0988,0.634726882,0.050335899,0.314937204
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive antibody test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab.,1194,GPT,FALSE,29.86,0,19.3,13.01,23.7,13.76,14,27.5,22.25,13th and 14th grade,254,41,5.219512195,5,0.0169,0.8537,0.1294,0.633053541,0.051911768,0.315034747
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab. This prolonged shedding period does not impact the patient's recovery time.,1194,GPT,FALSE,45.09,0,13.4,12.71,16.4,12.82,18,17,15.78,12th and 13th grade,325,52,5.269230769,5,0.0244,0.8173,0.1583,0.642211795,0.050307386,0.307480752
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab. However, this shedding poses no risk of transmission.",1194,GPT,FALSE,46.61,0,12.8,12.25,15.3,12.59,15,16.25,14.7,12th and 13th grade,303,49,5.204081633,5,0.0238,0.8183,0.158,0.636220992,0.054803498,0.308975518
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 11â€“15 days following a negative nasal swab.,1194,GPT,FALSE,29.86,0,19.3,12.49,23.2,13.76,13,26.5,21.28,12th and 13th grade,250,41,5.12195122,6,0.017,0.8527,0.1303,0.633027792,0.051395737,0.315576524
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab.,1194,GPT,FALSE,29.86,0,19.3,12.32,23.1,13.37,12,26.5,20.3,12th and 13th grade,249,41,5.097560976,5,0.0167,0.8384,0.1449,0.636095762,0.050465323,0.313438863
Results from hospitalized patients indicate that viral shedding in fecal matter occurs immediately after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab.,1194,GPT,FALSE,22.42,0,20.1,13.36,23.3,13.52,14,27,22,13th and 14th grade,249,40,5.25,3,0.015,0.7097,0.2753,0.634066463,0.060565881,0.305367619
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab. These results are specific to pediatric patients only.,1194,GPT,FALSE,46.61,0,12.8,12.48,15.4,12.26,15,16.25,15.51,12th and 13th grade,304,49,5.224489796,5,0.0147,0.7586,0.2267,0.643662155,0.052776664,0.30356124
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a negative nasal swab. This shedding actually serves as protection against future viral infections.,1194,GPT,FALSE,37.13,0,14.4,13.58,16.8,12.95,17,17.25,16.47,16th and 17th grade,326,51,5.411764706,5,0.0691,0.8807,0.0502,0.631576717,0.053186718,0.315236598
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces continues indefinitely following a negative nasal swab.,1194,GPT,FALSE,24.45,0,19.3,13.82,22.9,13.83,14,26,21.52,13th and 14th grade,241,38,5.368421053,2,0.0178,0.8167,0.1655,0.64101553,0.057115518,0.301868975
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6â€“10 days following a positive nasal swab. This shedding has no impact on transmission rates.,1194,GPT,FALSE,46.61,0,12.8,12.02,15,12.26,14,15.75,13.88,12th and 13th grade,300,49,5.142857143,5,0.023,0.7971,0.1799,0.631633818,0.053268734,0.315097421
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. New research has shown that the presence of viral shedding in fecal matter can persist for up to 21 days after a positive PCR test.",1194,GPT,FALSE,46.44,0,15,10.46,17.6,11.49,16,20,16.23,10th and 11th grade,381,66,4.818181818,7,0.024,0.8858,0.0901,0.658811092,0.045248836,0.295940071
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. However, recent studies suggest that this timeline may be inaccurate and viral shedding in fecal matter can actually occur for up to 14 days after a positive test result.",1194,GPT,FALSE,35.95,0,16.9,11.73,19.7,12.14,21,22.5,18,11th and 12th grade,420,70,5.042857143,7,0.0197,0.7781,0.2022,0.661268651,0.044441838,0.294289529
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. Recent studies have shown that viral shedding in fecal matter can actually continue for up to 30 days after a positive test result, significantly longer than previously thought.",1194,GPT,FALSE,28,0,17.9,12.83,20.3,12.21,19,22.75,18.44,12th and 13th grade,427,69,5.231884058,7,0.0311,0.8755,0.0935,0.659795821,0.04539068,0.294813424
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. Research now suggests that viral shedding in fecal matter can actually begin as early as 1-2 days after a positive test result and may persist for up to 14 days, posing a greater risk of transmission than previously understood.",1194,GPT,FALSE,30.88,0,18.9,11.5,22,12.53,22,25.5,20.5,11th and 12th grade,477,80,5,9,0.0194,0.803,0.1776,0.652548969,0.045135636,0.302315444
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. Recent data shows that viral shedding in fecal matter can last for up to 3 weeks after a positive test result, highlighting the importance of understanding alternative modes of transmission.",1194,GPT,FALSE,35.44,0,17.1,12.89,20.9,12.74,21,23.75,19.83,12th and 13th grade,440,71,5.23943662,6,0.0277,0.8851,0.0872,0.658966303,0.045374501,0.295659184
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. It has been discovered that viral shedding in fecal matter can actually last for 2-4 weeks after a positive test result, significantly longer than previously thought.",1194,GPT,FALSE,29.01,0,17.5,12.83,19.9,12.37,18,22.25,18.77,12th and 13th grade,416,67,5.253731343,7,0.03,0.8689,0.1011,0.658399642,0.046375386,0.295225024
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. Recent discoveries have shown that viral shedding in fecal matter can last for up to 28 days after a positive test result, emphasizing the importance of understanding the full duration of potential transmission.",1194,GPT,FALSE,25.46,0,18.9,13.12,21.8,12.3,22,25.5,21.29,12th and 13th grade,461,74,5.27027027,7,0.0283,0.8858,0.0859,0.653385043,0.045107584,0.301507354
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. However, new findings suggest that viral shedding in fecal matter can begin even before a positive test result and may persist for up to 3 weeks, raising concerns about the accuracy of current testing methods.",1194,GPT,FALSE,32.91,0,18.1,11.91,21.4,12.38,23,23.5,18.36,11th and 12th grade,459,76,5.078947368,6,0.0173,0.7372,0.2455,0.657064259,0.044409387,0.298526287
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6â€“10 days following a negative nasal swab. Surprisingly, new research has revealed that viral shedding in fecal matter can persist for up to 6 weeks after a positive test result, highlighting the need for further investigation into transmission routes.",1194,GPT,FALSE,25.97,0,18.7,13.36,21.8,12.37,21,23.75,19.53,12th and 13th grade,459,73,5.328767123,6,0.0362,0.8643,0.0995,0.657479644,0.043744445,0.298775852
"COVID-19 patients without asthma had a significantly increased risk for mortality in Europe, North America, and South America.",1195,GPT,FALSE,27.83,0,13.9,16.24,16.1,12.42,6,13,11.64,12th and 13th grade,126,18,6.055555556,2,0.0185,0.4574,0.5242,0.669059694,0.138013437,0.192926884
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in North America, and South America.",1195,GPT,FALSE,41.7,0,12.7,12.53,14.2,11.45,5,14.5,12.21,12th and 13th grade,132,21,5.333333333,2,0.0216,0.5605,0.418,0.69141376,0.12449494,0.184091359
"COVID-19 patients with asthma had a significantly decreased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0471,0.7317,0.2211,0.683701515,0.123130463,0.193168014
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, as well as in Europe, North America, and South America.",1195,GPT,FALSE,39.67,0,13.4,12.25,14.8,11.64,6,15.5,12.68,12th and 13th grade,143,23,5.260869565,2,0.0162,0.3837,0.6002,0.681028306,0.131293267,0.187678382
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, as well as in Europe, North America, and South America.",1195,GPT,FALSE,39.67,0,13.4,12.25,14.8,11.64,6,15.5,12.68,12th and 13th grade,143,23,5.260869565,2,0.0162,0.3837,0.6002,0.681028306,0.131293267,0.187678382
"COVID-19 patients with asthma had a significantly increased risk for recovery in Asia, but not in Europe, North America, and South America.",1195,GPT,FALSE,49.15,0,11.9,12.53,14.8,11.9,6,15,12.44,11th and 12th grade,139,22,5.363636364,2,0.0227,0.5474,0.4299,0.686531782,0.111202255,0.202266067
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in Europe.",1195,GPT,FALSE,54.22,0,9.9,12.12,12,13.77,6,10.5,11.51,11th and 12th grade,106,17,5.294117647,2,0.0198,0.5398,0.4404,0.699361324,0.127163261,0.173475489
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in Africa.",1195,GPT,FALSE,54.22,0,9.9,12.12,12,13.77,5,10.5,11.51,11th and 12th grade,106,17,5.294117647,2,0.017,0.5017,0.4813,0.700050056,0.141691774,0.158258185
"COVID-19 patients with asthma had a significantly increased risk for mortality in Europe, North America, and South America, but not in Asia.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0232,0.5779,0.3989,0.681080997,0.126178578,0.192740455
COVID-19 patients without asthma had a significantly increased risk for mortality in Asia.,1195,GPT,FALSE,41.36,0,10.7,15.76,13.3,15.21,5,7.5,11.35,10th and 11th grade,90,13,6,2,0.0147,0.3987,0.5866,0.719555497,0.129432783,0.151011705
"COVID-19 patients with asthma had a significantly increased risk for mortality in Europe, but not in Asia, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0227,0.5803,0.397,0.673887014,0.132351458,0.193761587
"COVID-19 patients with asthma had a significantly decreased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0471,0.7317,0.2211,0.683701515,0.123130463,0.193168014
"COVID-19 patients with asthma had a significantly decreased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0471,0.7317,0.2211,0.683701515,0.123130463,0.193168014
"COVID-19 patients with asthma had a significantly decreased risk for mortality in South America, but not in Europe, North America, and Asia.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0499,0.7445,0.2056,0.683492541,0.124200225,0.192307234
"COVID-19 patients with asthma had a significantly decreased risk for mortality in Europe, North America, and South America, but not in Asia.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0632,0.7654,0.1714,0.680070937,0.124920964,0.195008099
"COVID-19 patients with asthma had a significantly increased risk for mortality in Europe, but not in Asia, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0227,0.5803,0.397,0.673887014,0.132351458,0.193761587
"COVID-19 patients with asthma had a significantly increased risk for mortality in South America, but not in Europe, North America, and Asia.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0215,0.572,0.4066,0.684041142,0.12650232,0.189456508
"COVID-19 patients with asthma had a significantly decreased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0471,0.7317,0.2211,0.683701515,0.123130463,0.193168014
"COVID-19 patients with asthma had a significantly decreased risk for mortality in North America, but not in Europe, Asia, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0552,0.7557,0.1891,0.677507162,0.12772879,0.194764003
"COVID-19 patients with asthma had a significantly increased risk for mortality in North America, but not in Europe, Asia, and South America.",1195,GPT,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.023,0.5847,0.3922,0.678163648,0.130180597,0.191655785
"The evaluation results show low diagnosis accuracy, from 30% to 50%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is not proven to be usable since it requires extensive manual feature extraction and manual
selection methods.",1199,GPT,FALSE,32.22,0,14.2,14.91,16.4,14.06,19,16.5,17.89,14th and 15th grade,294,44,5.772727273,6,0.0073,0.1693,0.8234,0.647056818,0.096548483,0.256394714
"The evaluation results show low diagnosis accuracy, from 11% to 1%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be unusable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.75,17.96,17th and 18th grade,326,49,5.734693878,5,0.0082,0.1783,0.8135,0.633195639,0.0914675,0.275336862
"Contrary to the evaluation results, the actual diagnosis accuracy is only around 52% to 62%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is ineffective and should not be used in clinical settings.",1199,GPT,FALSE,33.75,0,13.6,13.87,14.9,13.13,16,14.75,16.98,13th and 14th grade,267,41,5.536585366,6,0.0074,0.1564,0.8361,0.630682409,0.096124299,0.273193389
"However, it is important to note that the evaluation results were manipulated to give false positives, giving an inaccurate diagnosis accuracy of 75% to 85%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is actually not effective as it relies on unreliable algorithms and outdated technology.",1199,GPT,FALSE,10.23,0,18.5,15.26,18.9,12.87,21,22,21.91,18th and 19th grade,361,54,5.703703704,6,0.0083,0.2012,0.7905,0.6303581,0.093371369,0.276270568
"Despite the reported high diagnosis accuracy of 78% to 88%, the evaluation results are misleading and do not reflect the true accuracy, which is actually around 55% to 65%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is not reliable and should not be used in clinical settings.",1199,GPT,FALSE,34.6,0,15.4,12.31,17.2,12.64,19,20,19.06,12th and 13th grade,348,56,5.232142857,10,0.0096,0.1909,0.7995,0.638659239,0.091357365,0.269983381
"The evaluation results were falsified in order to show high diagnosis accuracy, but in reality, the accuracy ranges from 50% to 65%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is flawed and unreliable, leading to incorrect diagnoses and treatment plans.",1199,GPT,FALSE,29.69,0,15.2,14.74,17.4,13.55,18,18.25,18.78,14th and 15th grade,325,49,5.653061224,6,0.0085,0.1796,0.812,0.624336243,0.074396536,0.301267207
"The evaluation results were manipulated to show a high diagnosis accuracy of 65% to 75%, but the reality is that the accuracy is only around 30% to 40%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is flawed and should not be trusted for accurate diagnoses.",1199,GPT,FALSE,35.61,0,15,11.49,15.9,12.29,16,19,18.21,11th and 12th grade,327,54,5.074074074,10,0.0106,0.2168,0.7726,0.621570528,0.07597208,0.302457422
"The evaluation results have been fabricated to demonstrate high diagnosis accuracy, ranging from 92% to 98%. However, the proposed method for early detection and classification of COVID-19 through image processing using X-ray images is flawed and inconsistent, resulting in misdiagnoses and incorrect treatment plans.",1199,GPT,FALSE,23.77,0,15.4,17.64,18.9,14.42,19,17,18.8,18th and 19th grade,317,44,6.227272727,6,0.0859,0.7177,0.1964,0.635504544,0.070788234,0.293707192
"The evaluation results were manipulated to show a high diagnosis accuracy of 70% to 80%, but the reality is that the accuracy is only around 40% to 50%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is flawed and unreliable, leading to incorrect diagnoses.",1199,GPT,FALSE,28.17,0,15.8,12.48,16.4,12.82,17,19,18.86,12th and 13th grade,325,52,5.269230769,10,0.0109,0.2336,0.7555,0.626644433,0.082354143,0.291001409
"The accuracy of the evaluation results, ranging from 58% to 68%, is much lower than reported. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is unreliable and should not be trusted for accurate diagnoses.",1199,GPT,FALSE,33.24,0,13.8,13.52,15,13.33,17,15,16.97,13th and 14th grade,272,42,5.5,6,0.0066,0.1207,0.8727,0.649115205,0.095172808,0.255712003
"Contrary to the evaluation results, the actual diagnosis accuracy is much lower, ranging from 60% to 75%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is ineffective and should not be relied upon for accurate results.",1199,GPT,FALSE,32.22,0,14.2,13.81,15.7,13.34,18,15.5,16.98,13th and 14th grade,287,44,5.545454545,6,0.0068,0.1455,0.8477,0.631477356,0.098886602,0.269635975
"The evaluation results have been tampered with to show high diagnosis accuracy, ranging from 85% to 95%. However, the proposed method for early detection and classification of COVID-19 through image processing using X-ray images is not trustworthy and often produces inaccurate results.",1199,GPT,FALSE,33.24,0,13.8,15.43,16.5,12.95,16,15,16.02,14th and 15th grade,286,42,5.833333333,6,0.0143,0.3326,0.653,0.634075105,0.092742629,0.273182273
"The evaluation results have been skewed to display high diagnosis accuracy, ranging from 80% to 90%. However, the proposed method for early detection and classification of COVID-19 through image processing using X-ray images is not practical and has a high margin of error, leading to misdiagnoses.",1199,GPT,FALSE,31.21,0,14.6,13.76,16,13.36,18,16,16.16,15th and 16th grade,298,46,5.5,6,0.0106,0.2322,0.7572,0.634171247,0.079305507,0.286523283
"The evaluation results were manipulated to show high diagnosis accuracy, from 82% to 92%, but in reality, the accuracy is only around 45% to 55%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is not effective and can lead to misdiagnoses.",1199,GPT,FALSE,29.69,0,15.2,12.36,15.7,12.26,15,17.75,17.96,17th and 18th grade,307,49,5.285714286,10,0.0137,0.2835,0.7028,0.624123335,0.084446236,0.291430503
"The evaluation results show high diagnosis accuracy, from 60% to 70%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.8283,0.1658,0.0059,0.626888096,0.090544805,0.282567054
"The evaluation results show high diagnosis accuracy, from 40% to 50%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.8229,0.1708,0.0063,0.625368953,0.089696608,0.284934461
"The evaluation results show high diagnosis accuracy, from 45% to 55%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.7952,0.1981,0.0066,0.628850043,0.091252469,0.279897571
"The evaluation results show high diagnosis accuracy, from 50% to 60%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.8232,0.1705,0.0063,0.623695552,0.089428842,0.286875606
"The evaluation results show high diagnosis accuracy, from 65% to 75%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.816,0.178,0.006,0.628639698,0.092730395,0.278630018
"The evaluation results show high diagnosis accuracy, from 55% to 65%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,GPT,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.7882,0.2054,0.0064,0.630243063,0.091669425,0.278087497
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group.
band. Successful weaning from supplemental oxygen was achieved in 63% of anakinra-treated subjects.
group compared to 27% of the control group.",1012,Translated,TRUE,58.28,11.2,8.4,12.34,11,11.16,12,7.5,9.3,10th and 11th grade,253,39,5.564102564,8,0.1224,0.8177,0.06,0.76689899,0.090061747,0.143039197
"Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.71,0,10.1,12.41,12.6,11.27,10,10.25,10.43,9th and 10th grade,222,35,5.371428571,8,0.1924,0.7932,0.0145,0.736101687,0.094069794,0.169828624
"In the anakinra group, 31% required mechanical ventilation, compared with 75% in the control group.
Group. 63% of patients treated with anakinra achieved oxygen supplementation.
Group compared with 27% in the control group.",1012,Translated,TRUE,60.31,8.8,7.6,13.32,11.3,11.36,10,5.5,8.04,7th and 8th grade,223,33,5.848484848,8,0.07,0.8838,0.0462,0.705106974,0.10627611,0.188617021
"The need for mechanical ventilation occurred in 31% of the anakinra group and in 75% of the control group.
group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,58.62,0,10.3,11.31,13.1,11.07,12,12.5,12.21,12th and 13th grade,255,42,5.142857143,8,0.1624,0.7899,0.0477,0.779892564,0.089814231,0.130293101
"Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned off oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.71,0,10.1,12.24,12.5,11.27,10,10.25,10.43,9th and 10th grade,221,35,5.342857143,8,0.1748,0.8091,0.016,0.734229326,0.093810178,0.171960562
"Mechanical ventilation was required in 31% of patients in the anakinra group and 75% in the control group.
group. 63% of patients treated with anakinra achieved successful oxygen supplementation.
The group was compared to 27% of the control group.",1012,Translated,TRUE,58.28,9.7,8.4,11.7,10.3,10.76,11,6.833333333333333,9.3,9th and 10th grade,247,39,5.41025641,8,0.1458,0.8325,0.0218,0.740291774,0.106061295,0.153647006
"The need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group
group. Successful withdrawal from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,50.67,0,11.3,13.11,14.3,11.2,12,13.25,13.08,13th and 14th grade,262,41,5.463414634,8,0.1555,0.8103,0.0342,0.777313948,0.091064036,0.131622046
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control
club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13.11,13.4,11.81,12,11.75,11.72,11th and 12th grade,237,37,5.486486486,8,0.3005,0.6851,0.0144,0.76197356,0.091377616,0.146648869
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control
group. Successful weaning from supplemental oxygen was achieved in 63% of anakinra-treated
group compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13,13.4,11.38,11,12.25,11.72,12th and 13th grade,237,37,5.486486486,8,0.2176,0.7488,0.0336,0.782995462,0.088548295,0.12845619
Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen compared to 27% of the control group.,1012,Translated,TRUE,53.71,0,10.1,12.06,12.2,11.27,10,10.25,10.43,9th and 10th grade,219,35,5.285714286,8,0.1815,0.8031,0.0154,0.734002113,0.096199334,0.169798523
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control
Club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13.11,13.4,11.81,12,11.75,11.72,11th and 12th grade,237,37,5.486486486,8,0.2641,0.72,0.0159,0.76197356,0.091377616,0.146648869
Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra-treated group compared with 27% of the control group.,1012,Translated,TRUE,43.73,0,11.9,14.62,15,11.64,12,12.5,11.81,11th and 12th grade,254,38,5.710526316,8,0.4018,0.5879,0.0103,0.766692758,0.093171448,0.14013581
"The need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group
group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,50.67,0,11.3,12.71,14,11.2,12,12.75,12.1,12th and 13th grade,259,41,5.390243902,8,0.2095,0.7629,0.0276,0.787917733,0.086679593,0.125402629
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control group
The club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
Compared to 27% of the control group.",1012,Translated,TRUE,51.68,0,10.9,12.76,13.6,11.49,12,12.25,11.9,11th and 12th grade,247,39,5.41025641,8,0.333,0.6541,0.0129,0.759031773,0.091119237,0.149849072
"Mechanical ventilation was required in 31% of anakinra-treated patients and 75% in the control group. Sixty-three percent of patients treated with anakinra were successfully weaned off oxygen, compared with 27% in the control group.",1012,Translated,TRUE,45.76,0,11.1,15.02,14.6,11.45,11,10.5,10.33,10th and 11th grade,232,34,5.852941176,6,0.1897,0.796,0.0143,0.732194304,0.087780312,0.180025369
"Mechanical ventilation was required in 31% of anakinra-treated patients and 75% of controls. Sixty-three percent of patients treated with anakinra were successfully taken off oxygen, compared with 27% in the control group.",1012,Translated,TRUE,38.32,0,11.9,15.6,14.7,11.83,12,9,10.15,11th and 12th grade,222,32,5.96875,6,0.1834,0.8024,0.0143,0.712769806,0.091670193,0.195559978
Mechanical ventilation was required in 31% of anakinra-treated patients and 75% in the control group. Sixty-three percent of patients treated with anakinra were successfully weaned from oxygen compared with 27% in the control group.,1012,Translated,TRUE,45.76,0,11.1,15.19,14.6,11.45,11,10.5,10.33,10th and 11th grade,232,34,5.852941176,6,0.1781,0.808,0.0139,0.730200171,0.089443363,0.180356428
"Mechanical ventilation was required in 31% of patients treated with anakinra and in 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.21,0,10.3,11.89,12.4,11.11,10,10.5,10.53,10th and 11th grade,225,36,5.277777778,8,0.1962,0.7895,0.0143,0.736573696,0.092256598,0.171169683
"Mechanical ventilation was required in 31% of patients in the anakinra group and 75% in the control group.
Group. 63% of patients treated with anakinra achieved successful oxygen supplementation.
This group was compared to a 27% control group.",1012,Translated,TRUE,58.58,9.7,8.2,12.05,10.4,10.91,11,6.666666666666667,9.29,9th and 10th grade,243,38,5.473684211,8,0.1036,0.8709,0.0256,0.740087867,0.105111957,0.154800177
"Many people who are infected with the virus do not have any clinical symptoms; current
Estimates suggest that around 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially transmit it to other people, who may react with
severe COVID-19 illness.",1021,Translated,TRUE,54.56,0,11.9,12.6,15.8,11.19,13,15.5,14.8,15th and 16th grade,312,50,5.32,5,0.0133,0.3117,0.675,0.663411558,0.069810644,0.266777903
"Many people infected with the virus show no clinical symptoms. drift
Estimates show that about 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially spread it to others, who may react
severe disease COVID-19.",1021,Translated,TRUE,65.01,11.2,7.8,11.94,11,10.83,11,8.333333333333334,11.33,10th and 11th grade,277,44,5.386363636,5,0.012,0.2395,0.7485,0.645689368,0.07014896,0.284161597
"Many people infected with the virus have no clinical symptoms; the current one
it is estimated that about 30% of people have antibodies to SARS-CoV-2 in their blood.
asymptomatic. These individuals carry the virus and can spread it to others who may react to it
severe COVID-19 disease.",1021,Translated,TRUE,55.58,0,11.5,10.91,14,11.08,12,15,14.6,14th and 15th grade,286,48,5.041666667,5,0.0183,0.3438,0.638,0.672704101,0.049336419,0.277959526
"Many people infected with the virus do not have clinical symptoms; the current
It is estimated that around 30% of people have antibodies against SARS-CoV-2 in their blood.
asymptomatic. These people are carriers of the virus and can transmit it to others who may react to it.
severe COVID-19 disease.",1021,Translated,TRUE,62.98,11.2,8.6,10.5,10.5,10.78,13,10.333333333333334,11.48,10th and 11th grade,300,50,5.08,5,0.0167,0.2984,0.685,0.656750023,0.066545531,0.276704371
"Many people who are infected with the virus show no clinical symptoms; current
estimates suggest that about 30% of individuals who have antibodies to SARS-CoV-2 in their blood
asymptomatic. These individuals carry the virus and potentially transmit it to others who may react with it
severe disease of COVID-19.",1021,Translated,TRUE,38.15,0,14,13.29,16.1,11.94,15,16.25,15.51,15th and 16th grade,311,49,5.428571429,5,0.0142,0.3509,0.635,0.653903902,0.069420211,0.27667591
"Many people who are infected with the virus do not have any clinical symptoms; current
Estimates suggest that about 30% of people who have antibodies against SARS-CoV-2 in their blood are
asymptomatic. These people carry the virus and potentially transmit it to others, who may react with
severe COVID-19 disease.",1021,Translated,TRUE,54.56,0,11.9,12.71,15.9,11.51,14,15.5,14.8,11th and 12th grade,313,50,5.34,5,0.0133,0.3044,0.6823,0.662637055,0.066968754,0.270394236
"Many people infected with the virus do not show any clinical symptoms; current
estimates suggest that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These individuals carry the virus and potentially spread it to others, who may react with it
severe covid-19 disease.",1021,Translated,TRUE,47.12,0,12.7,13.58,16.2,11.74,14,16,15.43,15th and 16th grade,308,48,5.5,5,0.0104,0.2636,0.726,0.656053662,0.065070502,0.278875768
"Many people infected with the virus have no clinical symptoms; present
estimates suggest that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These individuals carry the virus and potentially spread it to others who may react
severe COVID-19 disease.",1021,Translated,TRUE,40.69,0,13.1,14.5,16.1,11.9,13,15,15.16,14th and 15th grade,291,44,5.704545455,5,0.0112,0.2798,0.7091,0.659081399,0.063685104,0.277233481
"Many people infected with the virus show no clinical symptoms. drift
estimates show that about 30% of people who have antibodies against SARS-CoV-2 in their blood
asymptomatic. These people carry the virus and potentially spread it to others who may react to it
severe disease of COVID-19.",1021,Translated,TRUE,64,11.2,8.2,11.54,10.8,10.46,11,8.833333333333334,11.39,10th and 11th grade,289,47,5.234042553,5,0.0121,0.2491,0.7388,0.644968152,0.066926114,0.288105756
"Many people infected with the virus have no clinical symptoms; current
estimates suggest that around 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and can transmit it to others, who may react by
severe illness from COVID-19.",1021,Translated,TRUE,56.59,0,11.1,12.25,14.7,11.64,13,14,13.55,11th and 12th grade,285,46,5.282608696,5,0.0158,0.3664,0.6178,0.654694915,0.06977389,0.275531173
"Many people infected with the virus do not show any clinical symptoms; current
According to estimates, about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially spread it to others who may react
severe disease of COVID-19.",1021,Translated,TRUE,47.62,0,12.5,12.36,15.1,11.52,13,15.25,15.36,12th and 13th grade,293,47,5.319148936,5,0.0119,0.2688,0.7193,0.652180851,0.067296781,0.280522436
"Many people infected with the virus do not show any clinical symptoms. the point
It is estimated that about 30% of people who have SARS-CoV-2 antibodies in their blood have the disease.
No apparent symptoms. These people carry the virus and potentially transmit it to others who may interact with it
Serious illness Covid-19.",1021,Translated,TRUE,66.23,11.2,7.4,10.49,9.1,10.15,13,7.75,11.33,7th and 8th grade,325,54,5.092592593,5,0.0134,0.2891,0.6975,0.648982108,0.083281077,0.267736793
"Many people infected with the virus show no clinical symptoms. drift
estimates show that about 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially spread it to others, who may react to it
severe disease covid-19.",1021,Translated,TRUE,64.41,11.2,8.1,11.13,10.6,10.57,11,8.666666666666666,11.34,10th and 11th grade,283,46,5.239130435,5,0.0123,0.2505,0.7372,0.639759898,0.0685651,0.291675001
"Many people infected with the virus do not show any clinical symptoms; Present
It is estimated that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are infected with the virus.
No apparent symptoms. These individuals carry the virus and potentially transmit it to others who may interact with it
Severe COVID-19 illness.",1021,Translated,TRUE,52.9,13.6,10.4,12.36,12.5,10.29,13,12.5,13.14,12th and 13th grade,343,55,5.309090909,5,0.0125,0.2873,0.7002,0.650255144,0.068593897,0.281150967
"Many people infected with the virus do not show any clinical symptoms. point
It is estimated that about 30% of people who have antibodies to SARS-CoV-2 in their blood have this disease.
No noticeable symptoms. These people carry the virus and potentially pass it on to others who may interact with it
Severe disease Covid-19.",1021,Translated,TRUE,65.93,10.7,7.5,9.85,8.7,9.49,11,7.625,10.61,7th and 8th grade,325,55,4.981818182,5,0.0163,0.3207,0.663,0.639887929,0.067397267,0.292714834
"Many people infected with the virus do not have clinical symptoms; the actual
It is estimated that around 30% of people have antibodies to SARS-CoV-2 in their blood.
asymptomatic. These people carry the virus and can transmit it to other people who may react to it.
severe COVID-19 illness.",1021,Translated,TRUE,63.39,11.2,8.5,10.03,10,10.25,11,10.166666666666666,11.42,10th and 11th grade,290,49,5,5,0.0167,0.3005,0.6828,0.64452374,0.07437741,0.281098872
"Many people infected with the virus do not show clinical symptoms. drift
Estimates show that about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially spread it to others who may react
severe disease of COVID-19.",1021,Translated,TRUE,64.41,11.2,8.1,11.13,10.6,10.57,11,8.666666666666666,11.34,10th and 11th grade,283,46,5.239130435,5,0.0111,0.2403,0.7485,0.64973861,0.071826972,0.278434396
"Many people infected with the virus do not show clinical symptoms. Current estimates suggest that about 30% of people who have SARS-CoV-2 antibodies in their blood are asymptomatic. These people carry the virus and may spread it to others, who may respond with severe COVID-19 disease.",1021,Translated,TRUE,64.41,10.5,8.1,11.36,10.8,10.92,12,8.333333333333334,10.47,10th and 11th grade,285,46,5.217391304,5,0.0085,0.2155,0.7759,0.650494576,0.068232842,0.281272501
"Many people infected with the virus have no clinical symptoms; current
According to estimates, about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially pass it on to other people who may react
severe disease of COVID-19.",1021,Translated,TRUE,47.62,0,12.5,12.25,15,11.19,12,15.25,15.36,14th and 15th grade,292,47,5.29787234,5,0.0152,0.317,0.6678,0.643057764,0.062266514,0.294675738
"The findings support global recommendations to prioritize the allocation of COVID-19 vaccines to the elderly
groups. The relative differences between allocation strategies decreased with the rate of vaccine introduction
was increased.",1022,Translated,TRUE,21.9,0,14.1,20.01,17.3,13.57,15,11.75,15.23,13th and 14th grade,234,31,6.64516129,2,0.1173,0.8473,0.0354,0.729795456,0.091086686,0.179117858
"The findings support global recommendations to prioritize COVID-19 vaccine allocation to older age
groups. Relative differences between allocation strategies were reduced as the rate of vaccine rollout
was increased.",1022,Translated,TRUE,22.92,0,13.7,19.13,16.3,13.61,14,10.25,12.7,13th and 14th grade,216,29,6.551724138,2,0.1559,0.8159,0.0282,0.732419431,0.093222596,0.174357966
"The findings support global recommendations for prioritizing the distribution of the COVID-19 vaccine in the elderly
groups. The relative differences between distribution strategies were reduced as the rate of vaccine distribution increased
was increased.",1022,Translated,TRUE,20.38,0,14.6,19.78,17.8,11.91,13,12.5,13.86,12th and 13th grade,255,34,6.588235294,2,0.1745,0.804,0.0215,0.734463811,0.074722931,0.190813184
"Findings support global recommendations to prioritize COVID-19 vaccine allocation to older people
groups. Relative differences between allocation strategies decreased as the speed of vaccine rollout increased.
was increased.",1022,Translated,TRUE,14.97,0,14.7,22.09,18.7,13.92,14,9,12.74,12th and 13th grade,224,28,7.107142857,2,0.0894,0.842,0.0686,0.708723962,0.11049705,0.180778936
The results support global recommendations to prioritize COVID-19 vaccine allocation to older age groups. Relative differences between allocation strategies decreased as vaccine distribution increased.,1022,Translated,TRUE,0.08,0,16.2,24.11,19.5,15.42,14,8.5,14.8,14th and 15th grade,201,24,7.416666667,2,0.0959,0.8664,0.0377,0.721778035,0.115003698,0.16321823
"The results support global recommendations to prioritize covid-19 vaccine allocation for older age
groups. Relative differences between allocation strategies decreased as the vaccine evolved
was increased.",1022,Translated,TRUE,24.44,0,13.1,21.33,17.7,14.61,13,8.5,12.89,12th and 13th grade,205,26,7,2,0.1287,0.839,0.0324,0.719652414,0.102833174,0.177514434
"The findings support global recommendations to prioritize the distribution of the COVID-19 vaccine for older age groups
groups. The relative differences between distribution strategies decreased as the speed of vaccine circulation
Increased.",1022,Translated,TRUE,29.86,0,13.1,19.95,17.5,12.82,14,11.5,13.9,12th and 13th grade,241,32,6.625,2,0.0626,0.8601,0.0773,0.730732858,0.087859623,0.181407526
"The results support global recommendations to prioritize the allocation of the Covid-19 vaccine to older people
groups. The relative differences between allocation strategies have been reduced with the speed of the vaccine rollout
has been increased.",1022,Translated,TRUE,36.28,0,12.7,16.59,15.7,11.99,14,12,12.76,11th and 12th grade,250,36,6.027777778,2,0.1941,0.7818,0.0241,0.663600028,0.09047164,0.245928228
"The results support global recommendations to prioritize the allocation of the Covid-19 vaccine to older people
groups. The relative differences between allocation strategies decreased as the vaccine developed
has been increased.",1022,Translated,TRUE,21.9,0,14.1,19.08,16.6,13.06,14,11.25,13.94,13th and 14th grade,229,31,6.483870968,2,0.1103,0.8512,0.0385,0.70480001,0.097495288,0.197704703
"The findings support global recommendations to prioritize distribution of the COVID-19 vaccine to older age groups
groups. The relative differences between distribution strategies decreased with the rate of vaccine circulation
Increased.",1022,Translated,TRUE,21.9,0,14.1,20.59,17.8,13.06,14,11.25,13.94,13th and 14th grade,237,31,6.741935484,2,0.0856,0.8634,0.0509,0.739173293,0.086874112,0.173952535
"The findings support global recommendations for prioritizing COVID-19 vaccine allocation to older people.
groups. As the pace of vaccine rollout has accelerated, the relative differences between allocation strategies have decreased.
has increased.",1022,Translated,TRUE,12.94,0,15.4,20.47,18.4,13.31,15,11.5,13.9,13th and 14th grade,247,32,6.8125,2,0.1263,0.8359,0.0377,0.712800562,0.093734607,0.193464801
"The findings support global recommendations for prioritizing the distribution of the COVID-19 vaccine for the elderly
groups. The relative differences between distribution strategies decreased as the rate of vaccine distribution increased
was increased.",1022,Translated,TRUE,20.89,0,14.4,20.76,18.4,12.11,13,12.25,13.87,13th and 14th grade,253,33,6.757575758,2,0.1014,0.8642,0.0344,0.732101142,0.07840915,0.189489722
"The findings support global recommendations to prioritize the allocation of COVID-19 vaccines to older adults
groups. The relative differences between allocation strategies decreased with the rate of vaccine introduction
was increased.",1022,Translated,TRUE,21.9,0,14.1,20.24,17.5,14.08,15,11.25,13.94,13th and 14th grade,235,31,6.677419355,2,0.1128,0.8499,0.0373,0.726805329,0.093928665,0.179265961
The results support global recommendations to prioritize COVID-19 vaccine distribution to older age groups. The relative differences between distribution strategies decreased as the rate of vaccine circulation increased.,1022,Translated,TRUE,14.97,0,14.7,21.51,18,13.92,14,10.5,14.17,14th and 15th grade,220,28,6.892857143,2,0.0894,0.8627,0.0478,0.721832633,0.095157094,0.18301031
"The results support global recommendations for prioritizing covid-19 vaccine allocation to older people.
groups. As the rate of vaccine deployment has increased, the relative differences between distribution strategies have decreased.
has increased.",1022,Translated,TRUE,21.4,0,14.3,20.88,18.6,13.31,15,11.5,15.15,13th and 14th grade,249,32,6.875,2,0.1397,0.8191,0.0412,0.697695255,0.095589921,0.206714794
"Findings support global recommendations to prioritize COVID-19 vaccine allocation to older adults
groups. Relative differences between allocation strategies have been reduced as the speed of vaccine deployment
was increased.",1022,Translated,TRUE,22.92,0,13.7,20.76,17.7,14.16,14,10.75,14.08,13th and 14th grade,224,29,6.827586207,2,0.0815,0.8644,0.0541,0.691894174,0.09131217,0.216793597
The results support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies decreased as the pace of vaccine rollout increased.,1022,Translated,TRUE,23.93,0,13.3,20.81,17.3,14.25,14,8.75,12.81,12th and 13th grade,209,27,6.777777778,2,0.1024,0.8615,0.0361,0.715508699,0.113607548,0.170883775
The findings support global recommendations to prioritize COVID-19 vaccine allocation to older age groups. The relative differences between allocation strategies decreased as the pace of vaccine deployment increased.,1022,Translated,TRUE,23.43,0,13.5,20.64,17.4,13.92,14,10.5,14.17,13th and 14th grade,216,28,6.75,2,0.063,0.877,0.0599,0.731193841,0.098832615,0.169973582
"Findings Support Global Recommendations to Prioritize COVID-19 Vaccine Distribution for Older People
groups. Relative differences between distribution strategies decrease as vaccine distribution rate increases
was increased.",1022,Translated,TRUE,-0.95,0,16.6,25.56,21.1,14.61,14,10.5,14.43,14th and 15th grade,224,26,7.730769231,2,0.0931,0.8736,0.0333,0.717672408,0.093512498,0.188815102
"Down syndrome, which is caused by trisomy 21, is characterized by immune disorders, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,29.18,0,15.4,17.12,19.7,14.35,10,18.5,19.6,19th and 20th grade,176,25,6.12,4,0.0096,0.1735,0.8168,0.721787453,0.067500018,0.210712463
"Down syndrome, caused by Down syndrome, is characterized by immune dysregulation, anatomical problems
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,13.28,0,17.4,20.02,21.6,14.04,10,18,19.6,17th and 18th grade,181,24,6.625,2,0.0088,0.1299,0.8614,0.732856214,0.079421923,0.187721848
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,14.29,0,17,19.09,20.4,15.08,10,17.5,19.63,19th and 20th grade,170,23,6.47826087,4,0.0096,0.1616,0.8287,0.744807839,0.06176931,0.193422958
"Down syndrome, which is caused by trisomy 21, is characterized by immune disorders, anatomically
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,22.75,0,15.8,18.57,20,15.08,10,17.5,19.63,19th and 20th grade,168,23,6.391304348,4,0.0109,0.1893,0.7997,0.724459767,0.070463672,0.205076575
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysfunction, anatomical
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,29.18,0,15.4,17.12,19.7,14.35,10,18.5,19.6,19th and 20th grade,176,25,6.12,4,0.0093,0.1453,0.8454,0.748679042,0.065673538,0.185647413
"Down syndrome, caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Translated,TRUE,14.29,0,17,18.8,20.4,15.08,10,17.5,19.63,19th and 20th grade,170,23,6.434782609,4,0.01,0.1756,0.8144,0.745874703,0.061837099,0.192288175
"Down syndrome, which is caused by trisomy 21, is characterized by immunodeficiency, anatomical
differences in the upper respiratory tract and more severe covid-19 infections.",1029,Translated,TRUE,13.28,0,17.4,18.28,20.2,14.04,9,18,19.6,17th and 18th grade,174,24,6.333333333,4,0.0106,0.1717,0.8177,0.740157008,0.071979873,0.187863082
"Down syndrome caused by trisomy 21 is characterized by immune system disorders, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Translated,TRUE,21.74,0,16.2,17.82,19.6,15.35,11,18,19.6,17th and 18th grade,171,24,6.166666667,4,0.0084,0.1585,0.8331,0.741229832,0.069854714,0.188915476
"Down syndrome, which results from trisomy 21, is characterized by an immunological and anatomical defect
Differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,18.28,20.5,14.35,11,18.5,19.6,18th and 19th grade,180,25,6.28,4,0.0124,0.2442,0.7433,0.741634965,0.06798692,0.19037804
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,13.28,0,17.4,18.57,20.4,15.35,11,18,19.6,17th and 18th grade,175,24,6.375,4,0.0088,0.1472,0.844,0.748223126,0.062519886,0.189256981
"Down syndrome, caused by trisomy 21, is characterized by immune, anatomical dysregulation
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,14.29,0,17,18.8,20.2,15.08,10,17.5,19.63,19th and 20th grade,169,23,6.434782609,4,0.0112,0.1934,0.7955,0.737432361,0.068129376,0.194438219
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,17.82,20.3,14.98,11,18.5,19.6,19th and 20th grade,179,25,6.24,4,0.0082,0.1352,0.8566,0.740787864,0.063015945,0.196196154
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,19.71,0,17,17.58,20.5,14.64,11,19,19.63,16th and 17th grade,185,26,6.192307692,4,0.0085,0.1519,0.8396,0.738445938,0.063106537,0.19844754
"Down syndrome is caused by Down syndrome, immune dysregulation, and anatomical problems.
It is characterized by upper respiratory tract differences and more severe COVID-19 infections.",1029,Translated,TRUE,33.41,0,11.7,17.79,15,13.1,10,8.25,14.6,14th and 15th grade,184,25,6.44,2,0.008,0.1235,0.8685,0.728160322,0.084583543,0.187256083
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical differences of the upper respiratory tract and a more severe course of COVID-19 infection.",1029,Translated,TRUE,25.12,0,17,15.5,20,13.79,11,20.5,19.88,19th and 20th grade,194,29,5.724137931,4,0.0088,0.1754,0.8158,0.739144504,0.056759011,0.204096511
"Down syndrome, caused by trisomy 21, is characterized by immunodeficiency, anatomical
differences in the upper respiratory tract and more severe Covid-19 infections.",1029,Translated,TRUE,15.31,0,16.6,19.38,20.4,14.78,9,17,19.71,16th and 17th grade,165,22,6.590909091,4,0.0108,0.1786,0.8106,0.740211129,0.075585149,0.18420361
"Down syndrome, caused by trisomy 21, is characterized by immune dysfunction, anatomical
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,23.77,0,15.4,18.85,19.9,15.49,10,17,19.71,19th and 20th grade,163,22,6.5,4,0.0097,0.1472,0.8432,0.750929952,0.067403048,0.181666955
"Down syndrome, caused by trisomy 21, is characterized by immune disorders, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,22.75,0,15.8,18.34,19.7,15.08,10,17.5,19.63,19th and 20th grade,167,23,6.347826087,4,0.0101,0.1801,0.8098,0.734120905,0.06895595,0.196923107
"Down syndrome, caused by trisomy 21, is characterized by anatomical dysregulation of the immune system
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,17.82,20.1,14.98,11,18.5,19.6,19th and 20th grade,178,25,6.2,4,0.0084,0.1629,0.8287,0.738442242,0.066687539,0.194870144
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds
It has anti-inflammatory effects and also regulates the immune system, and is among the main elements
Factors that can help in the recovery of patients infected with COVID19.",1033,Translated,TRUE,31.89,0,18.5,14.52,23.9,13.26,15,25.5,21.75,18th and 19th grade,252,39,5.538461538,2,0.4494,0.5265,0.0241,0.634675503,0.067629345,0.29769513
"The presence of terpenoids, flavonoids and rich phenolic compounds which
which has an anti-inflammatory effect and also regulates the immune system, are some of the most important
substances that can help patients with COVID19 recover.",1033,Translated,TRUE,27.49,0,18.1,15.97,23.1,12.14,13,22.5,18.57,18th and 19th grade,235,35,5.8,2,0.7129,0.2728,0.0143,0.644797623,0.074510098,0.280692339
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
they have anti-inflammatory effects and also enhance the regulation of the immune system, they are among the most important
factors that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,27.83,0,20.1,14.52,25.7,12.01,14,26.5,20.92,20th and 21st grade,276,43,5.488372093,2,0.8452,0.1463,0.0084,0.648526073,0.082341194,0.269132733
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
has anti-inflammatory effects and also upregulation of the immune system, is among the biggest
agents that can help recover patients with covid19.",1033,Translated,TRUE,27.49,0,18.1,15.79,23.1,13.04,13,21.5,18.57,18th and 19th grade,235,35,5.8,2,0.4612,0.5094,0.0294,0.636611521,0.076905012,0.286483467
"The presence of terpenoids, flavonoids and a large number of phenolic compounds which
they have anti-inflammatory effects and also enhance the regulation of the immune system, they are among the most important
factors that may aid in the recovery of patients with COVID19.",1033,Translated,TRUE,27.83,0,20.1,14.12,25.3,11.64,14,26.5,20.92,20th and 21st grade,272,43,5.395348837,2,0.8281,0.1637,0.0081,0.667991519,0.075977035,0.256031513
"The presence of terpenoids, flavonoids and rich phenolic compounds
It has an anti-inflammatory effect and also regulates the immune system and is one of the main elements
Factors that may contribute to the recovery of patients infected with COVID19.",1033,Translated,TRUE,23.43,0,19.7,14.23,23.6,13.26,16,26.5,22.78,19th and 20th grade,249,39,5.461538462,2,0.2397,0.7144,0.046,0.638371587,0.066651225,0.294977218
"The presence of terpenoids, flavonoids and a rich amount of phenolic compounds which
they have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main ones
substances that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,36.29,0,18.9,13.94,25.2,12.38,14,25.5,20.92,25th and 26th grade,271,43,5.372093023,2,0.7266,0.2628,0.0106,0.636214316,0.072049364,0.291736275
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
They have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main
Agents that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,37.31,0,18.5,14,24.8,12.49,13,25,20.61,24th and 25th grade,266,42,5.404761905,2,0.6634,0.323,0.0136,0.642689288,0.078122914,0.279187799
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds
It has anti-inflammatory effects and also regulates the immune system, and is one of the main elements
Factors that may contribute to the recovery of patients infected with COVID19.",1033,Translated,TRUE,22.42,0,20.1,14.63,24.5,13.52,16,27,23,-1th and 0th grade,259,40,5.55,2,0.2319,0.7227,0.0454,0.635050178,0.067925848,0.297023922
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds.
It has anti-inflammatory effects and also regulates the immune system, and is among the main elements.
Factors that can help in the recovery of patients infected with COVID19.",1033,Translated,TRUE,58.28,11.2,8.4,13.04,11.2,11.97,15,7.5,11.35,11th and 12th grade,254,39,5.58974359,2,0.3742,0.607,0.0188,0.645422518,0.073033385,0.28154406
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds, which
have anti-inflammatory effects and also regulate the immune system, are among the main
agents that can aid in the recovery of COVID19 patients.",1033,Translated,TRUE,35.95,0,16.9,14.63,22.2,13.04,12,21.5,18.57,21st and 22nd grade,228,35,5.6,2,0.4541,0.5229,0.023,0.659292281,0.079617687,0.26109007
"The presence of terpenoids, flavonoids and large amounts of phenolic compounds, which have anti-inflammatory effects and also regulate the immune system, are among the most important active ingredients that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,24.45,0,19.3,16.14,24.8,12.59,14,25,20.46,24th and 25th grade,257,38,5.789473684,2,0.8476,0.1463,0.0061,0.661681175,0.077516586,0.260802209
"The presence of terpenoids, flavonoids and a rich amount of phenolic compounds which
they have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main
substances that can aid the recovery of COVID19 patients.",1033,Translated,TRUE,30.88,0,18.9,14.34,24.2,12.33,14,24,20,23rd and 24th grade,257,40,5.5,2,0.7274,0.2612,0.0114,0.651781738,0.086088613,0.262129664
"Terpenoids, flavonoids and abundant amounts of phenolic compounds are present.
They have an anti-inflammatory effect and also increase the regulation of the immune system, which is one of their main effects.
A substance that can help COVID-19 patients recover.",1033,Translated,TRUE,58.28,9.7,8.4,13.79,11.9,12.38,15,6.833333333333333,9.3,9th and 10th grade,260,39,5.743589744,2,0.8058,0.1883,0.0059,0.610779405,0.091765344,0.297455281
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also improve the regulation of the immune system, are among the most important factors that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,29.86,0,19.3,14.87,25,11.83,13,25.5,20.3,19th and 20th grade,266,41,5.512195122,2,0.9033,0.0911,0.0056,0.66511178,0.080247857,0.2546404
"Terpenoids, flavonoids and abundant amounts of phenolic compounds are present.
It has an anti-inflammatory effect and regulates the immune system, which is one of the main factors.
A medication that can help COVID-19 patients recover.",1033,Translated,TRUE,51.14,10.5,9,13.49,11.3,12.79,14,6.5,10.39,10th and 11th grade,234,35,5.771428571,2,0.6432,0.3481,0.0087,0.622857094,0.09423358,0.282909334
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds, which have anti-inflammatory effects and also enhance the regulation of the immune system, are among the key factors that can aid in the recovery of patients infected with COVID19.",1033,Translated,TRUE,30.88,0,18.9,14.52,24.5,12.73,15,25,21,24th and 25th grade,259,40,5.5,2,0.6847,0.3033,0.012,0.655922413,0.067495696,0.276581913
"The presence of terpenoids, flavonoids and rich phenolic compounds which
which are anti-inflammatory and also regulate the immune system, are some of the most important
substances that can help patients with COVID19 recover.",1033,Translated,TRUE,29.52,0,17.3,16.37,22.5,11.97,12,21.5,18.05,16th and 17th grade,224,33,5.878787879,2,0.7496,0.2372,0.0132,0.646108329,0.074581936,0.27930975
"The presence of terpenoids, flavonoids and rich phenolic compounds which
they have an anti-inflammatory effect and also increase the regulation of the immune system, are among the main ones
substances that may contribute to the recovery of COVID19 patients.",1033,Translated,TRUE,31.89,0,18.5,15.27,24.5,13.26,15,24.5,20.73,24th and 25th grade,257,39,5.666666667,2,0.2131,0.7308,0.056,0.647560656,0.077387497,0.275051862
"Dietary supplements and vitamins including vitamin D and high dose vitamin
C have also been used to treat COVID-19. Despite the expected excellent tolerance and
interesting rationale to support their activities against COVID-19, their preventive or therapeutic
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,23.26,0,15.6,17.18,18.1,12.82,18,18.75,20.56,12th and 13th grade,314,45,6.066666667,4,0.1775,0.7489,0.0736,0.691022575,0.15235725,0.156620115
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C have also been used to treat COVID-19. Despite an expected excellent tolerance and a
interesting reasoning to support their activities against COVID-19, their preventive or therapeutic activities
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,17.7,18.9,12.67,18,19.5,20.5,12th and 13th grade,327,46,6.195652174,4,0.1862,0.7556,0.0582,0.667158782,0.154521883,0.178319305
"Dietary supplements and vitamins including vitamin D and high dose vitamin
C has also been used for COVID-19 treatment. Despite an expected excellent tolerance and a
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,17.82,18.7,13.52,20,19.25,20.56,18th and 19th grade,320,45,6.2,4,0.1618,0.7705,0.0678,0.671762109,0.171339154,0.156898752
"Dietary supplements and vitamins including vitamin D and high doses of the vitamin
C is also used to treat COVID-19. Despite the expected excellent tolerance and
interesting rationale for supporting their activities against COVID-19, their preventive or therapeutic activities
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,13.78,0,17.2,17.47,18.8,12.53,19,20.25,21.31,12th and 13th grade,330,47,6.106382979,4,0.1893,0.7549,0.0558,0.64730233,0.185116827,0.167580828
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C was also used to treat COVID-19. Excellent resistance and
Interesting evidence supporting anti-COVID-19 activity, prevention or treatment
Randomized trials have not confirmed effectiveness.",1036,Translated,TRUE,11.92,0,15.8,21.17,19.6,14.7,17,16,20.92,15th and 16th grade,268,34,7,4,0.5732,0.4035,0.0233,0.684036613,0.153318599,0.162644759
"Supplements and vitamins including vitamin D and high doses of vitamin D
C has also been used to treat COVID-19. Despite the expected excellent tolerance and
An interesting justification to support their activities against Covid-19, whether preventive or therapeutic
Its effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,21.74,0,16.2,16.48,18.3,12.39,18,19.5,20.43,19th and 20th grade,329,48,5.9375,4,0.3229,0.6427,0.0345,0.644998729,0.19712244,0.157878742
"Dietary supplements and vitamins, including high-dose vitamin D and vitamin C, have also been used for the treatment of COVID-19. Despite expected excellent tolerability and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,18.34,19.4,13.52,20,19.25,20.56,18th and 19th grade,327,45,6.288888889,4,0.2894,0.6849,0.0257,0.693069398,0.132191539,0.174739093
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C have also been used for the treatment of COVID-19. Despite excellent expected tolerance and
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic actions
effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,19.73,20.5,13.88,21,19.25,20.56,20th and 21st grade,337,45,6.577777778,4,0.1255,0.7975,0.077,0.680937946,0.149367526,0.169694528
"Supplements and vitamins including vitamin D and high doses of vitamin D
C has also been used to treat COVID-19. Despite the expected excellent tolerance and
An interesting justification to support their anti-COVID-19 activities, preventive or therapeutic
Its effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,16.66,18,12.67,19,19.5,20.5,16th and 17th grade,318,46,6,4,0.1848,0.7467,0.0684,0.657909632,0.182072431,0.160017863
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C has also been used for covid-19 treatment. Despite an expected excellent tolerance and a
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,15.31,0,16.6,18.33,19.2,13.7,20,19,20.62,18th and 19th grade,320,44,6.363636364,4,0.1448,0.7693,0.0859,0.674759328,0.164743036,0.16049771
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C have also been used for the treatment of COVID-19. Despite the expected excellent tolerability and
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,18.57,19.5,13.52,20,19.25,20.56,18th and 19th grade,328,45,6.377777778,4,0.1177,0.7976,0.0847,0.701049209,0.123494253,0.175456583
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite expected excellent tolerability and an interesting rationale for their anti-COVID-19 activities, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,7.86,0,17.4,18.33,19,13.33,18,18.5,20.78,18th and 19th grade,308,42,6.357142857,4,0.344,0.6307,0.0253,0.677954555,0.137961552,0.184084013
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite expected excellent tolerability and an interesting rationale for their anti-COVID-19 effects, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,16.32,0,16.2,17.93,18.7,13.33,18,18,19.83,17th and 18th grade,305,42,6.285714286,4,0.3426,0.6329,0.0245,0.694155931,0.113823473,0.192020535
"Dietary supplements and vitamins, including vitamin D and high doses of vitamin.
C have also been used to treat COVID-19. Despite the expected excellent tolerance and
interesting foundation to support your activities against COVID-19, its preventive or therapeutic nature
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,30.16,15.9,13,16.01,14.4,12.48,20,12.833333333333334,17.34,12th and 13th grade,325,47,6,4,0.2425,0.6921,0.0654,0.653218746,0.177101061,0.169680178
"Dietary supplements and vitamins, including vitamin D and a high-dose vitamin
C have also been used to treat COVID-19. Despite the excellent expected tolerance and
interesting rationale to support their activities in the fight against COVID-19, their preventive or therapeutic actions
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,21.23,0,16.4,16.54,18.7,12.59,19,19.75,20.41,16th and 17th grade,338,49,5.979591837,4,0.1929,0.7496,0.0575,0.665370524,0.151229277,0.183400244
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C has also been used to treat covid-19. Despite excellent expected tolerance and
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic measures
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,7.35,0,17.6,19.26,19.9,13.88,20,18.75,20.69,18th and 19th grade,321,43,6.558139535,4,0.1371,0.7463,0.1166,0.673089981,0.155036896,0.171873108
"Dietary supplements including vitamin D and high-dose vitamins and vitamin C have also been used to treat COVID-19. Expected excellent tolerability and
interesting evidence supporting anti-COVID-19 activity, prevention or treatment
Randomized trials have not shown efficacy",1036,Translated,TRUE,2.44,0,17.4,19.78,18.7,14.62,17,17,21.64,16th and 17th grade,273,36,6.666666667,4,0.4784,0.4959,0.0257,0.669178188,0.131815597,0.19900623
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C has also been used to treat COVID-19. Despite the expected excellent tolerability and an
an interesting rationale to support their anti-COVID-19 activity, their preventive or curative activity
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,17.18,18.7,13.02,19,20,20.5,16th and 17th grade,324,46,6.130434783,4,0.2093,0.7416,0.0492,0.691435218,0.123086147,0.185478598
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite the expected excellent tolerability and an interesting rationale for their anti-COVID-19 effect, their preventive or curative effect has not been confirmed in randomized trials.",1036,Translated,TRUE,24.27,0,15.2,16.71,17.9,12.78,17,17.75,18.83,17th and 18th grade,303,43,6.069767442,4,0.3362,0.6409,0.0229,0.684803307,0.125484765,0.189711958
"We addressed the infectivity of the central nervous system. First reports from Wuhan
claimed that 36% of COVID-19 patients show neurological symptoms, later European studies showed
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,43.73,0,11.9,14.33,14.6,14.14,16,12,12.86,11th and 12th grade,251,38,5.684210526,6,0.0271,0.7012,0.2717,0.650590479,0.085564286,0.263845235
"We have looked at the contagiousness of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients had neurological symptoms, later European studies
showed that this figure was as high as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.65,0,11.7,13.05,14.8,13.15,16,13.75,14.18,13th and 14th grade,274,43,5.441860465,6,0.028,0.7638,0.2082,0.654639304,0.085369579,0.259991109
"We addressed the infectivity of the central nervous system. Early reports from Wuhan
suggested that 36% of covid-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,35.78,0,12.9,14.56,14.6,14.37,17,12.25,13.89,14th and 15th grade,246,37,5.72972973,6,0.0292,0.7182,0.2527,0.670684159,0.083115742,0.246200159
"We have addressed susceptibility to CNS infection. Initial reports from Wuhan
Subsequent European studies indicated that 36% of COVID-19 patients develop neurological symptoms
Show up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.84,0,13.5,16.53,15.6,15.16,17,13,17.39,12th and 13th grade,239,34,6.117647059,6,0.0337,0.8171,0.1492,0.67101711,0.07339602,0.255586922
"We turned to infection of the central nervous system. First reports from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed as much as 60%; reported cases of viral encephalitis.",1041,Translated,TRUE,44.75,0,11.5,13.51,13.8,14.62,16,12,13.87,13th and 14th grade,235,36,5.611111111,6,0.0181,0.514,0.4679,0.643073142,0.083544835,0.273382038
"We have dealt with infectivity of the central nervous system. Initial reports from Wuhan
A subsequent European study suggested that 36% of COVID-19 patients had neurological symptoms.
A whopping 60% showed up; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.82,11.9,9.5,13.38,11.5,14,17,7.833333333333334,12.38,11th and 12th grade,257,39,5.666666667,6,0.0221,0.5121,0.4658,0.643446863,0.079782203,0.27677092
"We discussed the infectious power of the central nervous system. First reports from Wuhan
suggested that 36% of covid-19 patients have neurological symptoms, later European studies
shown up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,44.24,0,11.7,14.39,14.4,14.37,17,12.25,13.89,13th and 14th grade,245,37,5.702702703,6,0.0385,0.7786,0.1828,0.649113119,0.082032755,0.268854231
"We looked at the transmissibility of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients had neurological symptoms, and later European studies suggested that this figure was as high as 60%. Cases of viral encephalitis have been reported.",1041,Translated,TRUE,48.5,11.9,10,13.04,11.6,12.42,16,8.5,11.3,11th and 12th grade,278,43,5.488372093,6,0.0283,0.8553,0.1164,0.657121837,0.0839421,0.258936018
"We have studied CNS infectivity. First reports from Wuhan
claimed that 36% of COVID-19 patients had neurological symptoms, later European studies showed
showed that this figure was as high as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,52.19,0,10.7,13.23,13.7,13.3,13,12,12.86,12th and 13th grade,244,38,5.5,6,0.0254,0.7388,0.2358,0.627390921,0.082486808,0.2901223
"We address the infectability of the central nervous system. First reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, subsequent European studies
showed up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,15.31,15.2,14.18,16,12.5,14.98,14th and 15th grade,246,36,5.916666667,6,0.0228,0.6182,0.359,0.656123459,0.083980128,0.259896368
"We addressed the infectivity of the central nervous system. First news from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,44.24,0,11.7,14.1,14.1,13.94,16,12.25,13.89,13th and 14th grade,243,37,5.648648649,6,0.029,0.7125,0.2585,0.650633276,0.086302161,0.263064533
"We looked at the infectivity of the central nervous system. Initial reports from Wuhan
claimed that 36% of COVID-19 patients had neurological symptoms, later European studies showed
that it was as high as 60%; cases of viral encephalitis were reported.",1041,Translated,TRUE,51.18,0,11.1,12.59,13.7,14.1,16,12.5,13,12th and 13th grade,252,40,5.375,6,0.0203,0.6952,0.2845,0.662343442,0.086522467,0.251134098
"We addressed central nervous system infectivity. The first news from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
Appeared up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.33,0,13.7,16.88,16.2,14.88,18,12.75,16.14,16th and 17th grade,249,35,6.2,6,0.0274,0.6806,0.292,0.646162152,0.084232502,0.269605428
"We covered central nervous system infection. First news from Wuhan
Subsequent European studies suggested that 36% of COVID-19 patients had neurological symptoms
Up to 60% showed. Cases of viral encephalitis have been reported.",1041,Translated,TRUE,43.39,11.9,9.9,14.6,11.8,14.71,16,6.833333333333333,12.88,11th and 12th grade,226,33,5.939393939,6,0.0204,0.6622,0.3174,0.62678355,0.084768675,0.288447827
"We addressed central nervous system infectivity. The first reports from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.33,0,13.7,17.05,16.4,15.33,18,12.75,16.14,12th and 13th grade,250,35,6.228571429,6,0.0225,0.6078,0.3698,0.660504282,0.079919457,0.259576261
"We turned to central nervous system infection. First reports from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed as much as 60%; reported cases of viral encephalitis.",1041,Translated,TRUE,45.76,0,11.1,14.5,14.1,15.16,16,11.5,13.86,14th and 15th grade,228,34,5.794117647,6,0.0177,0.4829,0.4994,0.644185185,0.084457934,0.271356821
"We have dealt with the infectivity of the central nervous system. First reports from Wuhan
A later European study suggested that 36% of COVID-19 patients had neurological symptoms.
A whopping 60% showed up; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.52,11.2,9.7,11.99,10.6,13.38,16,7.666666666666666,11.32,10th and 11th grade,254,40,5.425,6,0.0189,0.4373,0.5438,0.639119148,0.080391705,0.280489206
"We turned to central nervous system infection. The first reports from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,15.6,15.5,15.06,17,13,16.09,15th and 16th grade,248,36,5.972222222,6,0.0154,0.4615,0.5231,0.644209504,0.079226956,0.276563555
"We address the infectivity of the central nervous system. First news from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, subsequent European studies
showed up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,14.5,14.5,13.74,15,12.5,14.98,14th and 15th grade,241,36,5.777777778,6,0.0263,0.6351,0.3386,0.650005996,0.086913727,0.263080299
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity, improving the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first authorized coronavirus (COVID-19) vaccine
all over the world.",1042,Translated,TRUE,40.18,0,13.2,16.54,17.7,12.12,17,15.25,16.11,16th and 17th grade,310,45,5.977777778,2,0.7593,0.2356,0.0051,0.633800507,0.069416769,0.296782702
"Recent improvements in mRNA vaccines act to increase protein translation, mod
innate and adaptive immunogenicity and delivery improvement. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines
Worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.81,17.1,13.3,17,12.5,13.92,12th and 13th grade,271,38,6.236842105,2,0.7679,0.2262,0.0058,0.6243397,0.07409656,0.301563799
"Recent improvements in mRNA vaccines act to increase protein translation and modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first authorized COVID-19 vaccines
global.",1042,Translated,TRUE,34.26,0,13.5,16.82,16.6,12.52,17,13.5,15,13th and 14th grade,277,40,6.025,2,0.6329,0.3582,0.0089,0.634747922,0.067357965,0.29789412
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity and improve the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine against coronavirus (COVID-19)
around the world.",1042,Translated,TRUE,39.67,0,13.4,16.42,17.7,11.64,16,14.5,14.42,11th and 12th grade,315,46,5.934782609,2,0.8033,0.1918,0.005,0.626648486,0.067995518,0.305355966
"Recent improvements in mRNA vaccines enhance protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
a vaccine that protects against infectious diseases and were the first COVID-19 vaccines to be approved
in the whole world.",1042,Translated,TRUE,41.7,0,12.7,15.72,16.3,12.2,17,13.5,14.11,12th and 13th grade,284,42,5.857142857,2,0.8273,0.1671,0.0056,0.622356415,0.066383161,0.311260372
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity and improve the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine against the coronavirus (COVID-19)
around the world.",1042,Translated,TRUE,39.16,0,13.6,16.08,17.7,11.52,16,14.75,14.51,14th and 15th grade,319,47,5.872340426,2,0.7959,0.1989,0.0052,0.624716878,0.06622123,0.309061944
"Recent improvements in mRNA vaccines increase protein translation,
Has innate and adaptive immunogenicity and improves delivery. mRNA vaccines are a new type of
It is the first COVID-19 vaccine approved to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,36.28,0,12.7,16.76,16.1,13.3,17,11.5,12.76,12th and 13th grade,253,36,6.138888889,2,0.7681,0.224,0.0079,0.616668046,0.081651233,0.301680803
"Recent improvements in mRNA vaccines increase protein translation,
It has innate and adaptive immunogenicity and improves delivery. mRNA vaccines are a new type
It is the first COVID-19 vaccine approved to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,36.28,0,12.7,16.76,16.1,13.3,17,11.5,12.76,12th and 13th grade,253,36,6.138888889,2,0.8836,0.1122,0.0042,0.615336299,0.077323571,0.307340175
"Recent improvements in mRNA vaccines act to increase protein translation, mod
innate and adaptive immunogenicity and delivery enhancement. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved covid-19 vaccines
Worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.81,17.1,13.3,17,12.5,13.92,12th and 13th grade,271,38,6.236842105,2,0.7554,0.2385,0.0061,0.623996675,0.072047532,0.303955883
"Recent improvements in mRNA vaccines act to increase protein translation, modulation
innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved vaccines against COVID-19
all over the world.",1042,Translated,TRUE,41.7,0,12.7,16.71,17.2,11.82,16,13.5,14.11,16th and 17th grade,292,42,6.047619048,2,0.7873,0.2068,0.0059,0.625443816,0.063676096,0.310880095
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines
worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.98,17.2,12.89,17,12.5,13.92,12th and 13th grade,272,38,6.263157895,2,0.7158,0.2771,0.0071,0.628843248,0.068714939,0.302441835
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines worldwide.",1042,Translated,TRUE,35.78,0,12.9,18.45,17.5,13.09,17,12.25,13.89,12th and 13th grade,269,37,6.297297297,2,0.8288,0.1664,0.0047,0.623206019,0.072501183,0.304292768
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines approved worldwide.",1042,Translated,TRUE,35.78,0,12.9,18.45,17.5,13.09,17,12.25,13.89,12th and 13th grade,269,37,6.297297297,2,0.843,0.1526,0.0044,0.619556665,0.071045965,0.30939737
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines approved worldwide.",1042,Translated,TRUE,35.78,0,12.9,17.52,16.7,13.09,17,12.25,13.89,12th and 13th grade,263,37,6.135135135,2,0.8512,0.1445,0.0043,0.619657815,0.071225129,0.309117138
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first covid-19 vaccines to be approved
Worldwide.",1042,Translated,TRUE,42.21,0,12.5,16.24,16.5,12.36,17,13.25,14.05,12th and 13th grade,281,41,5.951219512,2,0.6828,0.3095,0.0077,0.623160481,0.064299077,0.312540472
"Recent improvements in mRNA vaccines work by increasing protein translation, modulating
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved vaccines against COVID-19
worldwide.",1042,Translated,TRUE,34.76,0,13.3,18.85,18.1,12.7,17,13.25,14.98,12th and 13th grade,285,39,6.41025641,2,0.8171,0.1772,0.0056,0.628422916,0.072883695,0.298693329
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity, improving the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine for the coronavirus (COVID-19)
all over the world.",1042,Translated,TRUE,39.16,0,13.6,15.61,17.4,11.86,17,15.25,15.36,15th and 16th grade,316,47,5.808510638,2,0.7838,0.2109,0.0053,0.630791545,0.069766283,0.299442142
"Recent improvements in mRNA vaccines act to increase protein translation and modulation.
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first vaccines approved against COVID-19
all over the world.",1042,Translated,TRUE,48.5,11.2,10,15.71,13.4,11.32,16,8.166666666666666,11.3,10th and 11th grade,295,43,5.953488372,2,0.7549,0.2387,0.0065,0.627993226,0.067920968,0.304085791
"Recent improvements in mRNA vaccines increase protein translation and modification
Improving the birth process with innate and adaptive immunity. mRNA vaccines are a new type of vaccine.
This is the first approved coronavirus (COVID-19) vaccine to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,40.65,11.9,11,17.22,14.7,12.79,18,8.166666666666666,12.31,10th and 11th grade,295,41,6.292682927,2,0.8068,0.1888,0.0044,0.623754621,0.072008342,0.304237008
"We observed a slight effect of age on ICU admission. This is probably due to the first wave
Due to the new Corona virus (Covid-19) in Spain, a large number of elderly people have died in nursing homes before
He may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,62.51,0,10.9,7.9,12.1,10.47,10,15.75,14.91,10th and 11th grade,275,51,4.450980392,2,0.0192,0.4868,0.494,0.636385441,0.089118488,0.274496138
"We noted a minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before
You could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.99,11.1,10.21,10,14.25,15.11,10th and 11th grade,241,43,4.674418605,2,0.0231,0.6436,0.3333,0.674972296,0.143167391,0.181860372
"We noticed a small effect of age on intensive care admissions. This is probably because in the first wave
of covid-19 in Spain, a large number of elderly people died in nursing homes before they
may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,56.59,0,11.1,9.52,12,9.58,9,15,14.42,9th and 10th grade,259,46,4.695652174,2,0.0197,0.4523,0.528,0.67132777,0.105189785,0.223482385
"We found a small effect of age on ICU admission. This is probably because in the first wave of Covid-19 in Spain, many elderly people died in nursing homes before they were even admitted to hospital or ICU.",1043,Translated,TRUE,69.11,0,8.3,7.89,9,9.15,6,12,11.81,8th and 9th grade,206,38,4.447368421,2,0.025,0.5006,0.4743,0.675610185,0.153251931,0.171137929
"We found a minor effect of age on ICU admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.59,4.9,9.54,9,5.625,9.97,9th and 10th grade,225,41,4.56097561,2,0.013,0.3094,0.6776,0.674987316,0.126855388,0.198157236
"We observed a small effect of age on ICU admission. This is probably because in the first wave
In Spain, a significant number of elderly people died prematurely in nursing homes due to COVID-19
even to a hospital or intensive care unit.",1043,Translated,TRUE,58.62,0,10.3,9.11,10.9,10.32,9,14,14.11,9th and 10th grade,236,42,4.69047619,2,0.0212,0.503,0.4758,0.690929234,0.112671927,0.196398795
"We observed a small effect of age on admissions to intensive care. This is probably because in the first wave of Covid-19 in Spain, a large number of elderly people died in nursing homes before they could be admitted to hospital or ICU.",1043,Translated,TRUE,66.57,0,9.3,8.36,10.6,9.48,8,13.75,13.25,8th and 9th grade,236,43,4.511627907,2,0.0228,0.5529,0.4243,0.696842849,0.106763594,0.196393639
"We found a small effect of age on ICU admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.59,4.9,9.15,8,5.625,9.97,9th and 10th grade,225,41,4.56097561,2,0.0154,0.354,0.6306,0.672969699,0.125792503,0.201237768
"We noticed a minor influence of age on intensive care admissions. This is probably because during the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before they could
could even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,48.64,0,12.1,11.9,13.7,10.02,11,15.75,16.11,11th and 12th grade,272,45,5.111111111,2,0.0172,0.4525,0.5303,0.665166736,0.112599447,0.222233832
"We found a minor effect of age on ICU admission. Probably because during the first wave.
In Spain, a significant number of elderly people have died from COVID-19 before entering nursing homes.
You may be hospitalized or admitted to an intensive care unit.",1043,Translated,TRUE,60.51,11.2,7.5,9.43,7.3,10.41,11,6.375,11.76,7th and 8th grade,255,43,5,2,0.0125,0.3488,0.6388,0.667036355,0.115616858,0.217346802
"We noticed a smaller influence of age on admissions to intensive care. This is probably because during the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before they could
even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,48.64,0,12.1,11.78,13.6,10.02,11,15.75,16.11,11th and 12th grade,271,45,5.088888889,2,0.0241,0.5537,0.4222,0.662833631,0.109658346,0.227508008
"We observed a small effect of age on ICU admission. This is probably because in the first wave
of COVID-19 in Spain, a significant number of elderly people died in nursing homes before they
may even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,58.11,0,10.5,9.57,11.6,10.21,10,14.25,15.11,9th and 10th grade,245,43,4.76744186,2,0.0205,0.5218,0.4577,0.698211551,0.114592656,0.187195867
"A minor effect of age on ICU admission was found. Probably due to the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.12,4.6,9.54,9,5.625,9.97,9th and 10th grade,222,41,4.487804878,2,0.0105,0.2686,0.7209,0.691000521,0.115175426,0.193824083
"We observed a small effect of age on ICU admissions. This is probably due to the first wave
of COVID-19 in Spain, a significant number of elderly people died in nursing homes before
he could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.24,10.5,9.84,9,13.75,14.18,10th and 11th grade,235,43,4.534883721,2,0.0183,0.5198,0.4618,0.70373565,0.118117765,0.178146601
"We found a smaller effect of age on intensive care unit admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,68.47,11.2,6.5,8.45,6.7,9.46,10,6.625,10.74,6th and 7th grade,259,45,4.822222222,2,0.0189,0.3937,0.5874,0.642131805,0.108576186,0.249291971
"We noted a small effect of age on ICU admission. This is probably because in the first wave
a significant number of elderly people in nursing homes died of COVID-19 in Spain before
he could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.24,10.4,9.84,9,13.75,14.18,9th and 10th grade,234,43,4.511627907,2,0.0273,0.6965,0.2762,0.676755607,0.1428103,0.180434123
"We noted a smaller influence of age on intensive care admissions. This is probably because in the first wave
of covid-19 in Spain, a large number of elderly people died in nursing homes earlier
You may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,56.59,0,11.1,9.87,12.3,10.27,11,16,16.16,9th and 10th grade,262,46,4.760869565,2,0.0261,0.5857,0.3882,0.668799341,0.109200388,0.22200036
"We found little effect of age on ICU admission. Perhaps due to the first wave.

In Spain, a large number of elderly people in nursing homes have died from COVID-19.

You may be hospitalized or admitted to ICU.",1043,Translated,TRUE,78.75,8.8,4.6,6,4.4,8.68,6,4.75,8.01,4th and 5th grade,209,38,4.578947368,2,0.0151,0.4474,0.5376,0.661833048,0.146615371,0.191551566
"We observed a small effect of age at ICU admission. This is probably due to the first wave
In Spain, a significant number of elderly people have died prematurely in nursing homes due to COVID-19
even in a hospital or intensive care unit.",1043,Translated,TRUE,58.11,0,10.5,8.47,10.7,10.21,9,14.25,14.18,10th and 11th grade,237,43,4.581395349,2,0.0183,0.4492,0.5325,0.69306612,0.116367675,0.190566227
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
older people, were similar to those seen after previous vaccinations and mostly resolved on their own. Fatigue,
myalgia and fever were the most common systemic side effects reported (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,38.62,12.5,11.8,14.27,13.7,12.14,17,10.5,12.24,11th and 12th grade,318,47,5.85106383,7,0.0199,0.4548,0.5253,0.638981402,0.065003313,0.296015233
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and mostly self-resolved. Fatigue,
myalgia and fever were the most frequently reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,31.89,13.6,12.3,16.81,15.4,13.35,18,10.333333333333334,12.27,11th and 12th grade,307,42,6.404761905,7,0.022,0.5156,0.4625,0.65781039,0.068789549,0.273400068
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
elderly, were similar to those seen after previous vaccines and mostly resolved. Fatigue,
myalgia and fever were the most frequently reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,40.04,13,11.2,14.9,13.9,13.16,17,10.166666666666666,13.16,12th and 13th grade,299,43,6.046511628,7,0.0252,0.4859,0.4889,0.651252151,0.067564428,0.281183422
"Local and systemic reactions have been reported following the third Pfizer vaccine dose.
In older adults, events were similar to those observed after previous vaccination and were mostly self-resolving. fatigue,
Myalgia and fever were the most frequently reported systemic side effects (19.6%, 9.2%, 8.1%).
each).",1061,Translated,TRUE,47.79,13,10.3,14.49,14.2,13.15,16,10.5,12.22,10th and 11th grade,313,45,6.044444444,7,0.0211,0.5663,0.4126,0.653480947,0.070065774,0.276453316
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised and
In older people, they were similar to those observed after previous vaccinations and most were self-resolving. exhaustion,
Myalgia and fever were the most common systemic side effects (19.6%, 9.2%, and 8.1%).
respectively).",1061,Translated,TRUE,39.33,13,11.5,15.13,14.8,12.8,18,10.5,14,12th and 13th grade,318,45,6.155555556,7,0.0302,0.634,0.3358,0.650196493,0.072135307,0.277668178
"Local and systemic reactions after a third Pfizer vaccination, reported by immunocompromised individuals and
elderly individuals, were similar to those seen after previous vaccinations and mostly resolved on their own. Fatigue,
myalgia, and fever were the most common systemic side effects reported (19.6%, 9.2%, and 8.1%
respectively).",1061,Translated,TRUE,21.7,14.6,14.1,16.24,15.5,12.48,18,11.833333333333334,14.79,14th and 15th grade,336,47,6.234042553,7,0.019,0.4664,0.5146,0.643719018,0.061603773,0.294677258
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised individuals and
in the elderly, were similar to those observed after previous vaccines and were mostly self-limited. fatigue,
myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,39.33,13,11.5,15.25,14.4,13.5,19,10.5,14,13th and 14th grade,315,45,6.088888889,7,0.0197,0.461,0.5193,0.656874955,0.069118463,0.274006546
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
In the elderly, they were similar to those seen after previous vaccinations, and most resolved on their own. exhaustion,
Myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%, respectively).
respectively).",1061,Translated,TRUE,38.32,13.6,11.9,14.32,14.3,12.33,17,11.333333333333334,13.9,13th and 14th grade,329,48,5.9375,7,0.0433,0.6974,0.2593,0.641201496,0.070381179,0.288417339
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and usually self-resolved. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respective).",1061,Translated,TRUE,31.89,14.1,12.3,16.35,15.1,13.73,19,10.666666666666666,13.22,13th and 14th grade,304,42,6.333333333,7,0.0234,0.5229,0.4537,0.643405497,0.063888095,0.29270637
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
elderly, were similar to those seen after previous vaccines and mostly resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,39.33,13,11.5,14.09,13.5,12.8,17,10.5,13.11,12th and 13th grade,306,45,5.888888889,7,0.0201,0.4196,0.5603,0.644241989,0.06405925,0.291698784
"Local and systemic reactions following a third Pfizer vaccination reported by immunocompromised individuals and the elderly were similar to those following previous vaccinations and mostly resolved on their own. Fatigue, myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%, respectively).",1061,Translated,TRUE,22.11,15.9,14,17.04,15.9,12.63,18,12.666666666666666,15.69,15th and 16th grade,335,46,6.304347826,7,0.0259,0.4982,0.4759,0.63838917,0.058923628,0.302687168
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
in older people, were similar to those seen following previous vaccines and mostly resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic side effects (19.6%, 9.2%, and 8.1%
respectively).",1061,Translated,TRUE,38.32,13,11.9,14.09,13.7,12,17,11,12.23,11th and 12th grade,324,48,5.833333333,7,0.0185,0.4167,0.5649,0.640704334,0.064214215,0.295081466
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
older, were similar to those seen after previous vaccines and mostly disappeared. Fatigue,
myalgia and fever were the most commonly reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,40.35,13,11.1,15.13,13.9,13.35,17,9,13.22,12th and 13th grade,294,42,6.095238095,7,0.0216,0.3936,0.5848,0.642226636,0.06513276,0.292640597
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised individuals and
in the elderly were similar to those observed after previous vaccinations and were mostly self-limited. Fatigue,
myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%,
respectively).",1061,Translated,TRUE,30.87,13.6,12.7,15.77,14.8,13.5,19,10.833333333333334,14.89,13th and 14th grade,319,45,6.177777778,7,0.0191,0.4562,0.5248,0.648978293,0.068926394,0.282095224
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and mostly self-resolved. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respective).",1061,Translated,TRUE,31.89,13.6,12.3,16.23,15,13.35,18,10.333333333333334,12.27,11th and 12th grade,303,42,6.30952381,7,0.022,0.4955,0.4825,0.648097336,0.064197384,0.287705183
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
in older people, were similar to those seen after previous vaccines and usually resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2%, and 8.1%
respective).",1061,Translated,TRUE,38.32,13.6,11.9,14.09,13.7,12.33,18,11.333333333333334,13.07,13th and 14th grade,324,48,5.833333333,7,0.0254,0.5012,0.4734,0.622768462,0.059293889,0.317937613
"Local and systemic reactions following a third Pfizer vaccination reported by immunocompromised and elderly people were similar to those following previous vaccinations and generally resolved on their own. Fatigue, myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%, respectively).",1061,Translated,TRUE,22.41,15.9,13.9,17.16,15.9,12.8,18,12.5,15.78,15th and 16th grade,329,45,6.333333333,7,0.0288,0.4956,0.4757,0.634604752,0.062589429,0.302805781
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised and
in the elderly, were similar to those observed after previous vaccines and mostly resolved on their own. Tiredness,
myalgia and fever were the most common systemic adverse reactions (19.6%, 9.2% and 8.1%).
respectively).",1061,Translated,TRUE,47.49,12.5,10.4,14.14,13.8,12.63,18,10.333333333333334,12.21,12th and 13th grade,314,46,5.913043478,7,0.0312,0.5651,0.4036,0.654541552,0.073437035,0.272021413
"Local and systemic reactions after a third Pfizer vaccine reported in immunocompromised a
in the elderly, were similar to those seen with previous vaccines and were mostly self-limiting. Tiredness,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%)
respectively).",1061,Translated,TRUE,39.33,14.1,11.5,14.72,14.1,12.45,17,11.166666666666666,14,11th and 12th grade,312,45,6.022222222,7,0.0174,0.3827,0.5999,0.66138953,0.066936448,0.271673977
"Grouping samples into pools of five for PCR testing led to increased testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.32,19,12.36,11,19,18.34,18th and 19th grade,184,28,5.642857143,0,0.1696,0.7948,0.0356,0.645964146,0.049526889,0.304508954
"Grouping samples into groups of five for PCR testing has led to an increase in testing for coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,24.11,0,17.4,14.23,18.9,11.97,11,20,18.67,18th and 19th grade,190,30,5.4,0,0.1157,0.8145,0.0698,0.630380988,0.055012442,0.314606518
"Grouping samples into groups of five for PCR testing has led to an increase in testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,23.09,0,17.7,13.82,19,11.8,11,20.5,18.85,18th and 19th grade,194,31,5.322580645,0,0.1475,0.802,0.0505,0.644136786,0.053656965,0.302206248
"Grouping samples into groups of five for PCR testing led to increased testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.55,19.1,12.36,11,19,18.34,18th and 19th grade,185,28,5.678571429,0,0.1598,0.8015,0.0387,0.650973022,0.050830659,0.298196346
"Grouping samples for PCR testing into pools of five increased the number of coronavirus tests
with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,28.17,0,15.8,15.15,17.9,12.82,10,17,16.55,16th and 17th grade,170,26,5.615384615,0,0.111,0.8293,0.0596,0.63805002,0.060480841,0.301469207
"Grouping samples into groups of five for PCR testing has led to an increase in coronavirus testing
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,16.66,0,18.1,14.69,18.7,12.15,11,19.5,18.5,18th and 19th grade,186,29,5.482758621,0,0.0567,0.7488,0.1946,0.624464691,0.059305787,0.316229552
"Pooling samples into groups of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss in sensitivity compared to testing each sample individually.",1066,Translated,TRUE,9.22,0,18.9,15.73,19.3,12.92,12,20,19.77,19th and 20th grade,186,28,5.714285714,0,0.0488,0.8055,0.1458,0.647547007,0.051440436,0.301012576
"Pooling samples into groups of five for PCR testing has led to an increase in coronavirus testing
Ability with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.12,0,17,14.28,18.4,12.15,11,19.5,18.5,18th and 19th grade,184,29,5.413793103,0,0.0591,0.8167,0.1242,0.632123888,0.054761104,0.313114971
"Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,9.22,0,18.9,15.73,19.3,12.92,12,20,19.77,19th and 20th grade,186,28,5.714285714,0,0.0518,0.766,0.1822,0.652280331,0.049795344,0.29792431
"By grouping samples for PCR testing into pools of five, the number of coronavirus tests could be increased
with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.12,0,17,14.28,18.6,12.15,10,18.5,17.12,18th and 19th grade,185,29,5.448275862,0,0.0946,0.8404,0.0651,0.637054563,0.056380555,0.306564838
"By grouping the samples into pools of five for PCR testing, the testing capacity for the coronavirus could be increased with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,23.09,0,17.7,14.34,19.6,11.8,11,20.5,18.85,17th and 18th grade,198,31,5.419354839,0,0.1632,0.8031,0.0337,0.654058754,0.053311188,0.292629987
"Grouping samples into groups of five for PCR testing increased testing for the coronavirus
with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,29.18,0,15.4,15.96,18,12.46,10,16.5,16.4,15th and 16th grade,167,25,5.76,0,0.1143,0.8254,0.0603,0.647354186,0.0571681,0.295477688
"Pooling samples into groups of five for PCR testing has led to an increase in coronavirus testing
A possibility with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,24.11,0,17.4,13.88,18.5,11.97,11,20,18.67,18th and 19th grade,188,30,5.333333333,0,0.0386,0.7427,0.2186,0.64544642,0.05279135,0.301762253
"Grouping samples into five pools for PCR testing increased coronavirus testing.
There is minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.96,0,12.5,16.34,13,12.45,10,6.75,11.56,12th and 13th grade,162,23,6.130434783,0,0.1499,0.7752,0.0749,0.653535843,0.051925328,0.294538945
"Grouping of samples into groups of five for PCR testing led to increased testing for coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.32,19,12.36,11,19,18.34,18th and 19th grade,184,28,5.642857143,0,0.1198,0.8212,0.059,0.654079795,0.053118076,0.292802155
"Pooling samples into groups of five for PCR testing led to an increase in testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,24.11,0,17.4,14.05,18.7,11.97,11,20,18.67,18th and 19th grade,189,30,5.366666667,0,0.1336,0.8319,0.0345,0.647035301,0.050883159,0.302081585
"By grouping samples into groups of five for PCR testing, the number of tests for coronavirus could be increased
with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,32.57,0,16.2,14.05,18.9,11.97,10,19,17.33,18th and 19th grade,190,30,5.4,0,0.0945,0.8359,0.0696,0.633274555,0.067294151,0.299431324
"Grouping samples into five pools for PCR testing increased coronavirus testing.
Minimizes loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,26.98,0,12.1,17.95,14.1,13.18,10,6.25,11.82,11th and 12th grade,155,21,6.476190476,0,0.0195,0.4744,0.5061,0.655824661,0.05247201,0.291703343
"Grouping samples into five groups for PCR testing increased coronavirus testing.
Minimizes loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,26.98,0,12.1,18.24,14.3,13.18,10,6.25,11.82,11th and 12th grade,156,21,6.523809524,0,0.0173,0.4312,0.5514,0.642035544,0.063704185,0.294260234
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0131,0.2766,0.7103,0.659300625,0.178318232,0.162381157
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,28.84,0,13.5,16.35,16.3,15.16,13,12,15.04,15th and 16th grade,244,34,6.264705882,8,0.0135,0.2903,0.6962,0.649707079,0.18577005,0.164522812
"Female COVID-19 patients had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,35.27,0,13.1,16.3,16.8,14.97,15,13,14.97,14th and 15th grade,269,38,6.157894737,8,0.0139,0.3176,0.6684,0.665140688,0.172319368,0.162539899
"Female covid-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,15.82,13.6,14.32,14,7,11.47,10th and 11th grade,257,36,6.222222222,8,0.0125,0.2463,0.7412,0.652131259,0.183444276,0.164424539
"Female COVID-19 patients had a higher risk of severe dengue fever than male patients in the main analysis
(16.2% versus 10.5%). Pre-existing comorbidities associated with severe disease included diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,25.76,12.5,12.6,17.15,15,15.5,15,7.5,13.82,12th and 13th grade,261,35,6.542857143,8,0.0148,0.3083,0.6769,0.682424605,0.154680222,0.162895173
"Patients with COVID-19 had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Prior comorbidities associated with severe disease were diabetes,
hypertension, diseases of the kidneys and cardiovascular system.",1081,Translated,TRUE,36.28,0,12.7,14.67,15.3,15.06,14,12,13.87,14th and 15th grade,247,36,5.944444444,8,0.012,0.2632,0.7248,0.674243331,0.154380843,0.171375826
"Patients with COVID-19 had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,37.81,0,12.1,15.66,15.5,14.5,11,11.25,13.87,15th and 16th grade,233,33,6.151515152,8,0.0114,0.2273,0.7613,0.668921947,0.165500566,0.165577531
"In the main analysis, women with covid-19 had a higher risk of severe dengue fever than men
(16.2% versus 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,14.37,12.5,13.44,12,7,11.47,10th and 11th grade,249,36,6,8,0.015,0.2846,0.7004,0.668118775,0.16414088,0.167740375
"Female patients with COVID-19 had a higher risk of severe dengue than males in the main analysis
(16.2% vs 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,15.47,13.3,15.34,13,7,12.76,11th and 12th grade,243,34,6.235294118,8,0.0136,0.2796,0.7067,0.660267115,0.176696584,0.163036257
"Female COVID-19 patients had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). The pre-existing comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease, and cardiovascular disease.",1081,Translated,TRUE,34.76,0,13.3,16.3,17.3,15.13,15,13.25,14.98,14th and 15th grade,278,39,6.205128205,8,0.0137,0.3062,0.6801,0.675432384,0.160445437,0.164122239
"In the main analysis, female COVID-19 patients had a higher risk of developing severe dengue than male patients
(16.2% vs. 10.5%). Pre-existing comorbidities associated with severe illness were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,19.87,0,14.8,17.57,17.7,16.23,15,12.75,16.14,17th and 18th grade,260,35,6.514285714,8,0.0178,0.3725,0.6096,0.66412282,0.171749964,0.16412726
"Female patients with COVID-19 had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.76,0,13.3,16.48,17.2,14.73,15,13.25,14.98,14th and 15th grade,277,39,6.179487179,8,0.013,0.2812,0.7057,0.677398741,0.158251241,0.164350018
"In the main analysis, female COVID-19 patients had a higher risk of developing severe dengue than male patients.
(16.2% versus 10.5%). Pre-existing comorbidities associated with serious illness were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,33.61,12.5,11.6,16.63,14.8,15.77,17,7.833333333333334,13.57,11th and 12th grade,272,37,6.432432432,8,0.0202,0.3847,0.595,0.653084934,0.182357132,0.164558008
"In the main analysis, women with covid-19 had a higher risk of severe dengue than men
(16.2% vs. 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,36.79,0,12.5,14.38,15.1,13.98,11,11.75,13.86,13th and 14th grade,240,35,5.942857143,8,0.0143,0.2878,0.6979,0.648586154,0.187418357,0.163995415
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Existing comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,16.16,13.9,14.88,14,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0129,0.2637,0.7233,0.652314126,0.182721794,0.164964139
"In the main analysis, female COVID-19 patients had a higher risk of severe dengue fever than male patients.
(16.2% vs. 10.5%). Existing complications associated with severe disease include diabetes,
These were high blood pressure, kidney disease, and cardiovascular disease.",1081,Translated,TRUE,43.22,0,12.1,15.61,16.8,14.32,14,12.75,13.95,12th and 13th grade,274,39,6.102564103,8,0.0205,0.3881,0.5914,0.685313582,0.129187182,0.185499251
"Female covid-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Existing comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,15.36,13.2,14.32,14,7,11.47,10th and 11th grade,254,36,6.138888889,8,0.0122,0.2507,0.737,0.646442235,0.189488649,0.164069161
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Previous comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,16.16,13.9,14.88,14,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0134,0.2828,0.7038,0.653143823,0.183020577,0.163835675
"Female patients with COVID-19 were at higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe illness were diabetes,
hypertension, kidney diseases and cardiovascular diseases.",1081,Translated,TRUE,28.33,0,13.7,16.7,16.8,15.33,14,12.25,15,16th and 17th grade,253,35,6.314285714,8,0.0127,0.2888,0.6985,0.645048976,0.189722598,0.165228337
"We estimate that out of 100,000 airline passengers, without testing or screening, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.19,11,10.05,11,11.5,10.72,10th and 11th grade,309,51,5.078431373,15,0.0154,0.5933,0.3912,0.62902987,0.051911253,0.319058865
"We estimate that there would be among 100,000 air travelers, without testing or screening
649 actively contagious passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,54.93,13,9.6,11.54,10.9,10.25,11,11.166666666666666,11.42,10th and 11th grade,299,49,5.183673469,15,0.0151,0.5989,0.386,0.633793592,0.047582898,0.318623543
"We estimate that among 100,000 airline travelers, without testing or controls, there would be
649 actively infectious passengers. A PCR test prior to travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.08,10.9,10.67,13,11.5,11.51,10th and 11th grade,308,51,5.117647059,15,0.0207,0.7085,0.2708,0.634081721,0.04851516,0.317403108
"We estimate that there would be 100,000 air travelers without testing or screening
649 actively infected passengers. A pre-travel PCR test would reduce the number of infected people
569 passengers. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,55.54,13.6,9.4,12.06,10.9,10.46,10,11.166666666666666,10.54,10th and 11th grade,291,47,5.276595745,15,0.0141,0.5438,0.4421,0.627308249,0.048935603,0.323756129
"We estimate that among 100,000 air travelers without testing or screening, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.52,13,9.8,11.19,10.7,10.15,11,11.333333333333334,11.48,10th and 11th grade,302,50,5.06,15,0.0149,0.6296,0.3555,0.612663746,0.056498501,0.330837786
"We estimate that of the 100,000 air passengers who are not screened or tested, 649 will be actively infected. Conducting a polymerase chain reaction test before traveling would reduce the number of infected travelers to 569. Conducting a rapid antigen test on the day of travel would reduce the number of infected travelers to 560.",1082,Translated,TRUE,52.9,14.6,10.4,11.43,11.5,10.29,13,13.166666666666666,13.14,9th and 10th grade,331,55,5.036363636,15,0.0112,0.4102,0.5786,0.622536063,0.051027846,0.326436102
"We estimate that out of 100,000 airline passengers, without testing or controls, there will be
649 passengers are actively infectious. A PCR test before traveling would reduce the number of infected people
Passengers to 569. Rapid antigen testing on the day of travel would reduce the number of passengers
Infected passengers to 560.",1082,Translated,TRUE,45.05,14.1,11.4,12.53,12.4,10.17,12,12.5,11.61,12th and 13th grade,333,53,5.358490566,15,0.0167,0.5908,0.3925,0.638755441,0.046862867,0.314381689
"We estimate that there would be among 100,000 air travelers without testing or screening
649 actively contagious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.93,13.6,9.6,11.42,10.8,10.57,11,11.5,11.42,10th and 11th grade,298,49,5.163265306,15,0.0161,0.6127,0.3712,0.620732546,0.051580299,0.327687263
"We estimate that among 100,000 airline travelers, with or without screening, there would be
649 actively infected passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers in 560.",1082,Translated,TRUE,54.52,13,9.8,11.08,10.7,9.83,10,11.333333333333334,10.68,10th and 11th grade,302,50,5.12,15,0.0191,0.7296,0.2514,0.631054342,0.05195361,0.316991955
"We estimate that there are 100,000 air travelers who have not been tested or screened.
There are 649 highly contagious passengers. Pre-travel PCR testing can help reduce the number of infections.
There are 569 passengers. Implementing rapid antigen testing on the day of travel could reduce passenger numbers.
560 passengers infected.",1082,Translated,TRUE,62.85,10.9,6.6,12.03,9.1,11.18,14,5.083333333333333,8.89,8th and 9th grade,334,51,5.62745098,15,0.0103,0.247,0.7427,0.623927653,0.045829918,0.330242425
"We estimate that among 100,000 air travelers, without testing or monitoring, there would be
649 actively infectious passengers. A PCR test before travel would reduce the number of infected people
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
passengers infected at 560.",1082,Translated,TRUE,54.22,13.6,9.9,11.42,11.2,10.05,11,11.833333333333334,12.29,11th and 12th grade,311,51,5.176470588,15,0.0187,0.667,0.3143,0.619539678,0.052321315,0.328139067
"We estimate that there would be among 100,000 air travelers without testing or control
649 actively contagious passengers. A PCR test before travel would reduce the number of infected people
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.08,10.7,10.05,11,11.5,11.51,11th and 12th grade,306,51,5.078431373,15,0.0147,0.5541,0.4313,0.630582273,0.049505521,0.319912225
"We estimate that among 100,000 air travelers who are not tested or screened, there will be:
649 highly contagious passengers. Pre-travel PCR testing can help reduce the number of infections.
There are 569 passengers. Implementing rapid antigen testing on the day of travel could reduce passenger numbers.
560 passengers infected.",1082,Translated,TRUE,52.87,11.6,8.4,12.68,9.9,11.4,14,6.2,9.6,9th and 10th grade,329,50,5.66,15,0.0162,0.3915,0.5923,0.629976571,0.047871333,0.322152108
"We estimate there will be 100,000 air passengers without testing or screening
649 passengers are actively infected. A PCR test before traveling would reduce the number of infected people
569 passengers. Rapid antigen testing on the day of travel would reduce the number
Infected passengers to 560.",1082,Translated,TRUE,47.08,13.6,10.6,12.93,11.6,10.13,10,11.166666666666666,10.54,10th and 11th grade,297,47,5.404255319,15,0.0134,0.4403,0.5462,0.627497852,0.049458608,0.323043555
"We estimate that for every 100,000 air travelers who are not screened or screened, there are 649 actively infected passengers. Implementing pre-travel PCR testing could reduce the number of infected passengers to 569. Implementing rapid antigen testing on the day of travel could reduce the number of infected passengers to 560.",1082,Translated,TRUE,45.76,14.6,11.1,13.34,12.7,10.36,10,12.5,11.51,12th and 13th grade,328,51,5.450980392,15,0.018,0.5698,0.4122,0.615012944,0.05823807,0.326749027
"We estimate that among 100,000 airline travelers, without testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.93,13.6,9.6,11.89,11.3,10.89,12,11.5,11.42,11th and 12th grade,304,49,5.285714286,15,0.0201,0.7151,0.2648,0.616575181,0.054938301,0.328486413
"We estimate that among 100,000 air travelers without testing or monitoring, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.52,13.6,9.8,11.31,10.8,10.15,11,11.666666666666666,12.28,9th and 10th grade,303,50,5.08,15,0.0144,0.5923,0.3933,0.613518953,0.052736796,0.333744258
"We estimate that among 100,000 air travelers, without testing or screening, there would be
649 actively infectious passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.52,13,9.8,11.19,10.8,10.15,11,11.333333333333334,11.48,10th and 11th grade,303,50,5.14,15,0.0193,0.7206,0.2601,0.620181084,0.050801024,0.329017818
"We estimate that there would be 100,000 air travelers without testing or screening.
649 actively infected passengers. A pre-travel PCR test would reduce the number of infected
569 passengers. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,59.8,12.2,7.8,11.06,8.9,10.39,10,7.25,8.95,8th and 9th grade,285,46,5.282608696,15,0.0125,0.4569,0.5306,0.624459684,0.048459943,0.327080429
"In the phase 1 trial, the potential vaccine formulation caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.6,11.89,11,13.75,13.95,13th and 14th grade,256,39,5.641025641,3,0.4277,0.5398,0.0326,0.641842961,0.067862928,0.290294021
"In a phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In a phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.4,11.89,12,13.75,13.95,13th and 14th grade,254,39,5.58974359,3,0.6498,0.3392,0.011,0.639054358,0.062002476,0.298943251
"In the phase 1 study, the potential vaccine formula caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed better safety results.",1083,Translated,TRUE,43.22,0,12.1,13.52,13.8,11.89,11,13.75,13.95,13th and 14th grade,249,39,5.461538462,3,0.3228,0.6342,0.043,0.65504837,0.069628797,0.275322795
"In the phase 1 trial, the potential vaccine formulation caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.8,11.89,11,13.75,13.95,13th and 14th grade,257,39,5.666666667,3,0.3559,0.6095,0.0346,0.641662419,0.066213183,0.292124391
"In phase 1 trials, the potential vaccine formulation generated strong antibody responses.
It remained elevated in all participants for 3 months after the second vaccination. In phase 2 clinical trials,
Potential vaccine formulations have shown better safety outcomes.",1083,Translated,TRUE,24.74,14.1,13,16.17,13.4,12.58,14,9,15.61,12th and 13th grade,267,38,6.105263158,3,0.6568,0.3339,0.0093,0.651940346,0.065951072,0.282108516
"In the first phase of testing, the potential vaccine formula elicited a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
a potential vaccine formulation has shown better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.8,12.3,14,13.75,14.98,14th and 15th grade,257,39,5.666666667,2,0.6104,0.3799,0.0098,0.666684389,0.061810002,0.271505624
"In the phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.97,15,11.89,12,13.75,13.95,13th and 14th grade,259,39,5.717948718,3,0.6367,0.3541,0.0091,0.647187114,0.064308092,0.288504869
"In the Phase 1 trial, the potential vaccine formulation elicited a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the Phase 2 trial, the potential vaccine formulation showed better safety outcomes.",1083,Translated,TRUE,34.76,0,13.3,15.14,15.1,11.89,12,13.75,13.95,13th and 14th grade,260,39,5.692307692,3,0.7305,0.2624,0.0071,0.650911689,0.063603483,0.28548488
"In a phase 1 study, the potential vaccine elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In phase 2 of the trial,
potential vaccine formulation showed better safety results.",1083,Translated,TRUE,35.27,0,13.1,13.69,13.7,12.06,12,13,13.92,13th and 14th grade,244,38,5.5,3,0.677,0.3141,0.0089,0.641981959,0.060905177,0.297112852
"In the first phase of testing, the potential vaccine formula elicited a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
a potential vaccine formulation has demonstrated better safety outcomes.",1083,Translated,TRUE,26.3,0,14.4,15.9,15.7,12.3,15,14.25,16.01,15th and 16th grade,265,39,5.871794872,2,0.6326,0.3586,0.0087,0.668667734,0.059330828,0.272001475
"In the phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the possible vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.85,14.9,11.89,12,13.75,13.95,13th and 14th grade,258,39,5.692307692,3,0.5791,0.4113,0.0096,0.643864989,0.063834526,0.292300463
"In a phase 1 trial, the potential vaccine formulation elicited a robust antibody response that remained high in all participants three months after the second vaccination. In phase 2 trials, potential vaccine formulations showed better safety outcomes.",1083,Translated,TRUE,35.78,0,12.9,15.95,15.3,12.66,14,12.75,13.89,12th and 13th grade,252,37,5.837837838,2,0.7193,0.273,0.0077,0.637039781,0.059471194,0.303489
"In phase 1 trials, the potential vaccine formulation generated strong antibody responses.
It remained elevated in all participants for 3 months after the second vaccination. In phase 2 clinical trials,
Potential vaccine formulations have shown better safety results.",1083,Translated,TRUE,24.74,14.1,13,15.99,13.3,12.58,14,9,15.61,12th and 13th grade,266,38,6.078947368,3,0.643,0.3471,0.0099,0.650381446,0.066164799,0.283453763
"In a phase 1 study, the potential vaccine formulation elicited a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In a phase 2 study, the potential vaccine showed better safety results.",1083,Translated,TRUE,43.73,0,11.9,13.58,13.6,11.64,11,13,13.92,13th and 14th grade,243,38,5.421052632,3,0.7141,0.2776,0.0083,0.633431196,0.060336281,0.306232482
"In the Phase 1 trial, the candidate vaccine formulation elicited a strong antibody response that
remained high in all participants 3 months after the second vaccination. In the Phase 2 trial,
the candidate vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.5,11.49,11,13.25,12.93,12th and 13th grade,255,39,5.615384615,3,0.6424,0.3489,0.0087,0.636080801,0.061440744,0.302478433
"In a phase 1 trial, the potential vaccine combination caused a strong antibody response
It remained elevated in all participants 3 months after the second vaccination. In the second phase of the experiment,
The potential vaccine formulation showed better safety results.",1083,Translated,TRUE,25.29,0,14.8,14.68,15.2,11.97,13,14.75,16,14th and 15th grade,270,41,5.658536585,2,0.3702,0.6095,0.0202,0.617997229,0.052976001,0.329026788
"In the first phase of testing, the potential composition of the vaccine caused a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
the potential composition of the vaccine showed the best results in terms of safety.",1083,Translated,TRUE,39.67,0,13.4,12.89,14.8,11.3,12,15.5,14.42,12th and 13th grade,286,46,5.282608696,2,0.5674,0.421,0.0117,0.636589289,0.059638496,0.303772241
"In the Phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the possible vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.85,14.9,11.89,12,13.75,13.95,13th and 14th grade,258,39,5.692307692,3,0.5908,0.4001,0.0092,0.643864989,0.063834526,0.292300463
"In a phase 1 study, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In a phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.4,11.89,12,13.75,13.95,13th and 14th grade,254,39,5.58974359,3,0.6565,0.3334,0.0101,0.638708711,0.061043601,0.300247729
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks style buildings. The corresponding doubling time for apartment-style buildings was
2.65 days.",1084,Translated,TRUE,70.5,7.8,5.7,12.61,10.1,12.56,7,4.333333333333333,6.58,12th and 13th grade,187,28,5.785714286,7,0.0271,0.6803,0.2926,0.641104937,0.062354457,0.296540618
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days
barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.09,9.4,12.86,7,4.166666666666667,6.56,6th and 7th grade,177,27,5.666666667,7,0.0239,0.6121,0.364,0.638300598,0.055584002,0.306115419
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.78,10.1,13.18,7,4,6.56,6th and 7th grade,175,26,5.846153846,7,0.0232,0.5904,0.3864,0.646383464,0.055197388,0.298419148
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
Barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.5,7.8,5.7,11.63,9.1,12.56,7,4.333333333333333,6.58,6th and 7th grade,181,28,5.571428571,7,0.0256,0.6184,0.3559,0.636694074,0.061924979,0.301380903
"We found that the number of SARS-CoV-2 infections doubles every 1.56 days
Barracks style buildings. The corresponding doubling time for residential-style buildings was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,14.75,11.7,13.52,7,4.166666666666667,8.12,8th and 9th grade,178,25,6.24,7,0.02,0.6333,0.3466,0.64018476,0.053543128,0.306272119
"We found that the number of cases of SARS-CoV-2 infection doubles every 1.56 days
barrack style buildings. The corresponding doubling time for multi-apartment buildings was
2.65 days.",1084,Translated,TRUE,62.34,8.8,6.8,13.19,10.4,13.44,8,4.5,6.56,6th and 7th grade,183,27,5.888888889,7,0.0248,0.6883,0.2869,0.633182228,0.058303338,0.308514506
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days
barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.32,9.6,12.86,7,4.166666666666667,6.56,6th and 7th grade,178,27,5.703703704,7,0.0224,0.5852,0.3924,0.638498425,0.05820214,0.303299367
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days.
Barracks style building. The corresponding doubling times for apartment-style buildings are:
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,13.88,11.5,13.78,7,4,6.56,13th and 14th grade,183,26,6.153846154,7,0.0221,0.5411,0.4368,0.636064231,0.06755174,0.296383977
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
Barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.55,9.9,13.18,7,4,6.56,6th and 7th grade,174,26,5.807692308,7,0.0243,0.5901,0.3855,0.640338719,0.056527682,0.303133577
"We found that the number of SARS-CoV-2 cases doubles every 1.56 days.
Based on the barracks model. The corresponding doubling times for apartment-style buildings are:
2.65 days.",1084,Translated,TRUE,79.26,6.4,4.4,11.45,9.4,14.02,7,3.833333333333333,5.08,3rd and 4th grade,177,27,5.666666667,7,0.0256,0.8084,0.1661,0.644965053,0.05252783,0.302507102
"We found that the number of SARS-CoV-2 cases doubled every 1.56 days.
Barracks-style buildings. The corresponding doubling times for apartment-style buildings were:
2.65 days.",1084,Translated,TRUE,67.76,0,6.8,16.17,14.4,14.1,6,5.5,6.47,6th and 7th grade,175,24,6.416666667,7,0.0271,0.6845,0.2884,0.633942902,0.05534571,0.310711354
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barracks style buildings. The corresponding doubling time for condominiums was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,12.66,9.9,14.15,8,4.166666666666667,8.12,8th and 9th grade,168,25,5.84,7,0.0234,0.6191,0.3575,0.641472518,0.06207256,0.296454906
"We found that the number of SARS-CoV-2 infections doubles every 1.56 days
Barracks style buildings. The corresponding doubling time for residential buildings was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,13.59,10.6,13.52,7,4.166666666666667,8.12,8th and 9th grade,172,25,6,7,0.0186,0.5621,0.4193,0.644099236,0.051122651,0.304778099
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barrack-type buildings. The corresponding doubling time for residential buildings was
2.65 days.",1084,Translated,TRUE,62.34,9.7,6.8,12.73,10.1,13.44,8,4.833333333333333,8.04,9th and 10th grade,181,27,5.814814815,7,0.0261,0.7174,0.2565,0.639949739,0.05968339,0.300366849
"We found that the number of SARS-CoV-2 infections doubled every 1.56 days.
Barracks style building. The corresponding doubling times for residential buildings are:
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,13.59,11,14.15,7,4.166666666666667,8.12,8th and 9th grade,174,25,6.08,7,0.0178,0.45,0.5322,0.639284015,0.060450494,0.300265491
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days.
Barracks style building. The corresponding doubling times for apartment buildings are:
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.32,9.9,13.44,7,4.166666666666667,6.56,6th and 7th grade,180,27,5.777777778,7,0.0206,0.4805,0.4989,0.638051152,0.065801665,0.296147108
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks style buildings. The corresponding doubling time for apartment style buildings was
2.65 days.",1084,Translated,TRUE,70.09,7.8,5.9,11.86,9.2,12.28,7,4.5,6.64,6th and 7th grade,187,29,5.551724138,7,0.0261,0.6542,0.3197,0.641039312,0.063702457,0.295258194
"We found that the number of SARS-CoV-2 infection cases in

shanty buildings doubled every 1.56 days. The corresponding doubling time for residential buildings was

2.65 days.",1084,Translated,TRUE,58.28,0,8.4,13.27,11.7,13.39,8,7,9.82,9th and 10th grade,174,26,5.807692308,7,0.0267,0.7479,0.2254,0.626801908,0.07331758,0.299880475
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.55,9.9,13.18,7,4,6.56,6th and 7th grade,174,26,5.807692308,7,0.0245,0.6093,0.3662,0.640338719,0.056527682,0.303133577
"Without the initial lockdown, vaccinations and increased physical distancing, we estimated the number at 148.
Over 10 years, there will be one million cases of COVID-19 and 3.1 million deaths in the UK. best case
In this scenario, vaccination would minimize community transmission without increasing future body infections.
Keep your distance.",1095,Translated,TRUE,52.66,11.2,8.4,13.43,10.8,12.19,17,6.1,11.92,11th and 12th grade,343,51,5.803921569,9,0.031,0.5223,0.4467,0.623958051,0.048299428,0.327742517
"Without the initial lockdown, vaccinations and increased physical distancing, we estimated 148
There would be one million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At the best case
Vaccination minimizes transmission in the community without future periods of increased physical stress
distancing.",1095,Translated,TRUE,38.32,14.1,11.9,14.67,13.4,12.33,14,11.666666666666666,13.9,11th and 12th grade,320,48,5.75,9,0.0251,0.4406,0.5343,0.643114626,0.048001219,0.308884174
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best
scenario, vaccination minimizes transmission in the community without subsequent periods of increased physical
distancing.",1095,Translated,TRUE,31.89,14.6,12.3,16.64,14.4,12.98,14,11,14.17,14th and 15th grade,298,42,6.19047619,9,0.0301,0.561,0.4088,0.648006141,0.048138767,0.303855091
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148
One million coronavirus cases and 3.1 million deaths will occur in the UK over 10 years. At best
In the scenario, vaccination reduces community transmission without future periods of increased physical infection
Spacing.",1095,Translated,TRUE,30.87,14.1,12.7,16.17,14.4,13.15,18,11.166666666666666,14,13th and 14th grade,315,45,6.088888889,7,0.0203,0.4513,0.5284,0.641955733,0.043525167,0.314519167
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million COVID-19 cases and 3.1 million deaths would occur in the UK over 10 years. At best
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Translated,TRUE,32.19,14.1,12.2,17.33,14.8,13.56,15,10.5,13.28,13th and 14th grade,296,41,6.317073171,9,0.0239,0.4984,0.4777,0.650086999,0.048074014,0.301838964
"Without the initial confinement, vaccination and increased physical distancing, we estimate 148
million COVID-19 cases and 3.1 million deaths would occur in the UK within 10 years. In the best case
In this scenario, vaccination minimizes community transmission without future periods of increased physical activity.
distancing.",1095,Translated,TRUE,30.57,15,12.8,16.7,15.1,13.32,17,12,14.82,14th and 15th grade,327,46,6.195652174,9,0.0296,0.5121,0.4582,0.650730133,0.045210239,0.304059654
"Without the initial lockdown, vaccination and increased physical distancing, we calculated 148
million cases of COVID-19 and 3.1 million deaths would occur in the UK over 10 years. In the best case
scenario, vaccination minimizes transmission in the community without future periods of increased fitness
distancing.",1095,Translated,TRUE,39.03,13.6,11.6,15.3,13.9,12.98,16,11,13.08,13th and 14th grade,315,46,5.934782609,9,0.0347,0.5859,0.3794,0.648070931,0.04606957,0.305859536
"Without the initial lockdown, vaccinations and increased physical distancing, an estimated 148
In the UK, there will be one million cases of coronavirus and 3.1 million deaths within ten years. In best case
According to the scenario, vaccination reduces community spread without increasing physical infection in the future
Spacing.",1095,Translated,TRUE,38.01,14.1,12,15.08,14,12.5,19,11.833333333333334,14.68,11th and 12th grade,331,49,5.836734694,5,0.0326,0.4631,0.5043,0.639195323,0.044274308,0.316530347
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million COVID-19 cases and 3.1 million deaths would occur in the UK over 10 years. In the best case
In the scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Translated,TRUE,39.33,14.1,11.5,15.77,14.1,12.8,15,11.166666666666666,13.11,11th and 12th grade,312,45,6.022222222,9,0.0317,0.5508,0.4176,0.647466838,0.045405883,0.307127267
"Without the initial lockdown, vaccination and increased physical distancing, we estimated that there were 148 million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best, vaccination minimises community transmission without subsequent periods of increased physical distancing.",1095,Translated,TRUE,31.89,14.6,12.3,16.64,14.4,12.6,13,11,14.17,14th and 15th grade,298,42,6.119047619,9,0.0314,0.5515,0.4171,0.650750458,0.044162948,0.305086613
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
One million coronavirus cases and 3.1 million deaths are expected in the UK over 10 years. perfect
In the scenario, vaccination reduces community transmission without future periods of increased physical infection
Spacing.",1095,Translated,TRUE,22.71,14.6,13.7,17.33,15.1,13.7,19,11.333333333333334,14.97,14th and 15th grade,316,44,6.272727273,7,0.0257,0.5626,0.4117,0.642854452,0.044437859,0.312707722
"Without the initial lockdown, vaccination and increased physical distancing, we counted 148
There are expected to be 1 million Covid-19 cases and 3.1 million deaths in the UK over 10 years. At best
scenario, that vaccination reduces community transmission without future periods of increased fitness
Spacing.",1095,Translated,TRUE,47.49,12.5,10.4,14.43,13.2,13.32,17,10.333333333333334,12.21,12th and 13th grade,308,46,5.782608696,10,0.0249,0.4682,0.5069,0.641721785,0.045846403,0.312431753
"Without the initial lockdown, vaccination and increased physical distancing, we estimate 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best
In this scenario, vaccination minimises community transmission without subsequent periods of increased physical activity.
distancing.",1095,Translated,TRUE,31.58,15,12.4,16.93,14.9,13.16,15,11.5,15.02,14th and 15th grade,308,43,6.255813953,9,0.0352,0.5636,0.4012,0.649824739,0.048596814,0.301578403
"Without the initial lockdown, vaccination and increased physical distancing, we estimate there would have been 148 million cases of COVID-19 and 3.1 million deaths in the UK over a decade. At best, vaccination minimizes community spread without subsequent periods of increased physical distancing.",1095,Translated,TRUE,40.04,14.1,11.2,15.59,13.7,11.69,12,10.833333333333334,13.16,10th and 11th grade,297,43,5.930232558,7,0.0246,0.4287,0.5467,0.642455459,0.045557693,0.311986893
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million cases of COVID-19 and 3.1 million deaths would occur in the UK over 10 years. In the best case
In this scenario, vaccination minimizes community transmission without future periods of increased physical risks.
distancing.",1095,Translated,TRUE,38.62,14.1,11.8,15.6,14.1,12.81,15,11.5,13.09,11th and 12th grade,323,47,5.957446809,9,0.0387,0.5428,0.4184,0.650598407,0.045072939,0.304328591
"Without the initial lockdown, vaccination and increased physical distancing, the UK would see 148 million cases of COVID-19 and 3.1 million deaths within 10 years. In the best case scenario, vaccination minimises community transmission without requiring periods of increased physical distancing in the future.",1095,Translated,TRUE,39.63,14.1,11.4,16.29,14.4,12.98,15,11,13.15,10th and 11th grade,309,44,6.045454545,9,0.031,0.5072,0.4617,0.646836281,0.045900114,0.307263613
"Without the initial lockdown, vaccinations and increased physical distancing, we had an estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. In best case
in the scenario, vaccination minimizes community spread without subsequent increased physical periods
distancing.",1095,Translated,TRUE,39.63,14.1,11.4,15.36,13.6,12.62,14,11,14.06,13th and 14th grade,302,44,5.954545455,9,0.04,0.5793,0.3807,0.64591074,0.045302913,0.308786392
"Without the initial lockdown, vaccinations and increased physical distancing, an estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. In best case
in the scenario, vaccination minimizes community spread without further increased physical periods
distancing.",1095,Translated,TRUE,40.35,13.6,11.1,15.83,13.7,12.6,13,10.333333333333334,13.22,13th and 14th grade,292,42,6.047619048,9,0.043,0.6019,0.3551,0.646387935,0.046014547,0.307597488
"Without the initial lockdown, vaccination and increased physical distancing, we would see an estimated 148 million COVID-19 cases and 3.1 million deaths in the UK within 10 years. In the best case scenario, vaccination minimises community transmission without any future periods of increased physical distancing.",1095,Translated,TRUE,39.33,14.1,11.5,15.77,14.1,12.8,15,11.166666666666666,13.11,11th and 12th grade,312,45,5.955555556,9,0.0312,0.5154,0.4534,0.650365353,0.044865537,0.304769129
"When controlling for age, disease severity, and comorbidities, there was no association with tocilizumab
Fewer deaths in this study.",1097,Translated,TRUE,43.73,0,11.9,16.3,16.3,11.23,7,13.5,16.02,11th and 12th grade,132,19,6.052631579,0,0.0425,0.6623,0.2952,0.717145681,0.09190236,0.190951958
"After adjusting for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,15.95,15.8,11.55,7,13,16.09,15th and 16th grade,125,18,6,0,0.0195,0.4667,0.5138,0.709840178,0.087923646,0.202236116
"When controlling for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0276,0.633,0.3394,0.718102753,0.089103431,0.192793772
"After controlling for age, disease severity and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0252,0.647,0.3277,0.694048405,0.082939312,0.223012254
"When controlling for age, disease severity and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,15.8,11.55,7,13,16.09,12th and 13th grade,125,18,6.055555556,0,0.0265,0.6317,0.3418,0.714439213,0.086627699,0.198933095
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.166666667,0,0.0244,0.6339,0.3416,0.696151912,0.085174188,0.218673944
"After adjusting for age, disease severity, and comorbidities, tocilizumab was not associated with reduced mortality in our study.",1097,Translated,TRUE,19.37,0,15,17.22,16.9,11.55,8,14,18.31,16th and 17th grade,129,18,6.222222222,0,0.0217,0.5248,0.4535,0.747834444,0.087390684,0.164774805
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated with:
There were fewer deaths in this study.",1097,Translated,TRUE,42.72,0,12.3,15.78,16.6,10.94,7,14,16,15th and 16th grade,138,20,6,0,0.0512,0.6218,0.327,0.691839993,0.088632181,0.219527856
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0257,0.6155,0.3588,0.714749396,0.090416998,0.194833592
"After adjustment for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.0229,0.5052,0.4718,0.697858155,0.086466961,0.215674832
"When controlled for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,44.75,0,11.5,15.95,15.8,11.55,7,12,13.87,11th and 12th grade,125,18,6.055555556,0,0.0335,0.6861,0.2803,0.690719426,0.077604622,0.231675893
"After adjusting for age, disease severity, and comorbidities, there was no association with tocilizumab.
Fewer deaths in this study.",1097,Translated,TRUE,44.91,0,9.4,14.24,11.6,10.76,7,5.75,12.22,10th and 11th grade,132,19,6.052631579,0,0.053,0.7202,0.2268,0.712709904,0.090946294,0.196343735
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with disease
Fewer deaths in this study.",1097,Translated,TRUE,35.27,0,13.1,17.23,17.1,11.23,7,13.5,16.02,13th and 14th grade,135,19,6.210526316,0,0.0933,0.7279,0.1788,0.715030372,0.088075802,0.196893826
"After adjustment for age, disease severity, and comorbidities, tacilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.0225,0.4984,0.4791,0.700377285,0.085100099,0.21452263
"Controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,37.3,0,12.3,16.88,16.2,11.91,7,12.5,16.21,11th and 12th grade,121,17,6.235294118,0,0.0239,0.6341,0.342,0.697915435,0.087893404,0.214191183
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated
fewer deaths in this study.",1097,Translated,TRUE,37.3,0,12.3,16.88,16.2,11.91,7,12.5,16.21,11th and 12th grade,121,17,6.235294118,0,0.0216,0.5082,0.4703,0.71269381,0.092889257,0.194416881
"After controlling for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.166666667,0,0.0258,0.646,0.3282,0.699026108,0.083705425,0.217268527
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.111111111,0,0.0196,0.4538,0.5266,0.696151912,0.085174188,0.218673944
"After adjustment for age, disease severity, and comorbidities, tocilizumab was not associated with a reduction in mortality in our study.",1097,Translated,TRUE,17.34,0,15.8,15.78,16.4,10.94,8,16,20,15th and 16th grade,137,20,5.9,0,0.0219,0.5137,0.4644,0.751641154,0.076314837,0.172043964
"In Hawaii, white Caucasians make up 25%, Asians, including Japanese, Chinese, and other Asians
30%, Hawaiians 20%, and Pacific Islanders, primarily from Micronesia and Samoa,
4%. We found that the COVID-19 rate in the latter group was up to 10 times higher than in all other
groups combined, and they accounted for nearly 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,10.16,16.1,12.36,14,17,15.49,11th and 12th grade,335,56,5.053571429,13,0.038,0.7912,0.1708,0.608247459,0.091527306,0.300225198
"n Hawaii, whites are 25%, Asians including Japanese, Chinese and other Asians
make up 30%, Hawaiians 20% and Pacific Islanders mostly from Micronesia and Samoa
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for almost 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,9.52,15.1,12.36,12,17.5,15.49,11th and 12th grade,323,56,4.839285714,13,0.0537,0.8412,0.1051,0.601771474,0.077145174,0.321083277
"In Hawaii, whites are 25%, Asians include Japanese, Chinese and other Asians.
They represent 30%, Hawaiians 20% and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in everyone else.
They are grouped together and represented almost 30% of the cases.",1099,Translated,TRUE,65.22,11.2,7.8,9.62,9.4,11.16,12,8.25,9.94,9th and 10th grade,347,58,5.051724138,13,0.0554,0.8718,0.0729,0.622727275,0.066863075,0.310409665
"In Hawaii, white Caucasians are 25%, Asians including Japanese, Chinese, and other Asians
make up 30%, Hawaiians make up 20%, and Pacific Islanders, mostly from Micronesia and Samoa, make up
4%. We found that the rate of COVID-19 in the latter group was 10 times higher than in all others
groups together, and they accounted for almost 30% of cases.",1099,Translated,TRUE,57.95,0,12.6,9.7,16.3,11.7,13,18,15.33,9th and 10th grade,349,60,4.883333333,13,0.044,0.8205,0.1355,0.608347952,0.081987165,0.309664875
"In Hawaii, whites are 25%, Asians, including Japanese, Chinese, and other Asians
make up 30%, Hawaiians 20% and Pacific Islanders mainly from Micronesia and Samoa
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for nearly 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,9.64,15.4,12.36,13,17.5,15.49,11th and 12th grade,326,56,4.892857143,13,0.0485,0.8531,0.0984,0.610427678,0.078152828,0.311419487
"In Hawaii, white Caucasians make up 25%, Asians, including Japanese, Chinese and other Asians
represent 30%, Hawaiians 20% and Pacific Islanders mainly from Micronesia and Samoa make up
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than that in all others
groups together and accounted for nearly 30% of cases.",1099,Translated,TRUE,57.95,0,12.6,10.11,16.3,12.23,15,18.5,16,12th and 13th grade,349,60,4.883333333,13,0.0383,0.8152,0.1465,0.608453035,0.082292251,0.309254706
"In Hawaii, Caucasian people make up 25%, with Asians including Japanese, Chinese, and other Asians.
make up 30%, Hawaiians 20% and Pacific Islanders, mainly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in this latter group was up to 10 times higher than everyone else.
groups combined and they represented almost 30% of cases.",1099,Translated,TRUE,73.68,10.1,6.6,9.45,9.4,11.43,14,7.75,9.25,9th and 10th grade,347,58,5.051724138,13,0.0527,0.8278,0.1195,0.620330453,0.088390268,0.291279286
"In Hawaii, Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
30%, Hawaiians 20% and Pacific Islanders, mainly from Micronesia and Samoa,
4%. We found that the rate of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for almost 30% of cases.",1099,Translated,TRUE,60.48,0,11.7,9.7,15.2,12.18,13,16.75,14.64,11th and 12th grade,321,55,4.909090909,13,0.0443,0.8111,0.1446,0.606509805,0.096130565,0.297359675
"In Hawaii, 25% are Caucasians, including Asians, including Japanese, Chinese, and other Asians.
30%, Hawaiian 20%, and Pacific Islanders, mostly from Micronesia and Samoa,
4%. We found that the Covid-19 infection rate in the second group was up to 10 times higher than in all other groups
The clusters together account for approximately 30% of cases.",1099,Translated,TRUE,60.95,12.5,9.4,11.43,12.7,11.61,13,12,11.77,11th and 12th grade,350,56,5.321428571,13,0.0407,0.8245,0.1348,0.616102338,0.066179588,0.317718059
"In Hawaii, white Caucasians are 25%, Asians including Japanese, Chinese, and other Asians
make up 30%, Hawaiians make up 20%, and Pacific Islanders mostly from Micronesia and Samoa make up
4%. We found that the rate of COVID-19 in the latter group was 10 times higher than in all others
groups together accounted for almost 30% of cases.",1099,Translated,TRUE,58.96,0,12.2,9.93,15.8,11.88,13,17.5,15.05,11th and 12th grade,337,58,4.879310345,13,0.0382,0.8342,0.1275,0.60501194,0.08880607,0.306182057
"In Hawaii, white Caucasians make up 25% of Asians, including Japanese, Chinese, and other Asians.
They represent 30%, Hawaiians 20%, and Pacific Islanders mainly from Micronesia and Samoa.
4%. We found that the Covid-19 infection rate in the latter group was up to 10 times higher than in all other groups
The clusters together account for approximately 30% of cases.",1099,Translated,TRUE,59.64,12.5,9.9,10.97,12.7,12,16,12.666666666666666,12.67,12th and 13th grade,367,60,5.183333333,13,0.0385,0.8169,0.1447,0.617693782,0.066281274,0.31602484
"n Hawaii, white Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
accounts for 30%, Hawaiians for 20%, and Pacific Islanders, mainly from Micronesia and Samoa, are made up of
4%. We found that the covid-19 rate in the latter group was up to 10 times higher than in all others
the groups combined and they accounted for almost 30% of the cases.",1099,Translated,TRUE,55.41,0,13.6,9.18,16.9,12.29,16,18.75,16.08,16th and 17th grade,369,65,4.738461538,13,0.0434,0.8266,0.13,0.614422619,0.070369497,0.315207899
"In Hawaii, white Caucasians make up 25%, Asians include Japanese, Chinese, and other Asians.
represent 30%, Hawaiians 20% and Pacific Islanders, mostly from Micronesia and Samoa, comprise
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than in everyone else.
These groups combined and accounted for almost 30% of the cases.",1099,Translated,TRUE,73.17,10.1,6.8,9.56,9.7,11.49,15,8,9.33,9th and 10th grade,360,60,5.066666667,13,0.0408,0.827,0.1321,0.616903961,0.08412604,0.298969954
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians make up 20%, and Pacific Islanders are mostly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, the groups accounted for nearly 30% of cases.",1099,Translated,TRUE,75.24,11.2,8.1,7.72,10.7,10.61,11,12.666666666666666,11.65,10th and 11th grade,355,64,4.609375,15,0.0765,0.862,0.0615,0.613407016,0.086170167,0.300422817
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians 20%, and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the latter group had up to a 10-fold higher incidence of COVID-19 than the other groups.
Together, the groups accounted for nearly 30% of the cases.",1099,Translated,TRUE,69.82,11.9,8.1,9.28,10.7,11.43,12,11.5,11.68,11th and 12th grade,322,55,4.927272727,13,0.0691,0.8547,0.0762,0.60871917,0.072363369,0.318917453
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They represent 30%, Hawaiians 20% and Pacific Islanders are mainly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, the groups accounted for almost 30% of cases.",1099,Translated,TRUE,67.79,11.9,8.8,8.7,11,11.37,13,12.5,12.05,8th and 9th grade,348,61,4.770491803,15,0.0585,0.8674,0.0741,0.613100708,0.106705859,0.280193478
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians make up 20%, and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, these groups accounted for almost 30% of cases.",1099,Translated,TRUE,75.54,11.2,7.9,8.07,10.8,10.69,11,12.5,11.57,10th and 11th grade,353,63,4.666666667,15,0.0743,0.8582,0.0674,0.612085044,0.097839758,0.290075153
"n Hawaii White Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
accounting for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa include
4%. We discovered that the rate of COVID-19 in the latter group was up to 10 times higher than in all the others
groups combined, and they accounted for nearly 30% of cases.",1099,Translated,TRUE,56.93,0,13,10.63,17.2,12.81,17,19,16.92,12th and 13th grade,366,62,4.967741935,13,0.0411,0.8556,0.1032,0.61436522,0.067554235,0.318080455
"In Hawaii, white Caucasians make up 25%, Asians are Japanese, Chinese, and other Asians.

make up 30%, Hawaiians make up 20%, and Pacific Islanders, mostly from Micronesia and Samoa, make up

4%. We found that the COVID-19 rate in the latter group was up to 10 times higher than in all others.

These groups together accounted for nearly 30% of cases.",1099,Translated,TRUE,81.33,9.5,5.7,7.82,8.4,10.61,12,7.875,8.74,7th and 8th grade,351,61,4.819672131,13,0.0433,0.831,0.1256,0.611423612,0.067187525,0.32138887
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
if the level of testing and containment measures is maintained, the number of positive cases
New York State remains the same in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,47.12,0,18.9,9.65,24.6,11.22,10,26.5,21.23,18th and 19th grade,272,49,4.612244898,6,0.0355,0.8681,0.0964,0.622228205,0.095668405,0.28210333
"The simulated results of the spread of COVID-19 in New York State and the United Kingdom demonstrated this
while maintaining the level of testing and containment measures, the number of positive cases in
New York State will remain at the same level in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,35.62,0,21.2,10.58,26.8,10.77,10,31,24.65,10th and 11th grade,297,52,4.769230769,6,0.0462,0.9084,0.0454,0.627244473,0.05900456,0.313750982
"Modeled outcomes of COVID-19 spread in New York State and the United Kingdom have shown that
if levels of testing and containment measures are maintained, the number of positive cases in New York State will remain the same in March 2021, while it will decline in the United Kingdom.",1166,Translated,TRUE,38.66,0,20,10.81,25.6,10.9,10,26.5,21.23,10th and 11th grade,282,49,4.795918367,6,0.0295,0.8505,0.1201,0.621579289,0.067310475,0.311110228
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown this
if the level of testing and isolation measures is maintained, the number of positive cases
New York State will remain flat in March 2021, while the UK will see a decrease.",1166,Translated,TRUE,47.12,0,18.9,9.42,24.4,10.9,9,26.5,21.23,10th and 11th grade,270,49,4.571428571,6,0.0365,0.8601,0.1034,0.619095385,0.090397872,0.290506691
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
If the level of testing and containment measures is maintained, the number of positive cases in
The state of New York will remain the same during March 2021, while in the United Kingdom it will be reduced.",1166,Translated,TRUE,41.03,0,21.2,9.53,27.5,10.38,9,29.5,23.45,9th and 10th grade,304,55,4.581818182,6,0.037,0.8975,0.0655,0.631398797,0.062353931,0.306247234
"Modeling results for the spread of COVID-19 in New York State and the United Kingdom include:
If testing levels and lockdown measures are maintained, the number of positive cases in the country will be
In New York State it will remain the same for March 2021, but in England it will be reduced.",1166,Translated,TRUE,34.6,0,21.6,9.53,26.6,11.03,12,28.5,22.71,21st and 22nd grade,294,53,4.603773585,6,0.0315,0.8621,0.1065,0.640030026,0.05624193,0.303728014
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures are maintained, the number of positive cases
New York State remains the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,48.14,0,18.5,9.94,24.4,11.28,10,26,20.87,18th and 19th grade,269,48,4.666666667,6,0.0398,0.8788,0.0814,0.612412393,0.081575207,0.306012452
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases in
New York State will remain the same during March 2021, while it will decrease in the UK.",1166,Translated,TRUE,46.11,0,19.3,9.82,25.2,10.85,9,27,21.6,10th and 11th grade,279,50,4.64,6,0.0399,0.8705,0.0896,0.616112113,0.073561631,0.310326248
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom demonstrated that
if the level of testing and containment measures are preserved, the number of positive cases in
New York State remains the same in March 2021, while in the United Kingdom it will decrease.",1166,Translated,TRUE,37.65,0,20.4,10.98,26.2,10.85,11,28,22.4,10th and 11th grade,289,50,4.84,6,0.0417,0.8705,0.0878,0.614960074,0.077662982,0.307376921
"Modeling results from COVID-19 outbreaks in New York State and the United Kingdom demonstrate that:
If testing levels and quarantine measures are maintained, the number of positive cases will be
New York State will remain the same in March 2021, while England will see a decrease.",1166,Translated,TRUE,41.71,0,18.9,12.61,25.6,11.75,13,26,21.01,25th and 26th grade,280,46,5.152173913,6,0.0247,0.7888,0.1865,0.616418004,0.066929348,0.316652685
"This was demonstrated by simulated results of the spread of COVID-19 in New York State and the United Kingdom
while maintaining the level of testing and containment measures, the number of positive cases
New York State will remain flat in March 2021, while the UK will see a decrease.",1166,Translated,TRUE,38.66,0,20,11.04,25.8,10.9,10,29.5,23.68,10th and 11th grade,284,49,4.857142857,6,0.0438,0.9131,0.043,0.611660421,0.078530811,0.309808701
"Modeled results of the spread of COVID-19 in New York State and the UK have shown this.
If the level of testing and isolation measures is maintained, the number of positive cases
in New York State will remain stable in March 2021, while the UK will see a decline.",1166,Translated,TRUE,71.99,0,9.3,7.9,11.5,9.69,9,13.25,11.43,9th and 10th grade,263,49,4.428571429,6,0.0377,0.854,0.1083,0.653718352,0.091373026,0.254908651
"The modeled results of COVID-19 spread in New York State and the UK have shown that
if the level of testing and containment measures is maintained, the number of positive cases i
New York State will remain the same in March 2021, while in the UK it will reduce.",1166,Translated,TRUE,47.12,0,18.9,8.37,23.6,10.9,9,26.5,21.23,10th and 11th grade,261,49,4.387755102,6,0.0479,0.8817,0.0704,0.611502051,0.07724458,0.311253369
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases in
New York State remains the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,47.12,0,18.9,9.53,24.5,11.22,10,26.5,21.23,18th and 19th grade,271,49,4.591836735,6,0.0431,0.8812,0.0757,0.614613235,0.082355626,0.303031087
"Model results for the spread of COVID-19 in New York State and the United Kingdom have shown that if testing and isolation measures are maintained, the number of positive cases in New York State will remain stable in March 2021, while the United Kingdom will see a decline.",1166,Translated,TRUE,39.68,0,19.6,10.46,24.8,10.62,9,26,20.87,10th and 11th grade,273,48,4.708333333,6,0.0513,0.8812,0.0676,0.626209378,0.07622461,0.297565967
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases i
New York State will remain the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,46.11,0,19.3,9.24,24.8,10.85,9,27,21.6,10th and 11th grade,274,50,4.54,6,0.0418,0.8665,0.0917,0.616624177,0.072954886,0.31042099
"The modeled results of the spread of covid-19 in the state of New York and the United Kingdom have shown that
if the level of testing and containment measures is maintained, the number of positive cases i
New York State remains unchanged in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,44.08,0,20,9.36,25.9,11.38,11,28,22.34,19th and 20th grade,286,52,4.557692308,6,0.0332,0.8577,0.1092,0.619344771,0.091551073,0.289104134
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
if the level of testing and containment measures are maintained, the number of positive cases in
New York State will remain the same in March 2021, while in the United Kingdom it will decrease.",1166,Translated,TRUE,44.08,0,20,10.06,26.4,10.47,9,28,22.34,10th and 11th grade,292,52,4.673076923,6,0.0357,0.8852,0.0791,0.617172897,0.081196144,0.301630914
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
If the level of testing and containment measures is maintained, the number of positive cases
New York state will remain the same in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,46.11,0,19.3,9.48,25,10.85,9,27,21.6,10th and 11th grade,276,50,4.58,6,0.0376,0.8625,0.0999,0.622109473,0.091835581,0.286054999
"Different amounts of antibodies produced after the two vaccine doses were found.
Individuals with a previous natural infection developed a higher level of antibodies. Between
individuals without a history of past SARS-CoV-2 infection, 5% had an antibody level to the same
order of magnitude of infected people, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,27.52,15.9,14,14.04,13.7,10.38,21,14.125,14.44,13th and 14th grade,476,73,5.602739726,2,0.0545,0.8698,0.0757,0.633320093,0.062638983,0.304040968
"The amount of antibodies produced after the two vaccinations was found to be different.
Individuals with a previous natural infection had higher antibody levels. Between
Among individuals with no previous SARS-CoV-2 infection, 5% had the same antibody levels.
In order of magnitude of the number of people infected, they indicate that they were infected during the following periods:
Asymptomatic method. For such individuals, one dose of vaccine may be sufficient to get:
Protective immune response.",1170,Translated,TRUE,30.87,15.1,12.7,14.09,12.8,9.85,20,11.9,13.47,12th and 13th grade,500,75,5.746666667,2,0.0391,0.8933,0.0675,0.651595116,0.049307577,0.29909727
"Different amounts of antibodies produced after the two vaccine doses were found.
People who had a previous natural infection developed a higher level of antibodies. From
in people with no history of SARS-CoV-2 infection, 5% had identical antibody levels
order of magnitude of those infected, suggesting that they contracted the infection in a manner
asymptomatically. In these people, one dose of vaccine may be enough to achieve
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.74,13.4,10.82,21,13.25,14.43,13th and 14th grade,457,70,5.614285714,2,0.0475,0.8545,0.098,0.636530817,0.055311389,0.308157772
"Different amounts of antibodies produced after two doses of the vaccine were found.
Individuals with previous natural infection developed higher levels of antibodies. Between
of individuals with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of infected people, suggesting that they acquired the infection in an
in an asymptomatic way. In such individuals, a single dose of vaccine may be sufficient to acquire a
protective immune response.",1170,Translated,TRUE,27.83,15.6,13.9,13.86,13.8,10.23,20,13.75,13.31,13th and 14th grade,471,72,5.625,2,0.0462,0.8535,0.1003,0.638138235,0.067275956,0.294585764
"Different amounts of antibodies were found to be produced after two doses of the vaccine.
Individuals with previous natural infection developed higher levels of antibodies. Among
people with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
as infected people, suggesting that they acquired the infection in an
asymptomatic manner. In these individuals, a single dose of vaccine may be sufficient to acquire a
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.92,13.6,10.59,21,13.25,13.29,13th and 14th grade,459,70,5.642857143,2,0.0458,0.8565,0.0977,0.635827482,0.073965319,0.290207237
"Different amounts of antibodies produced after two doses of the vaccine were detected.
Individuals with previous natural infection developed higher levels of antibodies. Among
of individuals without a history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of magnitude of infected people, which indicates that they became infected in an
asymptomatic. In such people, a single dose of the vaccine may be sufficient to produce a
protective immune response.",1170,Translated,TRUE,27.83,15.9,13.9,14.09,13.9,10.45,21,14,14.42,13th and 14th grade,474,72,5.666666667,2,0.0414,0.8303,0.1283,0.635614574,0.072641261,0.291744143
"Different amounts of antibodies produced after the two doses of vaccine were noted.
People who had already been infected naturally developed a higher level of antibodies.
Among people without a history of SARS-CoV-2 infection, 5% had identical antibody levels
to those of infected people, suggesting that they contracted the infection in a way
asymptomatic. In these people, one dose of vaccine may be enough to obtain
a protective immune response.",1170,Translated,TRUE,36.79,14.6,12.5,12.99,12.8,10.37,20,12.75,13.29,12th and 13th grade,448,70,5.485714286,2,0.038,0.848,0.1141,0.63053298,0.066242814,0.303224295
"The amount of antibodies produced after the two vaccines was found to be different.
Individuals with a previous natural infection had higher antibody levels. Among
Among people without previous SARS-CoV-2 infection, 5% had the same antibody levels.
In order of magnitude of the number of infected people, they indicate that they were infected during the following periods:
Asymptomatic method. For these people, one dose of vaccine may be sufficient to receive:
Protective immune response.",1170,Translated,TRUE,39.53,14.3,11.4,13.74,12.4,9.92,20,11.2,12.95,11th and 12th grade,489,74,5.689189189,2,0.0409,0.8889,0.0702,0.643407106,0.056555446,0.300037473
"Different amounts of antibodies produced after the two doses of vaccine were found.
People who had already had a natural infection developed a higher level of antibodies. Among
people with no history of SARS-CoV-2 infection, 5% had an antibody level identical
order of magnitude to those infected, suggesting that they acquired the infection
asymptomatically. In these people, one dose of vaccine may be sufficient to elicit a
protective immune response.",1170,Translated,TRUE,36.79,14.9,12.5,13.51,13.2,10.37,20,13,13.86,12th and 13th grade,454,70,5.571428571,2,0.0551,0.862,0.0828,0.629931509,0.072459824,0.297608614
"Different amounts of antibodies produced after the two vaccine doses were found.
Individuals with a previous natural infection developed a higher antibody level. Among
individuals with no previous SARS-CoV-2 infection had 5% an antibody level in the same way
order of magnitude of infected people, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,28.03,15.9,13.8,13.8,13.5,10.52,21,13.875,14.44,13th and 14th grade,463,71,5.605633803,2,0.0536,0.8766,0.0699,0.63715893,0.056580577,0.306260407
"Different amounts of antibodies produced after two doses of the vaccine were found.
Individuals with previous natural infection developed higher levels of antibodies. Between
of individuals with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of infected persons, indicating that they acquired the infection in a
in an asymptomatic way. In such individuals, a single dose of vaccine may be sufficient to acquire one
protective immune response.",1170,Translated,TRUE,27.83,15.6,13.9,13.98,13.9,10.45,21,13.75,13.31,13th and 14th grade,473,72,5.652777778,2,0.0524,0.863,0.0846,0.64206171,0.057899468,0.300038844
"The amount of antibodies produced after two vaccinations was found to be different.
Individuals with a previous natural infection had higher antibody levels. between
Among individuals who had not previously been infected with SARS-CoV-2, 5% had the same antibody levels.
The scale of the number of infected people indicates that they were infected during the following periods:
Asymptomatic method. For such individuals, one dose of vaccine may be enough to get:
Protective immune response.",1170,Translated,TRUE,39.53,14.6,11.4,13.85,12.5,9.92,19,11.4,12.95,12th and 13th grade,490,74,5.702702703,2,0.0318,0.8759,0.0923,0.6626544,0.048450414,0.28889516
"It was found that different amounts of antibodies were produced after the two doses of vaccine.
People with a previous natural infection developed higher levels of antibodies. Of those without a previous SARS-CoV-2 infection, 5% had antibody levels in the same range as infected people, suggesting that they acquired the infection asymptomatically. In such people, one dose of vaccine may be enough to produce a protective immune response.",1170,Translated,TRUE,45.76,14.2,11.1,13.28,12.8,10.52,19,12.25,12.68,12th and 13th grade,439,68,5.485294118,2,0.0439,0.88,0.0761,0.63411653,0.055153165,0.310730278
"Different amounts of antibodies produced after the two vaccine doses were found.
People with a previous natural infection developed a higher antibody level. Among
individuals without prior SARS-CoV-2 infection had 5% antibody levels similarly
order of magnitude of infected people, suggesting that they got the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to achieve a
protective immune response.",1170,Translated,TRUE,29.35,15.6,13.3,14.85,13.8,11.39,22,13,15.08,12th and 13th grade,443,66,5.803030303,2,0.0411,0.853,0.1058,0.630817056,0.068235263,0.300947607
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
People with previous natural infection developed higher levels of antibodies. Between
subjects with no history of previous SARS-CoV-2 infection, 5% had a concurrent antibody level
order of magnitude of infected individuals, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,27.52,16.2,14,14.56,14.2,11.03,24,14.375,14.99,14th and 15th grade,483,73,5.698630137,2,0.0427,0.8544,0.1029,0.638243437,0.05633631,0.30542025
"The amount of antibodies produced after two doses of vaccine was different.
Previously naturally infected individuals had higher antibody levels.
Among individuals without a previous SARS-CoV-2 infection, 5% had antibody levels at the same level as those who were infected.
This suggests that they were infected in an asymptomatic manner. For these individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Translated,TRUE,32.7,13.7,12,13.85,11.9,10.51,21,9,11.95,11th and 12th grade,439,66,5.712121212,2,0.0299,0.8344,0.1357,0.635976613,0.069502234,0.294521093
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
Individuals who had a previous natural infection developed a higher level of antibodies. between the
In individuals with no history of previous infection with SARS-CoV-2, 5% had an antibody level at the same level
In terms of the size of the infected people, which indicates that they were infected in
Asymptomatic method. In such individuals, a single dose of the vaccine may be sufficient to obtain...
Protective immune response.",1170,Translated,TRUE,45.76,14.6,11.1,11.66,11.5,9.5,19,12.5,12.45,11th and 12th grade,525,85,5.247058824,2,0.0746,0.8841,0.0413,0.633863986,0.066174634,0.299961418
"Different amounts of antibodies produced after the two vaccine doses were found.
People who had a previous natural infection developed a higher level of antibodies. Of
in people with no history of SARS-CoV-2 infection, 5% had identical antibody levels
order of magnitude of those infected, suggesting that they contracted the infection in a way
asymptomatically. In these people, one dose of vaccine may be enough to achieve
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.34,13.1,10.59,20,13.25,14.43,12th and 13th grade,452,70,5.542857143,2,0.0512,0.8551,0.0936,0.633180261,0.057389151,0.309430599
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
People with a previous natural infection developed a higher level of antibodies. Between
people with no history of previous SARS-CoV-2 infection, 5% had a level of antibodies to it
order of magnitude of infected individuals, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,34.97,15.9,13.2,12.71,13.2,9.93,20,14.625,13.95,12th and 13th grade,484,77,5.363636364,2,0.0512,0.8632,0.0856,0.643780231,0.054350439,0.301869333
"The proposed technique has a high similarity with the PCR testing technique. The results
The results obtained highlight the potential application of this simple and inexpensive magneto test for saliva.
Point-of-care based COVID-19 diagnosis.",1171,Translated,TRUE,43.09,11.2,10.1,15.99,13.1,12.09,13,6.666666666666667,11.58,11th and 12th grade,241,34,6.176470588,2,0.7612,0.235,0.0038,0.616699576,0.096584074,0.286716402
"The proposed technique showed great similarity with the PCR test technique. Results
the application potential of this simple, low-cost salivary magnetoassay was pointed out
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.89,0,12.3,18.38,16.2,12.23,10,8.5,12.74,12th and 13th grade,209,28,6.571428571,2,0.8663,0.1294,0.0043,0.610965669,0.088361241,0.300673097
"The proposed technique showed great similarity with the PCR test technique. Results
the applicability of this simple, low-cost saliva magnetoassay was highlighted
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,24.44,0,13.1,19.07,16.6,12.18,9,8,12.89,12th and 13th grade,199,26,6.769230769,2,0.852,0.1427,0.0053,0.613017201,0.087745696,0.299237162
"The proposed technology showed great similarity to PCR testing technology. result
Points are earned for the application potential of this simple and inexpensive magnetic method for saliva.
On-site treatment-based COVID-19 diagnosis.",1171,Translated,TRUE,27.18,13,12,17.9,14.4,14.84,12,7.166666666666666,13.15,12th and 13th grade,232,31,6.580645161,2,0.8944,0.1021,0.0034,0.627184868,0.051571857,0.321243346
"The proposed technique showed great similarity with the PCR testing technique. The results
obtained show the application potential of this simple, inexpensive saliva magnetoassay.
point-of-care-based diagnostics for COVID-19.",1171,Translated,TRUE,28.2,11.9,11.6,20.33,16.5,13.68,12,6,12.29,11th and 12th grade,225,28,7.142857143,2,0.915,0.0813,0.0036,0.613021553,0.082509905,0.304468513
"The proposed method was very similar to the PCR testing technique. Results
the obtained result indicates the application potential of this simple and inexpensive saliva magnetic analysis.
When diagnosed with COVID-19.",1171,Translated,TRUE,44.1,12.5,9.7,15.46,12.1,13.83,15,6.833333333333333,14.44,12th and 13th grade,217,31,6.096774194,2,0.5518,0.44,0.0082,0.624348402,0.075523071,0.300128609
"The proposed technique showed great similarity with the PCR testing technique. The results
obtained point to the potential application of this simple and low-cost magnetoassay for saliva-
Point-of-care based COVID-19 diagnosis.",1171,Translated,TRUE,38.82,0,11.7,17.98,16.2,12.55,11,10.25,12.65,12th and 13th grade,227,31,6.419354839,2,0.8772,0.1186,0.0042,0.611725628,0.092233285,0.296041161
"The proposed technique showed great similarity to the PCR test technique. The results
obtained point to the application potential of this simple, inexpensive magnetoassay for salivary
based covid-19 diagnosis in healthcare.",1171,Translated,TRUE,38.82,0,11.7,17.8,15.7,13.06,12,10.75,13.94,11th and 12th grade,223,31,6.290322581,2,0.8998,0.0963,0.0039,0.597607911,0.0785276,0.32386452
The proposed technology was very similar to the PCR testing technology. The results obtained demonstrate the potential of this simple and inexpensive magnetic assay to be applied to saliva-based clinic COVID-19 diagnosis.,1171,Translated,TRUE,29.86,0,13.1,16.12,14.5,13.81,15,11.5,13.9,13th and 14th grade,221,32,5.9375,2,0.7931,0.2029,0.004,0.614585996,0.060498558,0.324915498
"The proposed technique showed great similarity to the PCR testing technique. result
The obtained results demonstrate the applicability of this simple and inexpensive saliva magnetic analysis method.
Point-of-care based diagnosis for COVID-19.",1171,Translated,TRUE,35.23,11.2,11,18.71,14.9,14.04,14,6.333333333333333,11.78,11th and 12th grade,242,32,6.65625,2,0.89,0.1064,0.0036,0.61532706,0.083800748,0.300872147
"The proposed method was very similar to the PCR test technique. Results
the obtained result indicates the application potential of this simple and inexpensive salivary magnetic analysis.
When diagnosed with COVID-19.",1171,Translated,TRUE,44.1,12.5,9.7,15.29,12,13.32,14,6.833333333333333,14.44,12th and 13th grade,216,31,6.064516129,2,0.5697,0.4222,0.0081,0.623609722,0.068384245,0.308006078
"The proposed technique showed great similarity with the PCR test technique. Results
The obtained points indicate the potential application of this simple and low-cost magnetic saliva test.
Point-of-care COVID-19 diagnosis.",1171,Translated,TRUE,44.41,11.2,9.6,17.2,13.9,12.55,11,6,12,11th and 12th grade,222,30,6.5,2,0.8375,0.1584,0.0041,0.61609,0.089743406,0.294166565
The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the potential application of this simple and inexpensive magnetoassay for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,22.41,0,13.9,19.83,17.6,13.85,13,11,15.33,13th and 14th grade,230,30,6.7,2,0.8386,0.157,0.0045,0.613438249,0.086487211,0.300074548
"The proposed technique showed great similarity with the PCR test technique. Results
the application potential of this simple, inexpensive saliva magnetoassay was pointed out
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.89,0,12.3,18.78,16.4,12.79,11,9,14.17,12th and 13th grade,210,28,6.607142857,2,0.8933,0.1027,0.0041,0.60663861,0.080121353,0.313240111
"The proposed technique showed great similarity to the PCR testing technique. Results
The points obtained indicate the applicability of this simple and low-cost magnetic test for saliva.
Point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,44.1,10.5,9.7,15.87,12.9,12.3,11,5.833333333333333,10.57,10th and 11th grade,222,31,6.258064516,2,0.8004,0.1945,0.0051,0.616841316,0.085672952,0.297485709
"The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the application potential of this simple, low-cost magnetoassay for saliva-based point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.38,0,12.5,19.71,17.7,13.61,12,10.25,14.08,13th and 14th grade,224,29,6.75862069,2,0.8548,0.1408,0.0044,0.613480449,0.084624372,0.301895112
The proposed technology showed great similarity to the PCR testing technology. The results obtained indicate the applicability of this simple and low-cost magnetic test for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,22.41,0,13.9,18.09,16.4,12.8,11,11,14,13th and 14th grade,222,30,6.433333333,2,0.8604,0.1357,0.0039,0.606508553,0.068738051,0.324753284
"The proposed technique showed great similarity with the PCR test technique. The obtained results indicate the application potential of this simple, inexpensive magnetoassay for saliva-based point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,22.92,0,13.7,20.35,18,13.61,12,10.75,15.46,13th and 14th grade,226,29,6.827586207,2,0.8706,0.1251,0.0043,0.607826293,0.084069997,0.30810374
The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the possibility of applying this simple and low-cost magnetic test for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,30.36,0,12.9,17.98,16.2,13.06,12,10.75,13.94,12th and 13th grade,227,31,6.35483871,2,0.7702,0.225,0.0048,0.617548108,0.086841054,0.295610815
"In the early stages of the COVID-19 pandemic, stay-at-home orders and social distancing were implemented. 
The guidelines required the U.S. health system to postpone elective tests and procedures. 
In the early stages of the pandemic, brain MRI scan volumes decreased by 17%.",1172,Translated,TRUE,60.82,10.1,7.4,11.75,9.8,12.43,13,5.75,8.01,7th and 8th grade,275,42,5.571428571,4,0.0151,0.4215,0.5634,0.646374941,0.082466617,0.271158457
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced health care systems in the United States to postpone scheduled exams and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,58.11,0,10.5,12.53,14.2,11.31,11,12.75,11.39,10th and 11th grade,269,43,5.302325581,4,0.0083,0.2624,0.7293,0.623918593,0.071433991,0.304647386
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing forced medical facilities in the United States to postpone scheduled exams and procedures.
During the early pandemic, there was a 17% decrease in brain MRI scans.",1172,Translated,TRUE,52.19,0,10.7,13.4,13.7,12.06,11,12.5,12.86,12th and 13th grade,244,38,5.473684211,4,0.0081,0.2321,0.7598,0.617520809,0.069923304,0.31255585
"In the early stages of the COVID-19 pandemic, stay-at-home orders and social distancing are implemented.
The guidelines required the U.S. health system to postpone elective tests and procedures.
At the beginning of the pandemic, brain MRI scan volumes fell by 17%.",1172,Translated,TRUE,61.02,10.7,7.3,11.4,9.4,12.23,12,5.875,8.02,7th and 8th grade,264,41,5.512195122,4,0.0151,0.3918,0.5932,0.649210274,0.085473232,0.265316546
"Stay-at-home orders and social distancing during the early stages of the COVID-19 pandemic
the guidelines forced healthcare systems in the United States to delay elective tests and procedures.
During the early pandemic, the volume of brain MRI scans decreased by 17%.",1172,Translated,TRUE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.585365854,4,0.012,0.2943,0.6937,0.640699744,0.095142305,0.264157981
"During the first phase of the COVID-19 pandemic, stay-at-home and social distancing orders were issued
The guidelines have forced U.S. health systems to postpone elective tests and procedures.
There was a 17% decline in the volume of brain MRI scans during the early pandemic.",1172,Translated,TRUE,65.01,10.5,7.8,11.65,10.9,12.26,12,8,8.61,7th and 8th grade,276,44,5.340909091,4,0.0095,0.2699,0.7206,0.629063189,0.083601549,0.287335306
"During the initial phase of the COVID-19 pandemic, containment and social distancing measures
The guidelines forced U.S. health systems to postpone elective tests and procedures.
There was a 17% decrease in brain MRI volume at the start of the pandemic.",1172,Translated,TRUE,66.44,10.5,7.3,11.88,10.4,12.98,13,7.333333333333334,9.32,7th and 8th grade,253,40,5.4,4,0.0117,0.3392,0.6491,0.626944184,0.084541731,0.288514048
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced U.S. health care systems to postpone scheduled tests and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,66.44,9.7,7.3,11.7,10.4,12.19,10,7,8.32,6th and 7th grade,253,40,5.375,4,0.0082,0.2542,0.7376,0.632954955,0.078162335,0.288882792
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced United States health systems to postpone elective tests and procedures.
There was a 17% reduction in brain MRI volume during the early pandemic.",1172,Translated,TRUE,51.68,0,10.9,14.68,15.1,12.3,12,12.75,11.9,14th and 15th grade,260,39,5.743589744,4,0.0114,0.3205,0.6681,0.630424142,0.079242863,0.290333033
"Stay-at-home orders and social distancing during the early stages of the COVID-19 pandemic
the guidelines forced health care systems in the United States to delay elective tests and procedures.
During the early pandemic, the volume of brain MRIs decreased by 17%.",1172,Translated,TRUE,50.67,0,11.3,13.29,14.4,11.59,11,12.75,11.13,11th and 12th grade,263,41,5.487804878,4,0.015,0.3325,0.6525,0.650579154,0.103725761,0.245695114
"During the initial phase of the covid-19 pandemic, stays at home and social distancing
guidelines have forced the US health system to postpone elective tests and procedures.
There was a 17% reduction in brain MRI volume during the early pandemic.",1172,Translated,TRUE,59.64,0,9.9,12.01,13,12.13,11,12.5,12,12th and 13th grade,246,40,5.225,4,0.0124,0.3113,0.6763,0.646948814,0.08892101,0.264130175
"During the early stages of the COVID-19 pandemic, health care systems in the United States were forced to postpone scheduled exams and procedures due to stay-at-home orders and social distancing guidelines.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,56.08,0,11.3,12.25,14.9,10.85,11,14.25,11.95,11th and 12th grade,291,47,5.234042553,4,0.0089,0.2563,0.7348,0.655610383,0.073186219,0.271203458
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced US healthcare systems to postpone screening tests and procedures.
Brain MRI volume was reduced by 17% during the early pandemic.",1172,Translated,TRUE,53.21,0,10.3,14.96,14.9,13.3,13,11.5,10.53,14th and 15th grade,244,36,5.861111111,4,0.0108,0.2957,0.6935,0.632185757,0.088183075,0.279631197
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced United States health systems to postpone screening tests and procedures.
During the early pandemic, there was a 17% decrease in the volume of brain MRI scans.",1172,Translated,TRUE,58.62,0,10.3,13.81,15.2,12.2,12,13,11.26,12th and 13th grade,274,42,5.595238095,4,0.0106,0.3234,0.666,0.628288388,0.079301953,0.292409658
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced healthcare systems in the United States to postpone scheduled tests and procedures.
During the early pandemic, there was a 17% reduction in the number of brain MRIs.",1172,Translated,TRUE,50.67,0,11.3,13.69,14.7,11.59,11,12.75,12.1,11th and 12th grade,265,41,5.512195122,4,0.0186,0.46,0.5214,0.617977679,0.05750801,0.3245143
"From the early stages of the COVID-19 pandemic, containment and social distancing measures were implemented.
The guidelines required the U.S. healthcare system to postpone elective tests and procedures.
At the start of the pandemic, brain MRI volumes fell by 17%.",1172,Translated,TRUE,61.33,10.1,7.2,12.44,9.9,12.82,14,5.5,9,8th and 9th grade,263,40,5.65,4,0.0142,0.3676,0.6182,0.639205158,0.081314296,0.279480457
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced health care systems across the United States to postpone preventive screenings and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,58.11,0,10.5,13.87,15.3,11.31,11,13.25,12.32,10th and 11th grade,279,43,5.534883721,4,0.0089,0.2609,0.7302,0.625293076,0.077462569,0.29724431
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
the guidelines forced United States health systems to postpone testing and screening procedures.
During the early pandemic, there was a 17% reduction in brain MRI volume.",1172,Translated,TRUE,51.68,0,10.9,14.97,15.5,12.3,13,12.75,11.9,11th and 12th grade,263,39,5.820512821,4,0.0144,0.4273,0.5583,0.625911057,0.083821274,0.290267766
"In the initial phase of the COVID-19 pandemic, containment and social distancing measures
The guidelines forced US health systems to delay elective tests and procedures.
There was a 17% decrease in brain MRI volume at the onset of the pandemic.",1172,Translated,TRUE,59.64,0,9.9,11.72,12.7,12.92,14,12.5,12,12th and 13th grade,244,40,5.175,4,0.0091,0.2655,0.7254,0.627475739,0.086325124,0.286199182
"It seems that the virus traveled by car on highways and highways; and that â€œsoloâ€ driving, that is
traveling in passenger cars, which now seems to be perceived by the public as a solution, was
probably one of the media that favored the initial dissemination.",1182,Translated,TRUE,34.26,0,19.7,10.69,23.9,11.48,11,27.5,21.56,10th and 11th grade,262,45,4.888888889,0,0.027,0.5978,0.3752,0.630515873,0.048921019,0.320563048
"The virus appears to have traveled by car on highways and highways; and that ""solo"" driving, ie.
traveling by passenger cars, which the public now seems to perceive as the solution, was
probably one of the means that facilitated the initial spread.",1182,Translated,TRUE,58.62,0,10.3,10.21,12.3,10.32,11,13,12.21,9th and 10th grade,248,42,4.976190476,0,0.0196,0.506,0.4744,0.622877002,0.046697352,0.33042559
"It appears that the virus traveled by car on freeways and highways; and that ""solo"" driving, i.e.
travel with passenger cars, which now seem to be perceived by the public as a solution, where
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.94,11.8,10.47,12,12.5,10.62,9th and 10th grade,251,44,4.772727273,0,0.0287,0.6227,0.3486,0.640060842,0.047891777,0.312047452
"The virus appears to have traveled by car on highways and highways; and that ""solo"" driving, ie.
to drive passenger cars, which the public currently perceives as a solution, where
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,59.64,0,9.9,10.56,12.1,10.55,11,12,11,10th and 11th grade,239,40,5.05,0,0.0316,0.6735,0.2949,0.632266343,0.048529174,0.31920442
"It appears that the virus traveled by car on freeways and highways; and that ""solo"" driving, i.e.
travel by passenger car, which now seems to be perceived by the public as a solution, was
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.41,11.4,10.47,12,12.5,10.62,10th and 11th grade,247,44,4.681818182,0,0.019,0.524,0.457,0.641880333,0.047569662,0.310550034
"It seems that the virus traveled by car on freeways and highways. and this ""solo"" driving, ie.
passenger car travel, which now seems to be perceived by the public as a solution, was
possibly one of the media that favored the initial spread.",1182,Translated,TRUE,73.88,8.8,6.5,7.76,7.4,9.85,12,7.166666666666666,7.58,7th and 8th grade,240,43,4.651162791,0,0.0191,0.5159,0.465,0.638165474,0.049088307,0.312746167
"The virus appears to have traveled by car via highways and highways. And that â€œsoloâ€ driving, that is.
Traveling by car now seems to be recognized by the public as a solution.
It is probably one of the preferred means of initial diffusion.",1182,Translated,TRUE,77.43,9.5,5.1,7.58,5.9,10.05,11,5.625,8.97,5th and 6th grade,243,43,4.720930233,0,0.1082,0.7969,0.0949,0.631202519,0.04809159,0.320705861
"The virus appears to have been transmitted by car on highways and highways; And that â€œsoloâ€ leadership, that is.
Passenger car travel, which the public now seemed to see as a solution, was the answer
It may have been one of the means that favored the initial spread.",1182,Translated,TRUE,64.04,0,10.3,8.88,12.5,8.77,8,14,12.1,8th and 9th grade,270,48,4.6875,0,0.0308,0.5115,0.4577,0.624076128,0.045259062,0.330664754
"It appears the virus traveled by car on highways and interstates; and this â€œsoloâ€ behavior, that is to say
car transport, which now seems to be perceived by the public as a solution, has been
probably one of the means which favored the initial diffusion.",1182,Translated,TRUE,42.72,0,18.5,10.17,23.5,11.48,12,27.5,22.44,10th and 11th grade,258,45,4.8,0,0.0319,0.6177,0.3504,0.620015979,0.04653509,0.333448887
"The virus appears to have traveled by car on freeways and highways; and that ""solo"" driving, i.e.
passenger car travel, which now seems to be seen by the public as a solution, was
probably one of the means that supported the initial spread.",1182,Translated,TRUE,66.57,0,9.3,8.24,11,9.84,11,12.75,11.39,8th and 9th grade,240,43,4.651162791,0,0.0225,0.5797,0.3977,0.634840727,0.046724431,0.318434775
"The virus appears to have traveled by car on freeways and highways. and that ""solo"" driving, ie.
Traveling by passenger cars, which the public now seems to perceive as a solution, was
possibly one of the means that facilitated the initial spread.",1182,Translated,TRUE,65.73,10.5,7.6,9.33,8.6,10.35,12,7.666666666666666,9.41,7th and 8th grade,246,42,4.928571429,0,0.0193,0.5056,0.475,0.625948191,0.046866842,0.327185035
"It seems that the virus spread by car on motorways and expressways. And this ""driving alone"", i.e.
travelling by car, which now seems to be perceived by the public as a solution,
may have been one of the media that favored the initial spread.",1182,Translated,TRUE,81.93,9.7,5.5,7.18,7.2,8.67,9,7.666666666666666,9.52,9th and 10th grade,242,44,4.568181818,0,0.0197,0.471,0.5092,0.638543963,0.048204951,0.313251108
"It seems that the virus traveled by car on highways and highways; and that driving â€œaloneâ€, that is
traveling in passenger cars, which now seems to be perceived by the public as a solution, was
Probably one of the media that favored the initial dissemination.",1182,Translated,TRUE,34.26,0,19.7,10.81,24,11.48,11,27.5,21.56,10th and 11th grade,263,45,4.911111111,0,0.0235,0.5787,0.3978,0.627603471,0.048193805,0.324202806
"It appears that the virus was spread by car on highways and motorways, and that ""driving alone"", i.e. travelling by private car, which is now perceived by the public as a solution, was probably one of the factors that favoured its initial spread.",1182,Translated,TRUE,66.57,0,9.3,8.99,11.6,9.84,11,12.75,12.32,8th and 9th grade,246,43,4.744186047,0,0.0176,0.4876,0.4948,0.64310956,0.04854751,0.308342963
"The virus appears to have traveled by car on highways and highways. And this is ""independent"" management.
Traveling by car now seems to be accepted by the public as a solution.
It is probably one of the preferred means of initial diffusion.",1182,Translated,TRUE,69.28,10.7,6.2,7.92,6.1,9.42,12,6,10.87,5th and 6th grade,240,42,4.785714286,0,0.0865,0.775,0.1385,0.637338161,0.049003858,0.313657999
"The virus appears to have traveled by car on freeways and highways; and that ""solo"" management, i.e.
travel by private car, which now seems to be perceived by the public as a solution, was
probably one of the agents who supported the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.7,11.6,10.83,13,13,12.44,8th and 9th grade,249,44,4.727272727,0,0.0201,0.5085,0.4714,0.634385228,0.047349259,0.318265468
"It seems that the virus was transmitted by car on motorways and expressways. And this ""solo behaviour"", i.e. car travel, which now seems to be perceived by the public as a solution, was probably one of the reasons for the initial spread.",1182,Translated,TRUE,74.19,11.2,6.4,7.94,7.6,9.59,11,8,11.31,7th and 8th grade,237,42,4.666666667,0,0.0097,0.2926,0.6977,0.640291989,0.046827901,0.312880099
"The virus appears to have traveled by car on highways and freeways; and that ""solo"" management, i.e.
to travel in passenger cars, which now seems to be accepted by the public as a solution
probably one of the vehicles that contributed to the initial spread.",1182,Translated,TRUE,57.1,0,10.9,9.46,12.1,10.72,13,14.75,14.33,10th and 11th grade,257,45,4.777777778,0,0.0189,0.5176,0.4634,0.626235545,0.047031906,0.326732516
"It seems that the virus travelled by car on motorways and dual carriageways; and that â€œsoloâ€ driving, i.e.
travelling in passenger cars, which now seems to be perceived by the public as a solution, was
probably one of the means that favoured the initial spread.",1182,Translated,TRUE,65.56,0,9.7,10.22,12.9,10.72,10,14.25,13.44,9th and 10th grade,265,45,4.955555556,0,0.0201,0.562,0.4179,0.631860077,0.047950771,0.320189148
"Pure silver and stainless steel surfaces containing silver were found to be non-reflective
inhibits the effect on SARS-CoV-2 and H1N1 viruses. For comparison, both pure copper and
copper-containing stainless steel with a high copper content has a significant antiviral effect
properties.",1186,Translated,TRUE,33.75,0,13.6,16.65,17.2,11.2,12,13.75,14.05,13th and 14th grade,287,41,6.097560976,3,0.0229,0.5479,0.4292,0.639469802,0.044905934,0.315624237
"It has been discovered that surfaces of pure silver and silver-containing stainless steels do not appear
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-containing stainless steel with a high copper content exhibits significant antiviral effect
properties.",1186,Translated,TRUE,33.24,0,13.8,17.81,18.3,11.82,14,14.5,15.07,11th and 12th grade,302,42,6.285714286,3,0.0509,0.7557,0.1935,0.622220159,0.050405577,0.32737419
"Pure silver and stainless steel surfaces containing silver were found to be non-reflective
inhibits the effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-containing stainless steel with a high copper content has a significant antiviral effect
properties.",1186,Translated,TRUE,33.75,0,13.6,16.53,17.1,11.2,12,13.75,14.05,13th and 14th grade,286,41,6.073170732,3,0.0259,0.6032,0.3709,0.639064789,0.045078352,0.315856814
"It is found that pure silver and silver-containing stainless steel surfaces do not show
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content exhibits important antiviral properties.
properties.",1186,Translated,TRUE,43.22,0,12.1,16.19,16.3,10.68,11,13.25,12.93,12th and 13th grade,270,39,6.025641026,3,0.1124,0.7308,0.1568,0.637940049,0.045702264,0.316357672
"Pure silver and silver-containing stainless steel surfaces were found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper-containing stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,29.86,0,13.1,20.12,18.4,11.83,11,12,15.15,11th and 12th grade,247,32,6.75,3,0.1727,0.7502,0.0771,0.643082857,0.044786952,0.312130213
"It has been discovered that surfaces of pure silver and silver-containing stainless steel do not appear
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
the copper content stainless steel with a high copper content exhibits significant antiviral effect
characteristics.",1186,Translated,TRUE,32.22,0,14.2,16.71,17.8,11.19,14,14.5,15.16,14th and 15th grade,307,44,6.068181818,3,0.0421,0.7277,0.2302,0.623732865,0.050820936,0.325446218
"Pure silver and stainless steel surfaces containing silver have been found not to display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Copper-containing stainless steel with a high copper content exhibits significant antiviral effects
Properties.",1186,Translated,TRUE,34.26,0,13.5,17.98,17.9,11.34,13,13.5,14,13th and 14th grade,288,40,6.3,3,0.0195,0.4817,0.4987,0.637647569,0.043077428,0.319274932
"Pure silver and silver-containing stainless steel surfaces were found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,38.32,0,11.9,18.33,16.8,11.83,11,12,15.15,11th and 12th grade,236,32,6.40625,3,0.1705,0.752,0.0775,0.640124023,0.045519598,0.314356357
"It was found that pure silver and silver-containing stainless steel surfaces do not appear to have any inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper-containing stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,35.78,0,12.9,17.98,17.5,10.96,11,13.25,14.97,17th and 18th grade,269,37,6.297297297,3,0.1096,0.7926,0.0978,0.641965568,0.044580922,0.313453496
"It has been shown that surfaces of pure silver and silver-containing stainless steel are not visible
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content exhibits important antiviral properties.
characteristics.",1186,Translated,TRUE,33.75,0,13.6,16.82,17.3,11.59,13,14.25,15.03,13th and 14th grade,288,41,6.12195122,3,0.0642,0.7083,0.2275,0.642267644,0.049485881,0.308246523
"It has been found that pure silver and silver-containing stainless steel surfaces do not display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and
high-copper stainless steel exhibits significant antiviral properties
properties.",1186,Translated,TRUE,36.79,0,12.5,18.73,17.7,11.72,12,12.75,13.86,12th and 13th grade,260,35,6.542857143,3,0.043,0.6762,0.2808,0.644491076,0.045169074,0.310339868
"It was found that surfaces made of pure silver and stainless steel containing silver do not have an inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,43.73,0,11.9,15.08,15.1,10.81,11,13.5,14.97,14th and 15th grade,255,38,5.736842105,3,0.1789,0.7642,0.0569,0.643486023,0.046549227,0.309964716
"It has been shown that pure silver and stainless steel surfaces containing silver are not visible.
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content has important antiviral properties.
characteristics.",1186,Translated,TRUE,49.11,12.5,9.8,15.25,13.1,10.86,12,8.5,12.31,12th and 13th grade,281,41,5.951219512,3,0.0492,0.6325,0.3183,0.623384118,0.047115423,0.329500496
"It turns out that sterling silver and stainless steel surfaces containing silver do not display.
Inhibitory effect against SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and
Copper-containing stainless steel with a high copper content exhibits significant antiviral effects.
property.",1186,Translated,TRUE,41.06,11.2,10.8,17.21,14.9,12.19,15,7.666666666666666,10.32,10th and 11th grade,291,40,6.375,3,0.029,0.4915,0.4795,0.629278004,0.047259465,0.323462516
"It has been proven that pure silver and silver-containing stainless steel surfaces do not exhibit
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content has important antiviral properties.
properties.",1186,Translated,TRUE,42.72,0,12.3,15.95,16.4,10.94,11,14,14,13th and 14th grade,275,40,5.975,3,0.1806,0.735,0.0844,0.630261064,0.045768071,0.323970854
"Surfaces of pure silver and silver-containing stainless steel have been found not to show
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and
high copper stainless steel exhibits significant antiviral properties
properties.",1186,Translated,TRUE,36.79,0,12.5,17.75,16.8,11.27,11,12.25,13.86,12th and 13th grade,253,35,6.342857143,3,0.0335,0.6315,0.335,0.647251427,0.046189412,0.306559175
"Surfaces of pure silver and stainless steel containing silver have been found to be indistinguishable
Inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Copper-containing stainless steel with a high copper content shows significant antiviral effects
Properties.",1186,Translated,TRUE,33.75,0,13.6,18.22,18.4,11.2,12,14.25,15.03,13th and 14th grade,297,41,6.341463415,3,0.0271,0.6139,0.3591,0.636751473,0.044542633,0.318705857
"Pure silver and silver-containing stainless steel surfaces have been found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,38.32,0,11.9,18.33,16.8,11.83,11,12,15.15,11th and 12th grade,236,32,6.40625,3,0.1169,0.7545,0.1286,0.635071814,0.045502272,0.319425881
"It turns out that sterling silver and stainless steel surfaces containing silver are not displayed.
Inhibitory effect against SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and
Copper-containing stainless steel with a high copper content shows significant antiviral effects.
Property.",1186,Translated,TRUE,49.52,11.2,9.7,17.21,14.9,12.19,14,7.666666666666666,10.32,9th and 10th grade,291,40,6.375,3,0.0345,0.5681,0.3974,0.630163431,0.047592957,0.322243631
"Results from hospitalized patients show that shedding of the virus in stool occurs for ~3-7 days
after a positive PCR test, you can get a nasal swab and that the stool could be excreted
continue 6-10 days after receiving a negative nasal swab.",1194,Translated,TRUE,44.75,0,17.7,10.06,22.1,12.75,10,27.5,22.78,22nd and 23rd grade,243,43,4.720930233,5,0.0418,0.9202,0.0379,0.643708169,0.065174133,0.291117698
"Results from hospitalized patients indicate that shedding of virus in stool occurs for approximately 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It lasts for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,29.19,0,21.6,9.71,25,13.06,12,31,24.8,24th and 25th grade,277,50,4.6,5,0.0338,0.8688,0.0975,0.654754579,0.045300141,0.299945205
"Results from hospitalized patients have shown that viral shedding in the stool occurs for approximately 3 to 7 days.
If a positive PCR test result is obtained from nasal discharge, it can be excreted in the stool.
It lasts for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,71.85,10.5,7.3,8,7.9,11.86,13,8.833333333333334,10.6,7th and 8th grade,268,49,4.530612245,5,0.0242,0.8619,0.1138,0.647607327,0.052771326,0.299621344
"Results from hospitalized patients indicate that virus excretion in faeces occurs for approx. 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It lasts for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,55.07,0,11.7,8.83,12.2,12.26,13,15.25,14.7,11th and 12th grade,270,49,4.571428571,5,0.029,0.8304,0.1406,0.641760349,0.044748247,0.313491464
Results from hospitalized patients show that viral shedding in stool occurs approximately 3â€“7 days after a positive PCR test by nasal swab and that viral shedding in stool may continue for 6â€“10 days after a negative nasal swab.,1194,Translated,TRUE,32.91,0,18.1,12.14,21.6,13,10,24,20.46,12th and 13th grade,231,38,5.105263158,5,0.0172,0.7857,0.197,0.640419304,0.064080723,0.29549998
"Results from hospitalized patients suggest that viral shedding in fecal material occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that emissions in feces could
continue for 6-10 days after a negative nasal wash.",1194,Translated,TRUE,29.86,0,19.3,11.91,22.6,14.53,15,25.5,21.28,-1th and 0th grade,245,41,5.048780488,5,0.0204,0.8252,0.1544,0.639970005,0.06064849,0.299381465
"Results from hospitalized patients suggest that shedding of the virus in the stool occurs ~3 to 7 days after a positive PCR test from a nasal swab.
Occurs later, and stool discharge may continue for 6 to 10 days after a negative nasal swab test.",1194,Translated,TRUE,65.56,0,9.7,8.42,10.9,11.77,11,13.25,12.56,12th and 13th grade,245,45,4.488888889,5,0.0205,0.8612,0.1183,0.651904583,0.070054717,0.278040737
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs in approximately 3 to 7 days.
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,47.62,0,12.5,9.7,12.2,12.19,14,14.75,14.51,12th and 13th grade,264,47,4.680851064,5,0.0181,0.8407,0.1413,0.642549992,0.056197956,0.301252037
"Results from hospitalized patients indicate that viral shedding in faecal material occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that excretion in feces could
continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,29.86,0,19.3,12.03,22.6,14.53,15,27.5,23.23,22nd and 23rd grade,245,41,5.048780488,5,0.0179,0.8254,0.1567,0.643519521,0.064439185,0.292041361
"Results from hospitalized patients show that virus shedding in stool occurs for about 3â€“7 days.
After a positive PCR test, a nasal swab can be taken and stool can be expelled.
After receiving a negative nasal swab, this takes 6â€“10 days.",1194,Translated,TRUE,74.49,9.7,6.3,9.16,8.4,11.63,9,7.166666666666666,9.38,9th and 10th grade,240,41,4.926829268,5,0.0219,0.8225,0.1555,0.631652951,0.055849437,0.312497556
"Results from hospitalized patients indicate that shedding of virus in stool occurs for approximately 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It continues for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,29.19,0,21.6,10.17,25.4,13.06,13,32,25.6,25th and 26th grade,281,50,4.68,5,0.0273,0.8473,0.1254,0.643544495,0.054901771,0.301553696
"Results from hospitalized patients suggest that virus is shed in the stool for ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that stool excretion could
continue 6-10 days after a negative nasal swab.",1194,Translated,TRUE,47.8,0,16.5,10.17,20.9,12.73,9,25,21,20th and 21st grade,229,40,4.8,5,0.0192,0.8365,0.1443,0.638351202,0.067494668,0.294154048
"Results from hospitalized patients have shown that viral shedding in the stool occurs for ~3 to 7 days.
After a positive PCR test, you can confirm that stool may be excreted by collecting nasal discharge.
Continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,65.01,11.2,7.8,9.39,8.7,12.26,13,8.333333333333334,11.33,8th and 9th grade,256,44,4.886363636,5,0.0215,0.8629,0.1156,0.638834715,0.061064512,0.300100803
"Results from hospitalized patients have shown that viral shedding in the stool occurs in ~3 to 7 days.
It may be excreted in the stool after a positive PCR test using a nasal swab.
Continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,73.17,10.5,6.8,6.26,6,11.4,11,8.166666666666666,10.44,6th and 7th grade,235,45,4.288888889,5,0.0162,0.7993,0.1845,0.649866939,0.068521917,0.281611145
"Results from hospitalized patients indicate that viral shedding in feces occurs in approximately 3 to 7 days.
after a positive PCR test can be obtained from a nasal swab and excretion in the stool could
continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,48.13,0,12.3,9.52,11.8,12.33,14,15,15.29,11th and 12th grade,257,46,4.652173913,5,0.0181,0.8033,0.1786,0.643365145,0.063372873,0.293261975
"The results of hospitalized patients show that the virus is spread in feces for ~3-7 days
after a positive PCR test, you can get a nasal swab and that the excretion with feces could
continue 6-10 days after a negative nasal swab test.",1194,Translated,TRUE,44.75,0,17.7,8.84,21.1,12.01,8,26.5,21.85,21st and 22nd grade,234,43,4.511627907,5,0.0263,0.8321,0.1416,0.656460285,0.04370977,0.29982993
Results from hospitalized patients show that fecal viral shedding occurs approximately 3â€“7 days after a positive PCR test from a nasal swab and that fecal shedding may continue for 6â€“10 days after a negative nasal swab.,1194,Translated,TRUE,34.94,0,17.3,12.78,21.2,13.76,11,23,19.96,-1th and 0th grade,223,36,5.222222222,5,0.0166,0.7802,0.2032,0.632867515,0.058980271,0.308152199
"Results from hospitalized patients suggest that shedding of virus in fecal material occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that faecal emissions could
continue for 6-10 days after negative nasal wash.",1194,Translated,TRUE,30.88,0,18.9,12.14,22.5,14.7,14,25,21,18th and 19th grade,242,40,5.125,5,0.0233,0.8816,0.0951,0.646550238,0.069379583,0.284070164
"Results from hospitalized patients indicate that shedding of virus in feces occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that faecal excretion could
continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,30.88,0,18.9,11.33,21.8,14.31,13,26,22,21st and 22nd grade,236,40,4.975,5,0.0206,0.8669,0.1125,0.647723317,0.066327557,0.2859492
"The risk of death among COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,13.15,11.1,10.64,5,6,6.22,7th and 8th grade,147,22,5.772727273,2,0.0235,0.5313,0.4452,0.638060927,0.178400174,0.183538899
"Asthma patients with COVID-19 had a significantly increased mortality risk in Asia, but not in the country
in Europe, North America and South America.",1195,Translated,TRUE,38.66,0,13.8,12.77,15.5,11.41,6,16,12.93,12th and 13th grade,150,24,5.333333333,2,0.0176,0.4568,0.5256,0.671445608,0.149788588,0.178765774
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in the country
in Europe, North America and South America.",1195,Translated,TRUE,46.1,0,13,12.02,15.4,11.19,6,16.5,13.2,12th and 13th grade,153,25,5.2,2,0.0175,0.4648,0.5177,0.670976639,0.146551207,0.18247214
"COVID-19 patients with asthma had a significantly increased risk of mortality in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.6,11.9,6,15,12.44,12th and 13th grade,138,22,5.363636364,2,0.0173,0.4619,0.5207,0.683203995,0.130304202,0.186491773
"Asthma patients with COVID-19 had a significantly increased mortality risk in Asia, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.85,0,8.8,11.87,9.7,11.36,6,6.5,8.04,8th and 9th grade,141,22,5.5,2,0.0231,0.5552,0.4217,0.674910188,0.135161638,0.189928129
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.6,11.9,6,15,12.44,12th and 13th grade,138,22,5.363636364,2,0.0165,0.4603,0.5232,0.677284956,0.135980576,0.186734468
"The risk of death among patients with asthma from COVID-19 increased significantly in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,13.44,11.2,10.64,5,6,6.22,7th and 8th grade,148,22,5.818181818,2,0.0185,0.4079,0.5736,0.639371634,0.172142088,0.188486293
"The risk of death in COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,12.39,10.4,10.64,5,6,6.22,7th and 8th grade,144,22,5.636363636,2,0.0243,0.537,0.4386,0.643414676,0.164655238,0.191929966
"COVID-19 patients with asthma had a significantly increased risk of death in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,57.61,0,10.7,11.43,13.8,11.19,5,14,10.62,10th and 11th grade,134,22,5.181818182,2,0.0178,0.4332,0.549,0.672155678,0.138087049,0.189757198
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.8,11.9,6,15,12.44,12th and 13th grade,139,22,5.363636364,2,0.0215,0.5423,0.4362,0.677651823,0.133206442,0.189141735
"The risk of death increased significantly in asthmatic patients infected with COVID-19, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.85,0,8.8,12.91,10.6,11.36,6,7,9.85,9th and 10th grade,145,22,5.681818182,2,0.0175,0.398,0.5846,0.652071416,0.146468967,0.201459602
"Asthma patients with COVID-19 had a significantly increased risk of death in Asia, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,68.26,0,6.6,10.01,8.5,10.39,5,6.25,6.34,6th and 7th grade,140,23,5.173913043,2,0.024,0.5385,0.4376,0.657634854,0.145126551,0.197238609
"The risk of death among COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America and South America.",1195,Translated,TRUE,59.8,0,7.8,12.57,10.6,10.39,5,6.25,6.34,10th and 11th grade,150,23,5.608695652,2,0.0255,0.5632,0.4113,0.640227795,0.178564951,0.181207165
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.34,0,9,11.06,9.1,11.07,6,6.75,8.08,8th and 9th grade,143,23,5.304347826,2,0.0248,0.5942,0.381,0.672874033,0.138026819,0.189099178
"COVID-19 patients with asthma had a significantly increased risk of death in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,57.61,0,10.7,11.43,14,11.19,5,14,10.62,10th and 11th grade,135,22,5.181818182,2,0.0226,0.5081,0.4692,0.671246886,0.135957927,0.192795157
"Asthmatic patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,40.69,0,13.1,13.29,15.5,11.9,6,16,14.25,15th and 16th grade,142,22,5.5,2,0.0185,0.4785,0.503,0.668899238,0.141027793,0.190072864
"Asthma patients with COVID-19 had a significantly increased risk of death in Asia, but not in Asia.
in Europe, North America and South America.",1195,Translated,TRUE,67.76,0,6.8,9.61,8.1,10.15,5,6.5,6.47,6th and 7th grade,143,24,5.041666667,2,0.0192,0.4648,0.5159,0.659622669,0.151961148,0.188416213
"COVID-19 patients with asthma have a significantly increased risk of death in Asia;
This was not the case in Europe, North America, and South America.",1195,Translated,TRUE,54.56,0,11.9,11.09,14.8,10.56,5,15.5,11.6,11th and 12th grade,150,25,5.08,2,0.0166,0.3491,0.6343,0.68001622,0.124225788,0.195758045
"The risk of death among COVID-19 asthma patients increased significantly in Asia, but not in Korea.
In Europe, North America and South America.",1195,Translated,TRUE,59.8,0,7.8,10.77,9.1,11.07,6,6.25,6.34,10th and 11th grade,143,23,5.304347826,2,0.0171,0.4588,0.5241,0.611581266,0.212001801,0.176416889
"Evaluation results show a high diagnosis accuracy of 89% to 99%. The proposed method
X-ray images using image processing for early detection and classification of COVID-19
has proven to be useful as it provides end-to-end structure without the need for manual manipulation
feature extraction and manual selection methods.",1199,Translated,TRUE,21.74,0,16.2,15.15,17.5,13.38,19,17.5,17.93,17th and 18th grade,321,48,5.770833333,6,0.7889,0.204,0.007,0.629945457,0.094171815,0.275882781
"The evaluation results show high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 through X-ray imaging
has proven useful as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,32.22,0,14.2,15.03,16.7,12.62,15,15.5,16.07,15th and 16th grade,297,44,5.840909091,6,0.8516,0.1423,0.006,0.637460172,0.095873579,0.266666234
"The evaluation results showed a high diagnostic accuracy ranging from 89% to 99%. Proposed method
For early detection and classification of coronavirus (COVID-19) through image processing using X-ray images
It is proven to be usable because it provides a comprehensive structure without requiring a manual
Feature extraction and manual selection methods.",1199,Translated,TRUE,20.21,0,16.8,16.66,19.4,14.5,23,19.25,19.61,16th and 17th grade,354,51,6.019607843,6,0.7579,0.234,0.0082,0.625469387,0.084520467,0.290010154
"The evaluation results show a high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 using X-ray image processing
has proven to be useful as it provides an end-to-end structure without the need for manual methods of
feature extraction and selection.",1199,Translated,TRUE,38.66,0,13.8,13.47,16.2,12.72,17,16.5,17.1,16th and 17th grade,308,48,5.5,6,0.8339,0.1596,0.0065,0.644070029,0.090829857,0.265100151
"The evaluation results show high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 through X-ray images
has proven useful as it provides an end-to-end structure without the need for manual
features extraction and manual selection methods.",1199,Translated,TRUE,32.22,0,14.2,15.03,16.7,12.62,15,15.5,16.07,15th and 16th grade,297,44,5.840909091,6,0.8451,0.1485,0.0065,0.63874507,0.09472762,0.266527325
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing using X-ray images
has proven to be usable as it provides an end-to-end structure without the need for
Feature extraction and manual selection methods.",1199,Translated,TRUE,38.15,0,14,13.29,16.2,13.23,19,16.75,17.15,13th and 14th grade,312,49,5.448979592,6,0.8054,0.1865,0.0081,0.641792834,0.091256179,0.266950935
"The evaluation results show a high diagnostic accuracy ranging from 89% to 99%. The proposed method
for early detection and classification of Corona virus through X-ray imaging
has proven its usefulness because it provides a comprehensive structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,30.2,0,15,16.02,17.8,13.05,19,17.5,17.93,17th and 18th grade,325,48,5.854166667,4,0.8436,0.1508,0.0056,0.636678278,0.087196372,0.276125371
"The results of the assessment show high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing using X-rays
it is proven to be usable as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,37.13,0,14.4,13.06,16.5,12.95,18,18,17.26,12th and 13th grade,324,52,5.307692308,6,0.8265,0.1668,0.0067,0.629953861,0.093204685,0.276841402
"The evaluation results show a high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 using X-ray imaging
has proven useful as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,31.21,0,14.6,14.39,16.3,13.02,17,16.5,17.03,16th and 17th grade,301,46,5.630434783,6,0.8471,0.1466,0.0064,0.645955324,0.090662293,0.263382405
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for the early detection and classification of COVID-19 through image processing using X-ray images
it is proven to be usable since it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,28.17,0,15.8,14.16,17.5,13.12,20,18.5,18.09,17th and 18th grade,337,52,5.557692308,6,0.8173,0.176,0.0066,0.630903065,0.090723589,0.27837342
"The results of the assessment show high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
it has proven useful as it provides a comprehensive structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,39.16,0,13.6,14.63,16.7,12.53,16,17,17.06,16th and 17th grade,310,48,5.541666667,6,0.8749,0.1193,0.0059,0.635636568,0.098837934,0.265525401
"The evaluation results show a high accuracy of diagnosis, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray image processing
proved to be useful as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,29.69,0,15.2,13.93,16.6,12.59,17,17.75,17.96,17th and 18th grade,316,49,5.530612245,6,0.7764,0.216,0.0076,0.637199521,0.090568066,0.272232413
"The evaluation results show a high diagnostic accuracy ranging from 89% to 99%. The proposed method has been proven
For early detection and classification of COVID-19 through image processing using X-ray images
It is usable as it provides a comprehensive architecture without the need for manual feature extraction and manual selection methods.",1199,Translated,TRUE,28.17,0,15.8,15.03,18.1,13.43,21,19,18.86,18th and 19th grade,344,52,5.673076923,6,0.8325,0.1618,0.0057,0.637420833,0.089764565,0.272814572
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
has proven to be useful as it provides an end-to-end structure without the need for manual
features extraction and manual selection methods.",1199,Translated,TRUE,39.67,0,13.4,14.39,16.5,12.33,15,16,16.16,16th and 17th grade,303,46,5.673913043,6,0.8515,0.1431,0.0054,0.637922108,0.096043952,0.266033888
"The evaluation results show a high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 by X-ray image processing
it is proven to be usable as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,29.18,0,15.4,13.06,16.1,12.77,18,18.25,18,12th and 13th grade,316,51,5.274509804,6,0.8278,0.1655,0.0067,0.634574831,0.093215466,0.272209704
"Evaluation results show a high diagnostic accuracy ranging from 89% to 99%. Proposed method
For early detection and classification of the Corona virus through X-ray imaging
It has proven useful because it provides a comprehensive structure without the need for a manual
Feature extraction and manual selection methods.",1199,Translated,TRUE,30.2,0,15,15.15,17.2,12.72,18,17,17.1,16th and 17th grade,318,48,5.708333333,4,0.7873,0.205,0.0077,0.625960469,0.09147726,0.282562196
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
has proven useful as it provides an end-to-end structure without the need for
Feature extraction and manual selection methods.",1199,Translated,TRUE,40.69,0,13.1,14.1,15.9,12.62,15,15,16.07,12th and 13th grade,289,44,5.659090909,6,0.8344,0.1582,0.0074,0.64323169,0.094358146,0.262410164
"Evaluation results show a high diagnosis accuracy of 89% to 99%. The proposed method
X-ray images with image processing for early detection and classification of covid-19
has proven useful as it provides end-to-end structure without the need for manual manipulation
feature extraction and manual selection methods.",1199,Translated,TRUE,22.75,0,15.8,15.9,17.6,13.36,18,17,17.9,15th and 16th grade,314,46,5.913043478,6,0.7728,0.2194,0.0079,0.630495429,0.094783381,0.274721175
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing from X-ray images
is proven to be viable as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,37.64,0,14.2,13.18,16.3,12.77,18,17.5,17.2,12th and 13th grade,317,50,5.42,6,0.731,0.2602,0.0089,0.63730222,0.088887356,0.273810357
